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Abstract 
Alzheimer’s disease (AD) is a complex neurodegenerative disease that still evades 
effective treatment. Developing treatments to slow or prevent AD will require a 
detailed understanding of the early stages of AD at the molecular level. 
Unfortunately, the pathogenesis of AD progresses silently over decades and, in the 
case of genetically inherited familial AD, may involve subtle changes starting during 
young adulthood. The difficulties associated with studying human brains at young 
ages have meant that transcriptome analyses of accurate animal models are 
essential. This is the approach taken in the work here, which uses a data-driven, 
bioinformatics-led approach to analyse brain transcriptomes from knock-in zebrafish 
models of AD developed to resemble the genetic background of human AD. 
In the Introduction, the importance of transcriptome analysis in understanding AD at 
the molecular level is explained. Chapters 2, 3 and 4 describe the first brain 
transcriptome analyses of two different knock-in zebrafish mutation models 
(psen1K97fs and psen1Q96_K97del) modelling different aspects of human AD. In both 
zebrafish models, young adult brains revealed notable transcriptome changes, 
including changes to immune/stress responses and energy metabolism respectively. 
Gene network and gene set analysis approaches revealed that some of these gene 
expression changes were preserved in human AD datasets, suggesting the validity 
and utility of the approach used. The work in Chapter 4 supported an important role 
for iron dyshomeostasis in AD across animal models and human AD and 
demonstrated, for the first time, the viability of detecting iron dyshomeostasis 
IV
changes relevant to AD at the transcriptional level. This was achieved using a unique 
computational approach to the definition of gene sets based on predicted Iron 
Responsive Elements. Lastly, Chapter 5 used an advanced dimension reduction 
method to integrate zebrafish and mouse AD model datasets with human familial 
and sporadic AD. This resulted in the first preliminary comparison of human familial 
and sporadic AD transcriptomes as well as confirmation that the brains of a knock-in 
familial AD mutation-like zebrafish model (psen1Q96_K97del) and the commonly used 
5XFAD mouse model show extensive differences at the molecular level. 
Overall, analysis of young adult zebrafish brains revealed potential molecular 
mechanisms relevant to early stages of human AD that were significantly preserved 
in human familial and sporadic AD datasets. This work demonstrates the value to our 
understanding of AD of a bioinformatics-led approach involving transcriptome 
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Chapter 1   Introduction 
Transcriptome analysis enables 
study of Alzheimer’s disease at 
the molecular level 
 2 
1 Molecular and genetic basis of Alzheimer’s disease 
 
 
The cognitive decline experienced during normal aging is accompanied by structural, 
functional and molecular changes in the human brain [1]. These changes are 
exacerbated in individuals with dementia, who experience markedly accelerated 
cognitive decline. A complex neurodegenerative disease known as Alzheimer’s 
disease (AD) causes the majority (50–70%) of the >50 million dementia cases 
worldwide [2, 3]. Aging is the most significant risk factor for AD [2], but AD brains 
clearly differ from those undergoing normal, healthy aging. At the structural level, AD 
brains exhibit atrophy, astrogliosis, neuronal loss, synaptic loss and hypometabolism 
[4], while at the molecular level, they often display amyloid-beta (Aβ) protein 
aggregates in extracellular spaces and blood vessels [5–8], and aggregates of 
hyperphosphorylated tau proteins within neurons [8–11]. While tau aggregates 
contributes to neurodegeneration in other diseases including frontotemporal 
dementia, argyrophilic grain disease and Huntington’s disease [12–14], the 
accumulation of Aβ appears to be a unique molecular feature of AD. Consequently, 
significant efforts have been made to elucidate the “amyloid hypothesis”, describing 
the pathological role of Aβ in AD.  
 
The production, processing and pathological role of Aβ has been studied in detail. 
Figure 1 summarises the cellular production of Aβ and several of its proposed 
pathological roles in AD. Aβ peptide monomers of various lengths are formed when 
amyloid precursor proteins (encoded by APP) are sequentially cleaved by β-
secretase and γ-secretase enzymes. The catalytic subunit of γ-secretase is a 
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presenilin-1 or presenilin-2 aspartyl protease encoded by PSEN1 or PSEN2 (Li et al. 
2000). Familial forms of AD are mainly caused by heterozygous, autosomal 
dominant mutations in PSEN1, PSEN2 or APP, which seem to favour increased 
accumulation of the more neurotoxic Aβ-42 species relative to the more 
neuroprotective Aβ-40 species [15–20]. Studying Aβ kinetics suggests that soluble 
Aβ-42 species (including monomers, dimers and oligomers) are more neurotoxic 
than Aβ-40 species because Aβ-42 species readily undergo nucleation-dependent 
polymerisation along neuronal cell surfaces [21, 22]. The polymerisation process 
itself appears to permeabilise cell membranes [23] and contribute to widespread 
disruption of signalling pathways [24, 25]. Soluble Aβ species that re-enter neurons 
can also induce tau phosphorylation [26], and interfere with diverse cellular 
processes to further exacerbate AD progression. It is also likely that loss of the 
neuroprotective functions normally performed by Aβ-40 species may further worsen 
AD; for example, Aβ-40 is more effective at binding and transporting metal ions 
across membranes compared to Aβ-42 [27]. Although many mechanisms of Aβ-
mediated toxicity have been described, it is evident that excess Aβ in vivo is 
neurotoxic. Extraction of Aβ oligomers from human AD brains followed by direct 
injection into mice hippocampi impairs long-term potentiation, synaptic function, and 
memory, in addition to reducing dendritic spine density [28]. Likewise, repeated 
injections of soluble Aβ-42 oligomers into mice hippocampi induces neuronal loss, 
tau hyperphosphorylation and memory deficits [29]. Injection itself is unlikely to be 
responsible for these neurotoxic effects, as transgenic mouse lines producing high 
but physiologically relevant levels of soluble Aβ-42 species also display genotype 















Figure 1. Cellular production of amyloid beta (Aβ) and its potential molecular 
mechanisms in Alzheimer’s disease. Amyloid precursor protein (APP) is an integral 
membrane protein cleaved by two distinct pathways. (1) The non-Aβ-producing pathway 
involves cleavage of APP by α-secretase, producing a membrane-bound C83 fragment and 
soluble APPα fragment. (2) Alternatively, the pathway generating Aβ involves initial 
cleavage of APP by β-secretase, producing a membrane-bound C99 fragment and soluble 
APPβ fragment. (3) C99 is subsequently cleaved by γ-secretase to release Aβ monomers of 
various lengths (usually either 40 or 42 amino acids) into the extracellular space. Notably, 
presenilin 1 or presenilin 2 is the active protein subunit of γ-secretase and is encoded by the 
PSEN1 or PSEN2 gene. The Aβ-42 isoform is more prone to polymerisation than Aβ-40. (4) 
Polymerisation of Aβ forms Aβ oligomers, which aggregate to form plaques. Plaques act as 
reservoirs of Aβ oligomers which are neurotoxic. They can (5) activate microglia and 
astrocytes, resulting in neuroinflammation, (6) permeabilise plasma membranes and disrupt 
calcium ion homeostasis, and (7) induce generation of reactive oxygen species which 
damage cellular structures and impair cellular processes. A cellular cascade of events is 
believed to be initiated, which eventually triggers 8 phosphorylation of cytoskeletal tau 
proteins, formation of neurofibrillary tangles, and neuronal loss, leading to the clinical 
symptoms of Alzheimer’s disease. Figure modified from Abcam [31]. 
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Despite evidence supporting the neurotoxicity of aberrant Aβ accumulation and its 
contribution to familial AD, there is insufficient evidence to conclude that Aβ is the 
primary cause of all cases of AD, particularly in sporadic AD which represents over 
95% of all AD cases [4].  Unlike familial AD, the etiology of sporadic AD is 
heterogenous and likely involves a combination of genetic and environmental 
factors. In contrast to familial AD genes, risk genes for sporadic AD are not 
necessarily related to amyloid precursor protein processing or Aβ accumulation. The 
most well-known genetic risk factor for sporadic AD is possession of the ε4 allele at 
APOE [32, 33]. APOE encodes an apolipoprotein involved in cholesterol transport in 
the brain. Although studies have been quick to implicate APOE in Aβ clearance [34–
36], it is important to note that ε4 allele possession is also associated with diseases 
like athleroschlerosis, HIV, sleep apnea and ischemic cerebrovascular disease, 
where evidence supports a broader role for APOE in innate immunity through 
suppressing TNF secretion from inflammatory cells [37, 38]. Genome-wide 
association studies have since identified several other genes consistently associated 
with sporadic AD in diverse populations, including CLU, CR1, PICALM, TREM2 and 
CD33 [39–44]. Unfortunately, the functions of these genes are still primarily 
interpreted in terms of Aβ processing or clearance [45–49], although it is important to 
note that most do not play direct roles in Aβ processing and also participate in 
diverse processes like innate immunity, inflammatory processes, macroautophagy 
and cholesterol homeostasis in the brain [50–52]. Likewise, environmental risk 
factors for sporadic AD show strong association with those in varied diseases 
including cerebrovascular disease [53, 54], metabolic diseases like type II diabetes 
[55–57], and chronic pathogenic infection [58–60].  
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Several key lines of evidence collectively imply that aberrant Aβ accumulation may 
not initiate AD or contribute significantly to its pathogenesis. First, rather than being 
the initiator of AD, Aβ appears to have a physiological role in innate immunity. Aβ 
oligomerisation, which is typically viewed as a pathological event in AD, appears to 
be required for Aβ-mediated antimicrobial activity against gram-positive and gram-
negative bacteria [61]. This response occurs in vivo with bacterial infection in the 
brain and seems to be evolutionarily conserved in organisms as diverse as 
nematodes and mice [62]. Association between infection and AD has been well-
documented, with a greater-than-expected incidence of fungal and bacterial 
infections detected in post-mortem brain tissues of AD patients [58, 60]. As not all 
AD patients display brain infections, it is unclear whether Aβ is responding to a real 
or perceived pathogenic threat in AD. However, it is evident that Aβ accumulation 
should not be viewed as an isolated event in AD, and the causes of its accumulation 
should be investigated in more detail. Second, while it is evident that Aβ is correlated 
with AD, it may not be sufficient or necessary to account for all AD cases; most 
notably, a sizable number (15 – 31%) of cognitively normal individuals apparently 
display substantial Aβ deposits in their brains [63–65], while 16 – 25% individuals 
clinically diagnosed with mild to moderate AD display only low levels of soluble and 
insoluble Aβ [63, 66]. The existence of these individuals with Aβ pathology 
seemingly uncorrelated to their cognitive state raises concerns about the current use 
of Aβ as a diagnostic marker of AD.  Lastly, no therapeutic aimed at reducing Aβ 
activity has improved patient outcomes to date. A long-term follow-up study with AD 
patients previously immunised with human Aβ-42 revealed that despite decreased 
mean Aβ load and plaque density in patients, AD symptoms worsened at the same 
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rate as the placebo group [67]. Similar results were obtained from recent Phase 3 
clinical trials of two different antibodies capable of binding and reducing soluble 
human Aβ, which demonstrated no differences in AD patient outcomes compared to 
placebo groups [68, 69].  
 
Collectively, these studies indicate that although Aβ is neurotoxic and tends to 
accumulate in at least some portion of AD brains, it may not possess a primary role 
in AD pathogenesis, underscoring the need to study other pathological mechanisms 
of AD that precede both cognitive decline and Aβ accumulation.   
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2 Transcriptome analysis reveals the diversity of 
molecular pathology in Alzheimer’s disease 
 
 
While the amyloid hypothesis of AD is a major area of research, the evidence 
against Aβ as the sole cause of AD underscores the importance of investigating 
other potential causes or underlying factors of AD. Importantly, in humans, 
longitudinal studies reveal early structural and functional brain changes decades 
before clinical onset of familial or sporadic AD. For example, young adult (18-26 
year-old) carriers of the familial AD E280A PSEN1 mutation already display 
accelerated brain atrophy and increased soluble Aβ levels in blood plasma and 
cerebrospinal fluid, despite dementia tests indicating they are cognitively normal [70]. 
Similarly, young adult carriers of the ε4 allele of APOE (the major sporadic AD risk 
gene) consistently display lower glucose metabolism rates in several brain regions 
corresponding to those with lowered glucose metabolism in AD patients [71]. These 
studies are valuable as they demonstrate clear structural and functional changes in 
the brains of individuals long before onset of AD, presence of amyloid plaques, or 
any cognitive deficits.  
 
The techniques used in these types of studies means that identifying the early 
cellular processes and molecular mechanisms driving these changes is beyond their 
scope. Instead, omics techniques that measure expression of genes 
(transcriptomics) or proteins (proteomics) are able to fill this need as they capture 
molecular changes without prior assumptions of disease etiology. This is especially 
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relevant for complex diseases such as AD where much of the underlying molecular 
pathology (aside from Aβ biology) is still not well characterised.  
 
The transcriptome of a particular biological sample describes its global RNA 
transcript expression at a particular time. Two techniques are commonly used to 
collect transcriptome data from biological samples: cDNA microarrays, and whole-
transcriptome sequencing (RNA-seq). The key differences between these methods 
is shown in Figure 2. Compared to microarrays, RNA-seq is more recent technology 
that allows for improved reproducibility as well as access to sequence-level 
information that facilitates observation of phenomena that are not readily detected by 
microarrays (e.g. splicing events, non-coding RNA quantification and discovery [72]). 
Comparing the transcriptomes of different conditions (e.g. disease state, time period, 
tissue type) allows changes in molecular pathways between conditions to be 
inferred.  
 
Existing transcriptome analyses of brain tissue from post-mortem AD brains 
suggests vast dysregulation of genes with roles in diverse biological activities 
including membrane organisation, immune responses, inflammation, vesicle 
trafficking, synaptic transmission and plasticity, axon transport, neuron 
differentiation, protein homeostasis, cytoskeletal rearrangement, and metabolic 
processes (see summarised findings of relevant studies in Table 1). It is important to 
note that all gene expression studies of AD are performed on tissue samples taken 
from post-mortem AD brains representing very late stages of AD. During these late 
stages, extensive disruption to normal brain function and structure is expected. A 
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major limitation of this is that it is difficult to discern earlier, causative events in AD 
pathogenesis from later changes arising as symptoms. From present transcriptome 
analyses, it is evident that dysregulation of diverse processes has occurred, but their 





Figure 2. Comparison of Affymetrix microarray and RNA-seq technologies for 
transcriptomic data collection. Microarrays and RNA-seq sample preparation initially 
involves the extraction of RNA from a sample, followed by fragmentation and conversion to 
complementary DNA (cDNA) by reverse transcription. For microarrays, cDNA samples are 
labelled with fluorescent probes, while for RNA-seq, the RNA samples are ligated with 
adapters. In Affymetrix microarrays, probe sequences complimentary to target RNA 
sequences are placed at pre-defined locations on the microarray. For the RNA-seq system, 
a flow cell and sequencing-by-synthesis method is used to generate millions of sequences 
per sample. The raw data from a microarray workflow are CEL files containing continuous 
intensities corresponding to gene expression for each probe, while for RNA-seq, the raw 
data are the reads corresponding to RNA sequences. By mapping RNA-seq reads to a 
reference genome, discrete gene counts can be obtained [72].  
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Table 1. Selected microarray and RNA-seq studies focusing on brain transcriptome 
analysis of human patients with Alzheimer’s disease (AD). 




19 brain regions 











1558 co-expressed gene 
network modules in AD, with 
enriched processes including 
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cognitive decline in MCI (Mild 
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AD implicated in aging-
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associated with synaptic 
vesicle trafficking, SNARE 
complex, neurotransmitter 
receptors, cell adhesion 
regulating synaptic stability, 
and neuromodulatory 




1.0 ST Array 
temporal cortex 8 controls,  






22 genes with evidence of 
differential splicing in AD; one 
gene, FynT, was linked to an 
astrocytic inflammatory 




1.1 ST Array 
posterior cingulate 7 controls,  
7 early-onset 








3183-3350 DE genes in AD 
associated with calcium and 
metal ion signalling, 
neuroactive ligand-receptor 
interactions, axon guidance, 
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including cholinergic 
transmission and ribosomal 
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genes regulating translation 
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32 differentially expressed 
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interacts with the influential 
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23 controls,  





Differential splicing patterns 
and promoter usage of the 
APOE gene in AD compared 
to controls; enrichment in 
protein localisation, vesicle 
transport, phosphate 













Identification of 8681 binding 
sites on transcripts for the 
Neuronal ELAV-like RNA 
binding proteins; enrichment 















genes in AD, including 143 
protein-coding genes, 90 
lincRNAs, 31 antisense 
transcripts. Enriched 
pathways include nerve 
impulse transmission, 





whole brain 1 control,  





125 upregulated piRNAs 
responsible for 
downregulation of 1923 
genes in AD. Enriched 
pathways include NMDA 
receptor trafficking and 




whole brain 1 control (2 
time points),  






Upregulation of immune 
response genes, 
downregulation of synaptic 
plasticity genes [88]. 
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3 Limitations in the previous use of animal models for 
studying Alzheimer’s disease 
 
 
Post-mortem AD brains display extensive structural and molecular pathology, so it is 
clear that studying young adult brains predisposed to AD would give more insight 
into earlier disease pathogenesis. However, it is evidently not feasible to extract 
brain tissue from the living brains of young adults for transcriptome analysis. 
Because of this, animal models have been developed to investigate AD 
pathogenesis at any age.  
 
Early mouse models of AD possessed single endogenous knock-in mutations in 
mouse orthologs of familial AD-causing genes like PSEN1 or APP. This was done in 
an attempt to model the genetic state of familial AD as closely as possible. 
Unfortunately, further research with these models was largely abandoned when it 
was discovered that these mouse models only recapitulated partial AD phenotypes, 
with mutant APP mice demonstrating substantial Aβ plaque formation but negligible 
neurodegeneration [89], and mutant PSEN1 mice exhibiting neurodegeneration 
without Aβ plaques [90, 91]. Furthermore, these phenotypes were only observed in 
old (13-month-old) mutant mice, with young adult (6-month-old) mutant mice 
showing normal or only subtle phenotypes compared to age-matched, wildtype 
siblings. These findings were interpreted as a failure on the part of the models to fully 
capture human AD. At the time of these studies, transcriptome analysis was still in its 
infancy, so any potential changes to the brains of these models at the molecular 
level were not interrogated at all.   
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At the time, the common sentiment was that Aβ and tau aggregates comprised the 
characteristic molecular pathology causing AD, so the next mouse models that were 
developed prioritised Aβ and tau pathology over having a genetic background 
resembling human familial AD. To create models with extensive Aβ and tau 
pathology, transgenic mouse models were developed that possessed several human 
transgenes with multiple familial AD-linked mutations (e.g. 5XFAD [92] and 3XTG 
[93]). It is important to note that while these models phenotypically resemble human 
AD in terms of Aβ plaques and cognitive deficits being present, these characteristics 
are accomplished by overexpressing multiple mutant human familial AD genes [89, 
94]. There have been concerns that this could induce unnatural artifacts and 
confound AD pathogenesis. For example, the order of appearance and degree of 
severity of key symptoms like neuronal loss, synaptic impairment and cognitive 
decline is unexpectedly variable between different models [95, 96]. These 
observations are consistent with results from a recent meta-analysis comparing the 
transcriptomes of five mouse models of AD and human AD. While human AD cases 
displayed similar gene expression changes that differed from cognitively-normal, 
age-matched controls, the transcriptomes of AD mouse models differed from both 
each other and human AD [97]. This lack of similarity between different mouse 
models as well as human AD raises concerns about whether these transgenic 
mouse models are able to give relevant insight into AD pathogenesis, especially 
when findings from these models are being applied to pharmaceutical interventions. 
Concerningly, there has been evidence that overexpression of human wild-type APP 
in both wildtype and transgenic mice with familial AD mutations itself induces 
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memory deficits at 8 months of age despite minimal Aβ-42 levels [98]. Similarly, 
overexpressing APP and PSEN1 in at least one mouse model induces p25 
generation independently of increased Aβ levels [99]. The results of the latter study 
are particularly concerning, given that the p25 generation detected was an artifact, 
while multiple studies have interpreted p25 generation in the 5xFAD mouse model as 
a mechanism of Aβ-mediated neurotoxicity in AD [92, 100, 101].  
 
Collectively, these results suggest while overexpression of multiple human 
transgenes may result in animal phenotypes resembling AD, the underlying 








The concerns regarding transgenic models have seen an increase in popularity of 
knock-in mouse models in recent years [102, 103]. Aside from mouse models, 
zebrafish models have also been emerging in popularity as complementary model 
organisms of AD. They are optically transparent, undergo rapid development 
(reaching full maturity in 3-4 months), have comparable lifespans to mice (median 
lifespan of 31 months, maximum lifespan of 45 months [104], produce many 
offspring (50-200 embryos per week from one pair of parents), and are amenable to 
genetic manipulation with TALENs, CRISPR and morpholino antisense 
oligonucleotides [105–107]. Zebrafish share some advantages with other simpler 
vertebrate models (e.g. fly, nematode) that facilitate identification of highly conserved 
AD mechanisms [108–111], while possessing more similar brain physiology to 
humans [107, 112]. Approximately 70% of human genes have at least one zebrafish 
orthologue, so zebrafish models may be useful to independently verify genes 
implicated in AD from current mouse models [113]. Importantly, zebrafish express 
orthologues of human AD genes including APP, PSEN1, PSEN2, APOE and SORL1 
[105, 114], and their functions appear to be conserved. For example, zebrafish 
presenilin 1 possesses the critical aspartate residue required for cleavage of human 
APP to produce Aβ-42 [115]. Ultimately, applying transcriptome analysis to zebrafish 
models possessing endogenous familial AD mutations appears to be an unexplored 
and reasonable approach for investigating AD pathogenesis. 
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The Alzheimer’s Disease Genetics Laboratory (ADGL) has developed the first 
zebrafish models possessing distinct endogenous familial AD mutations at the 
zebrafish psen1 locus (orthologous to human PSEN1). Similar to humans with 
familial AD, these models express mutant psen1 in a heterozygous state, resulting in 
physiologically relevant levels of presenilin 1 protein [116]. Like early knock-in mouse 
models of familial AD with endogenous familial AD mutations, these zebrafish 
models avoid confounding effects that might arise from overexpression of human 
transgenes [90, 91, 99]. Consequently, the underlying physiological state of these 
zebrafish models are relevant for studying human familial AD at the molecular level.  
 
Although several zebrafish models have been developed by the ADGL, the 
Q96_K97del and K97fs zebrafish lines are important to introduce for the work done 
in the following manuscripts. In both of these lines, zebrafish are heterozygous for a 
different endogenous familial AD mutation at the psen1 locus. The Q96_K97del 
mutation is a double-codon deletion that preserves the open-reading frame to result 
in full-length, mutant presenilin-1 protein, similar to mutations causing familial AD in 
humans. This model will be termed the fAD-mutation-like model. In contrast, the 
K97fs line mimics a human mutation, K115fs, found in the human PSEN2 gene. In 
humans, this mutation results in increased expression of an alternative protein 
isoform, PS2V, that is also often seen to be increased in the brains of late onset, 
sporadic AD patients [117]. In previous studies by the ADGL, the PS2V isoform was 
shown to be evolutionarily conserved in zebrafish psen1 rather than psen2, where 
the zebrafish PS2V-like protein still retained γ-secretase activity, Notch signalling 
activity, and suppression of the unfolded protein response similar to human PS2V 
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[117]. Consequently, rather than being a direct familial AD model, the K97fs line 
models the effects of forced PS2V-like expression in the brain. The location of both 
zebrafish psen1 mutations on the orthologous human presenilin-1 protein are shown 






Figure 3. Human presenilin-1 protein. The location of the orthologous zebrafish 
psen1 mutations Q96_K97del and K97fs in Exon 4 are indicated. Other known 




Figure 4. Summary of experimental design and statistical comparisons 
between groups in the (A) K97fs zebrafish sibship and (B) Q96_K97del 
zebrafish sibship. Each sample represents a whole zebrafish brain. Samples are 
derived from total RNA (K97fs sibship) or polyA enriched RNA (Q96_K97del 
sibship). 6-month-old zebrafish represent a young adult stage while 24-month-old 
zebrafish represent an aged, infertile stage. The lines connecting each biological 
group indicate the statistical pairwise comparisons to be performed to identify 
differentially expressed genes between the two groups. n is the number of biological 





Figure 5. RNA-seq data processing workflow. Raw paired-end reads from RNA-
seq libraries are processed with a range of Unix-based computational tools to 
quantify gene expression in each library. At each step of the data processing 
pipeline, quality control is performed to assess the impact of program parameters on 
data quality. In this workflow, gene expression is quantified at both the transcript- 
and gene-levels. Quantification data is typically used for differential gene expression 
analysis.  
  
Total RNA extracted 
from whole brains of 
female zebrafish














(e.g. MDS) to identify 
variation between 


























RNA extr ct d from
whole zebr fish brains 
 23 
5 Bioinformatics methods for transcriptome analysis  
 
In the manuscripts later described, RNA-seq is used to capture the transcriptional 
states present in whole brains of knock-in mutant zebrafish models and compare 
them to those of healthy, wild type siblings. The comparisons of interest are 
summarised in the experimental design diagrams in Figure 4. In this section, the 
methods underlying RNA-seq data processing and analysis are briefly described.  
 
A computational pipeline that can be used to process the raw RNA-seq data is 
shown in Figure 5. Raw paired-end or single-end RNA-seq reads are the initial input, 
which are then subject to adapter-trimming and quality-filtering using tools such as 
AdapterRemoval [119], alignment of trimmed reads to the zebrafish reference 
genome assembly with an alignment tool such as HISAT2 [120] or STAR [121], and 
quantification of gene expression from the aligned reads as gene-level counts using 
featureCounts [122]. Alternatively, instead of aligning reads to the reference genome 
assembly, it is also possible to obtain transcript abundance estimates from trimmed 
reads using approaches such as kallisto [123] or salmon [124], where transcript 
abundance estimates can then be imported into R using tools like tximport [125] or 
edgeR’s “catchSalmon” or “catchKallisto” functions [126]. Importantly, the effect of 
each pre-processing step on the quality of the output data is assessed through a 
range of diagnostic plots (e.g. per-base read quality, GC content of reads, average 
read length, k-mer content in reads) which are implemented in FastQC [127] and 
ngsReports [128]. Depending on output data quality, different parameters or 
computational tools will be tested, and additional steps to improve data quality (e.g. 
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discarding reads mapping to multiple loci, filtering out PCR duplicates or other 
technical artifacts) may be implemented.  
 
Gene-level counts are the primary output of the RNA-seq data pre-processing 
pipeline, and are typically analysed with various Bioconductor packages [129]. 
Bioconductor is an open-source, R-based collection of software packages focused 
on the statistical analysis of genomics data including microarrays, PCR, protein-
arrays and RNA-seq. The aim of differential gene expression analysis is to determine 
genes that are differentially expressed between specific experimental conditions. 
Numerous Bioconductor software packages support differential expression analysis 
[130]. They differ in statistical approaches like normalisation methods and 
assumptions about the distribution of gene counts in RNA-seq libraries. In the work 
later described, the limma package is utilised to determine genes which are 
differentially expressed between conditions. limma implements weights to handle 
variable quality across genes and libraries, making the differential gene analysis 
potentially more robust to outlier samples and genes without the need for ad hoc 
data removal [131–133]. limma also has favourable power to detect differential 
expression compared to other methods, even for small sample sizes [125]. After 
differentially expressed genes are identified for desired comparisons, a range of 
analyses can be performed to gain further insight on biological changes 
corresponding to gene expression pattern changes. These include gene ontology 
over-representation analysis, promoter motif over-representation, gene set 
enrichment analysis, and gene co-expression network analysis are summarised in 
Table 2.   
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Table 2. Summary of analyses performed on a processed RNA-seq dataset.  
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co-regulated genes; infer 










6 Integration of multiple datasets 
 
Many of the techniques described in Table 2 are effective at providing biological 
insight into a single gene expression dataset. However, different techniques are 
required for the integrative analysis of multiple datasets simultaneously (known as 
data integration). There are many reasons why data integration would be useful, 
especially in the context of studying complex diseases such as AD. These include 
being able to take advantage of existing publicly available datasets from past 
studies; analysing different omics data types (e.g. proteomics and transcriptomics) 
from the same samples to give greater confidence into findings; and getting insight 
into whether findings from animal models also apply to human AD datasets.  
 
Unfortunately, data integration is often not straightforward. Part of this is because the 
nature of high-throughput technologies like microarrays or RNA-seq depends on a 
complex system of reagents, hardware, and highly trained individuals to facilitate 
accurate measurements. Variance in these conditions (e.g. differences in RNA-seq 
library preparation or sequencing platform used) will cause the measurements to be 
affected by both technical and biological factors in ways that are not fully predictable 
or reproducible. This phenomenon is known as introducing batch effects into the 
data. Concerningly, when multiple gene expression datasets are analysed together 
without accounting for batch effects, the majority of differentially expressed genes 
tends to occur across batches rather than across biological conditions [143]. Many 
bioinformatics tools have been developed that use statistical approaches to account 
for and reduce batch effects within datasets (e.g. RUVSeq [144] or surrogate 
variable analysis (sva) [145]). In contrast, techniques for the integration of different 
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datasets must be capable of accounting for batch effects between datasets. These 
techniques include network-based approaches, dimension reduction, gene set 




Table 3. Approaches for omics dataset integration. 




Convert each dataset into 
graph to model interactions 
or correlations between 
genes and/or proteins. 
 
Datasets are represented as 
separate graphs (nodes, 
edges) which can then be 
compared using graph-based 
measures (e.g. degree, 
connectivity, subgraphs, 
clusters)  
Filtering of genes / proteins 
before constructing the graph 
limits batch effects arising from 
low-expressed or low-variance 
genes / proteins; comparing 
graph-based measures (e.g. 
clusters) between datasets 
rather than individual 
measurements reduces impact 
of individual noisy genes. 
Multi-omics interaction 
networks to infer 
relationships between 
genes and/or proteins 
[146]; co-expression 
network analysis for 
comparing multiple gene 
expression datasets [142] 
Dimension 
reduction 
Unsupervised method for 
summarising dataset into 
fewer latent variables 
capturing the majority of 
information. The small 
number of latent variables 
from multiple datasets can 
be simultaneously visualised 
and compared in an 
interpretable manner. 
As batch effects are strong, 
they are typically isolated into 
separate latent variables away 
from biological sources of 
variation. 
Non-negative matrix 
factorisation with latent 
variables representing 
data-driven sources of 
variation [147]; sparse 
Principal Component 
Analysis approaches like 
AES-PCA reduce the 
number of genes 
contributing to latent 
variables [148]  
Meta-
analysis  
Each dataset is analysed 
separately, and significantly 
preserved changes in 
measurements (e.g. genes, 
proteins) between datasets is 
determined using post-hoc 
statistical meta-analysis 
methods. 
Meta-analysis techniques can 
take direction of the change as 
well as dataset-specific 
weighting into account across 
multiple datasets, making the 
findings more robust to batch 
effects. 
Concordance analysis for 
assessing whether gene 
expression changes are 
similar between datasets 







AD is a complex neurodegenerative disease that is still yet to respond to any 
pharmaceutical intervention. While current paradigms emphasise the importance of 
protein aggregates such as amyloid beta and tau, the molecular basis of the disease 
is more complicated than expected, highlighting the need for further studies to 
understand how the disease initially develops. While late stages of AD have been 
extensively characterised from studies of post-mortem AD brains, the earliest 
molecular changes in the brain driving incipient stages of AD are still unclear. In 
familial AD, these earliest changes may start during young adulthood, making it 
clearly unfeasible to study these early stages in humans and emphasising the 
necessity of accurate animal models of AD. Due to confounding artifacts associated 
with humanised, transgenic models of AD, knock-in models in particular appear more 
suitable for this purpose. Importantly, several large gaps remain in the field. For 
example, no transcriptome analysis has ever been performed on any knock-in model 
of AD, despite the earliest knock-in mouse models existing for decades. There have 
been no studies to assess whether the brain transcriptomes of knock-in models of 
AD might resemble human AD more than transgenic models. In addition, while 
zebrafish have several advantages compared to mice as complementary model 
organisms, comparisons of these AD models at the transcriptome level have not 
been performed. The earliest molecular events and cellular pathways in the brain 
driving early stages of familial AD remain unclear, along with potential differences in 
molecular mechanisms between different familial AD mutations. Importantly, familial 
and sporadic AD brains have not been subject to a single comparison at the 
transcriptional level, and this may be associated with the difficulties associated with 
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data integration. While high-throughput omics technologies and bioinformatics 
methods have been increasing in popularity, there remain significant gaps in their 
application to the context of AD. The following manuscripts aim to address these 
gaps through using bioinformatics-focused strategies to analyse novel zebrafish 
datasets from the ADGL and integrate findings with existing knowledge from publicly 
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The molecular changes involved in Alzheimer’s disease (AD) progression remain unclear
since we cannot easily access antemortem human brains. Some non-mammalian verte-
brates such as the zebrafish preserve AD-relevant transcript isoforms of the PRESENILIN
genes lost from mice and rats. One example is PS2V, the alternative transcript isoform of
the PSEN2 gene. PS2V is induced by hypoxia/oxidative stress and shows increased
expression in late onset, sporadic AD brains. A unique, early onset familial AD mutation of
PSEN2, K115fs, mimics the PS2V coding sequence suggesting that forced, early expres-
sion of PS2V-like isoforms may contribute to AD pathogenesis. Here we use zebrafish to
model the K115fs mutation to investigate the effects of forced PS2V-like expression on the
transcriptomes of young adult and aged adult brains.
Methods
We edited the zebrafish genome to model the K115fs mutation. To explore its effects at the
molecular level, we analysed the brain transcriptome and proteome of young (6-month-old)
and aged (24-month-old) wild type and heterozygous mutant female sibling zebrafish.
Finally, we used gene co-expression network analysis (WGCNA) to compare molecular
changes in the brains of these fish to human AD.
Results
Young heterozygous mutant fish show transcriptional changes suggesting accelerated
brain aging and increased glucocorticoid signalling. These early changes precede a
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transcriptional ‘inversion’ that leads to glucocorticoid resistance and other likely pathological
changes in aged heterozygous mutant fish. Notably, microglia-associated immune
responses regulated by the ETS transcription factor family are altered in both our zebrafish
mutant model and in human AD. The molecular changes we observe in aged heterozygous
mutant fish occur without obvious histopathology and possibly in the absence of Aβ.
Conclusions
Our results suggest that forced expression of a PS2V-like isoform contributes to immune
and stress responses favouring AD pathogenesis. This highlights the value of our zebrafish
genetic model for exploring molecular mechanisms involved in AD pathogenesis.
Introduction
Alzheimer’s disease (AD) is the leading cause of dementia, a condition characterised by the
progressive decline of memory and cognition. Like other neurodegenerative diseases, AD
affects diverse cellular processes in the brain, including mitochondrial function [1, 2], metal
ion homeostasis [3–5], lipid metabolism [6–8], immune responses [9, 10], synaptic transmis-
sion [11], and protein folding and trafficking [12, 13]. Dysregulation of these processes eventu-
ally results in severe atrophy of several brain regions (reviewed by Braak and Braak [14] and
Masters et al. [15]). Consequently, late stages of AD are likely to be much more difficult to
treat than earlier stages of AD, contributing to our failure to discover ameliorative drugs [16].
The pathological processes that result in AD are likely to initiate decades before clinical
symptoms arise. Decreased levels of soluble amyloid beta (Aβ) peptides in the cerebrospinal
fluid is one of the earliest markers of both sporadic and familial forms of AD, preceding disease
onset by 20–30 years [17, 18], while vascular changes are likely to occur even earlier [19].
Individuals possessing highly penetrant, dominant mutations in genes linked to the familial
form of AD (fAD) such as PSEN1 show structural and functional changes in their brains as
early as 9 years of age, despite being cognitively normal [20, 21]. Similar findings are evident
in young adults carrying the ε4 allele of APOE, the major risk gene for the sporadic form of
AD [22]. To prevent AD, we must identify the stresses underlying these early pathological
changes. However, detailed molecular analysis of the brains of asymptomatic young adult fAD
mutation carriers is currently impossible.
Analysing high-throughput ‘omics data (e.g. transcriptomic, proteomic) is a comprehensive
and relatively unbiased approach for studying complex diseases like AD. Over the past decade,
numerous post-mortem AD brains have been profiled using microarray and RNA-seq technol-
ogies, exposing an incredibly complex and interconnected network of cellular processes impli-
cated in the disease [23, 24]. Unfortunately, analysing post-mortem AD brains does not discern
which cellular processes are responsible for initiating the cascade of events leading to AD.
Animal models can assist exploration of the early molecular changes that promote AD.
However, early “knock-in” mouse models that attempted to model the genetic state of
human fAD showed no obvious histopathology [25–27]. Modern ‘omics technologies pro-
vide molecular-level descriptions of disease states, but these technologies were not available
when the early knock-in models were made. Subsequent transgenic models of AD con-
structed with multiple genes and/or mutations have displayed what are assumed to be AD-
related histopathologies and these have also been analysed by ‘omics methods. However
recent analysis of brain transcriptomes from five different transgenic AD models showed
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little concordance with human, late onset, sporadic AD brain transcriptomes. Worse still,
none of the models were concordant with each other [28].
The overwhelming majority of fAD mutations are present in a heterozygous state in human
patients. Despite this, there has been a lack of detailed molecular investigation of the young
adult brains of any animal model closely imitating the human fAD genetic state–i.e. heterozy-
gous for a fAD-like mutation in a single, endogenous gene. Previously, we used zebrafish to
analyse the unique, frameshifting fAD mutation of human PRESENILIN2 (PSEN2), K115fs,
that inappropriately mimics expression of a hypoxia-induced truncated isoform of PSEN2 pro-
tein, PS2V [29–32]. Mice and rats have lost the ability to express PS2V [33] (and the fAD genes
of these rodents are evolving more rapidly than in many other mammals [33]), but in zebra-
fish, this isoform is expressed from the animal’s psen1 gene [32]. Consequently, to model and
explore early changes in the brain contributing to AD pathogenesis, we have now used gene-
editing technology to introduce a K115fs-equivalent mutation into the zebrafish psen1 gene,
K97fs. In this paper, we analyse data collected from young adult (6-month-old) and aged
(24-month-old) adult heterozygous mutant and wild type zebrafish brains to comprehensively
assess gene and protein expression changes in the brain due to aging and this mutation. At
the molecular level, we find that the young heterozygous mutant brains show elements of
accelerated aging while aged heterozygous mutant brains appear to ‘invert’ into a distinct,
and presumably pathological, state. Our results highlight the important role that non-trans-
genic models of fAD mutations in a heterozygous state play in elucidating mechanisms of AD
pathogenesis.
Results
Gene editing in zebrafish to produce the psen1 K97fs mutation is described in the Materials
and Methods and in Fig A in S1 File. To confirm that the K97fs mutation of psen1 forces
measurable expression of a PS2V-like transcript under normoxic conditions we performed
digital quantitative PCR (dqPCR) specifically detecting either heterozygous mutant or wild
type transcript sequences in cDNA synthesised from the brains of female 6-month-old
(young) and 24-month-old (aged) psen1K97fs/+ (heterozygous mutant) and psen1+/+ (wild type)
zebrafish (Fig 1). We only included female fish to reduce variability between samples and
minimise confounding by potential gender-specific gene expression patterns, given that
females are more vulnerable to AD and that gender-specific changes have been documented in
AD [34, 35]. K97fs transcripts constitute approximately 30% of the psen1 transcripts detected
in young brains and over 70% of the detected transcripts in aged brains. Despite these different
biases in heterozygous mutant and wild type transcript expression, the total levels of psen1
transcript appeared similar between heterozygous mutant and wild type fish at either age. This
supports that the K97fs mutant transcript (like PS2V transcripts in humans) is not completely
degraded by nonsense mediated decay despite possession of a premature termination codon
[29]. PCR tests on cDNA from heterozygous mutant brains did not detect aberrant splicing of
the psen1 gene due to the K97fs mutation. We currently have no explanation for the observed
bias, or its age-dependent change, between the expression of the heterozygous mutant versus
wild type psen1 transcripts. The extent of the decrease in the wild type psen1 transcript in the
aged heterozygous mutant brains means that this may contribute to any molecular phenotype
caused by heterozygosity for the K97fs mutation in addition to the effects of the PS2V-like
transcripts.
To determine whether the K97fs mutation in the zebrafish psen1 gene induces changes in
the expression of other genes and proteins, we removed entire brains of heterozygous mutant
and wild type adult zebrafish for total RNA sequencing (RNA-seq) and label-free tandem mass
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spectroscopy (LC-MS/MS) when zebrafish were 6 months (young adult) and 24 months (aged
adult) old. We used three biological replicates to represent each of the four experimental
conditions (young wild type, young heterozygous mutant, aged wild type, aged heterozygous
mutant), and performed pairwise comparisons between experimental conditions to determine
differentially expressed (DE) genes and differentially abundant (DA) proteins (Fig 2). Full lists
of DE genes and DA proteins are provided in S1 and S2 Tables.
Gene expression changes in the heterozygous mutant zebrafish reveal
accelerated brain aging followed by inversion into a presumably
pathological state
The brains of children or young adults carrying fAD mutations display morphological and
functional differences compared to age-matched individuals without these mutations
[20, 21]. Consequently, we hypothesised that gene expression in the brains of young adult
(6-month-old) zebrafish carrying this K115fs-like mutation would also be altered when
compared to wild type zebrafish siblings. Overall, we find supporting evidence for 105 genes
that are differentially expressed in young heterozygous mutant brains relative to wild type
brains (65 up-regulated, 40 down-regulated; FDR-adjusted p-value < 0.05) (Fig B in S1 File).
Fig 1. Quantification of heterozygous mutant and wild type allele relative transcript expression. Digital quantitative
PCRs specifically detecting transcripts from the heterozygous mutant (K97fs) or wild type (+) alleles of psen1 were performed
using cDNA synthesised from total brain mRNA from fish at 6 and 24 months of age. Means and standard error of the means
are indicated, and p-values are from two-sample t-tests assuming unequal variances.
https://doi.org/10.1371/journal.pone.0227258.g001
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Of these 105 genes, 65 have an estimated log2 fold change greater than 0.5 (or less than -0.5)
in the ‘young heterozygous mutant vs. young wild type’ comparison (Fig 3A). By examining
the expression of these genes in the other three comparisons described in Fig 2, we observe
two important phenomena:
1. Accelerated aging genes are associated with increased immune response: 62% (65/105)
of the genes that are DE in 6-month-old heterozygous mutant brains (‘young heterozygous
mutant vs. young wild type’) show the same direction of expression change during normal
aging (‘aged wild type vs. young wild type’). However, far more genes are DE during normal
aging (1,795 compared to 105). This suggests that the 6-month-old heterozygous mutant
brains may demonstrate accelerated aging for a subset of cellular functions. As an initial
step to explore these altered cellular functions, we applied functional enrichment analysis
on these 65 genes and discovered significant enrichment in an MSigDB gene set relating to
immune response genes that are up-regulated following lipopolysaccharide treatment
“GSE9988 LPS VS VEHICLE TREATED MONOCYTE UP” (Bonferroni adjusted p-value
0.000948) (S3 Table).
Fig 2. Summary of experimental groups, differentially expressed (DE) genes and differentially abundant (DA) proteins. Three
biological replicates (entire zebrafish brains) were subjected to RNA-seq and LC-MS/MS for each of the four experimental
conditions. Arrows indicate pairwise comparisons (to identify DE genes and DA proteins) between experimental conditions. The
numbers of DE genes and DA proteins determined from RNA-seq and LC-MS/MS analyses are indicated underneath the arrow for
each comparison. We considered genes to be DE and proteins to be DA if the False Discovery Rate [FDR]-adjusted p-value of their
moderated t-test (limma) was below 0.05. All zebrafish of the same age are siblings raised in the same tank.
https://doi.org/10.1371/journal.pone.0227258.g002
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2. Age-dependent ‘inversion’ pattern: A subset of 63 genes with increased expression in
6-month-old heterozygous mutant brains (‘young heterozygous mutant vs. young wild
type’) show decreased expression in 24-month-old heterozygous mutant brains (‘aged het-
erozygous mutant vs. aged wild type’). We call this expression pattern an age-dependent
‘inversion’ between heterozygous mutant and wild type brains, and explore the biological
relevance of the genes involved in this inversion pattern later.
By comparing gene expression in 24-month-old heterozygous mutant and wild type zebra-
fish brains, we can gain insight into a putatively pathological transcriptomic state present in
the brains of aged zebrafish carrying this mutation. We find supporting evidence for 177 genes
that are differentially expressed in heterozygous mutant brains relative to wild type brains (139
down-regulated, 38 up-regulated; FDR-adjusted p-value < 0.05) (Fig 3B; Fig B in S1 File).
Note that not all of these genes are shown in Fig 3B, which only includes genes with log2 fold
change values greater than 0.5 or less than -0.5. To allow for easier interpretation of these 177
genes, we used hierarchical clustering to separate them into groups with distinct expression
patterns based on all four brain-types:
• Inverted (63 genes): Defined as genes showing opposite fold-changes in young heterozygous
mutant brains (‘young heterozygous mutant vs. young wild type’) compared to aged
Fig 3. Differential gene expression between heterozygous mutant (psen1K97fs/+) and wild type (psen1+/+) zebrafish brains at 6
months (young) and 24 months (aged). Only genes with absolute log2 fold change> 0.5 are shown. Genes were considered
differentially expressed if their moderated t-test FDR-adjusted p-value was below 0.05. (A) Differentially expressed genes at 6
months. (B) Differentially expressed genes at 24 months. The differentially expressed genes are grouped into clusters based on
gene expression changes across the four comparisons. Overall, note the similar expression changes in ‘young heterozygous mutant
vs. young wild type’ and ‘aged wild-type vs. young wild-type’ and the contrast of these to comparisons involving aged heterozygous
mutants. This illustrates the accelerated brain aging in young heterozygous mutant brains and the "inverted" gene expression pattern
of aged heterozygous mutant brains.
https://doi.org/10.1371/journal.pone.0227258.g003
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heterozygous mutant brains (‘aged heterozygous mutant vs. aged wild type’). To be included
in this group, genes were required to have an FDR-adjusted p-value < 0.05 in either the
‘young heterozygous mutant vs. young wild type’ or ‘aged heterozygous mutant vs. aged wild
type’ comparison and an unadjusted p-value < 0.05 in the other comparison.
• Inappropriately down-regulated (57 genes): Defined as genes that are down-regulated in
the ‘aged heterozygous mutant vs. young heterozygous mutant’ and ‘aged heterozygous
mutant vs. aged wild type’ comparisons (FDR-adjusted p-value< 0.05 in both).
• Failure to up-regulate (94 genes): Defined as genes that are up-regulated during normal
aging (FDR-adjusted p-value < 0.05 in the ‘aged wild type vs. young wild type’ comparison)
but not up-regulated in the ‘aged heterozygous mutant vs. aged wild type’ comparison.
• Failure to down-regulate (26 genes): Defined as genes that are down-regulated during
normal aging (FDR-adjusted p-value < 0.05 in the ‘aged wild type vs. young wild type’
comparison) but not down-regulated in the ‘aged heterozygous mutant vs. aged wild type’
comparison.
To determine whether these different component groups of the gene expression patterns
are biologically relevant, we assessed each group’s functional enrichment using Gene Ontology
terms, MSigDB gene sets, and Reactome and Interpro pathways (summarised in S3 Table; full
results in S4 Table. Overall, we find statistically significant enrichment (Bonferroni adjusted
p-value< 0.05) for all groups except for the ‘failure to down-regulate’ group. The ‘inverted’
group is significantly enriched in several gene sets related to stress and immune response; the
‘inappropriately down-regulated’ group is significantly enriched in developmental transcrip-
tion factors including homeobox genes; the ‘failure to up-regulate’ group is significantly
enriched in immune responses.
Gene expression changes during aging of the heterozygous mutant
zebrafish brains partially overlap with normal brain aging
Gene expression changes associated with aging in the wild type and heterozygous mutant zeb-
rafish brains only partially overlap. When comparing 24-month-old and 6-month-old wild
type zebrafish brains, 1,795 genes show differential expression. However, when comparing
24-month-old and 6-month-old heterozygous mutant zebrafish brains, 1,072 genes show
altered expression (FDR-adjusted p-value < 0.05). When comparing these two sets of genes,
only 525 genes show fold-changes in the same direction during wild type and heterozygous
mutant aging. These genes can be considered an ‘aging signature’ and are functionally
enriched in gene ontology terms relating to immune function (S3 Table). This suggests that
the heterozygous mutant fish still preserve some immune-related gene expression changes that
occur during normal aging.
Gene expression changes are likely not due to changes in proportions of
brain cell types
It is possible that changes in the proportions of different cell types in the brain could result in
genes being falsely interpreted as differentially expressed. As a preliminary test to see whether
our observations of differential gene expression were artefacts of change in the proportions of
major brain cell types (e.g. astrocytes, microglia, neurons, oligodendrocytes), we checked for
noticeable changes in the average expression for sets of marker genes characteristic of each of
the major brain cell types across the samples in each experimental condition (young wild type,
young heterozygous mutant, aged wild type, aged heterozygous mutant). Representative
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marker genes for microglia were obtained from Oosterhof et al. [36] while gene markers for
astrocytes, neurons, and oligodendrocytes were obtained from Lein et al. [37] The number of
genes used to calculate the average gene expression (in logCPM) was 41 (astrocyte), 99 (micro-
glia), 77 (neuron) and 78 (oligodendrocyte). Although this method is limited in that it does
not account for the significant diversity within these broader cell types nor regional brain dif-
ferences, this level of analysis suggests that broadly, the average expression of gene markers for
the major neural cell types does not appear to change much across experimental conditions. In
addition, no obvious outlier samples were evident (Fig C in S1 File).
Regulation of gene expression in the heterozygous mutant zebrafish brains
differs from normal brain aging
A transcription factor can regulate gene expression by binding to a specific DNA motif in the
promoter region of a gene. We hypothesised that changes in gene expression during normal
aging or differences in gene expression between heterozygous mutant and wild type brains
could be driven by differences in transcription factor activity. To test this, we examined gene
promoter regions for enriched motifs corresponding to known transcription factor binding
sites (summarised in S5 Table; full results in S6 Table). Overall, we find:
1. Numerous known transcription factors likely drive the gene expression changes that
occur during normal zebrafish brain aging. As wild type brains age, the genes which are
differentially expressed are significantly enriched in many known motifs. These motifs cor-
respond to binding sites for interferon regulatory factors (e.g. IRF1, IRF2, IRF8); a binding
site for the PU.1-IRF8 complex; an interferon-stimulated response element (ISRE); and
binding sites for various transcription factors important for essential cellular processes like
proliferation, differentiation, and apoptosis (Atf3, Fra2, Ets-distal, AP-1, Fra1, JunB, BATF,
and ZNF264).
2. Altered glucocorticoid signalling in heterozygous mutant zebrafish brains is likely to
contribute to a pathological state. Promoters of genes that are differentially expressed in
the ‘aged heterozygous mutant vs. aged wild type’ comparison are significantly enriched in
the glucocorticoid receptor element motif (GRE) (Bonferroni p-value = 0.0057). Interest-
ingly, the subset of genes showing inappropriate downregulation (down-regulated in the
‘aged heterozygous mutant vs. young heterozygous mutant’ and ‘aged heterozygous mutant
vs. aged wild type’ comparisons) is more strongly enriched again in the GRE motif (Bonfer-
roni p-value = 0.0001), suggesting that genes that are normally activated by glucocorticoid
signalling during aging may not be activated in aged heterozygous mutant brains. This
altered glucocorticoid signalling appears to be present even in young zebrafish brains, as
genes showing inverted behaviour (opposite direction of differential expression in ‘young
heterozygous mutant vs. young wild type’ and ‘aged heterozygous mutant vs. aged wild
type’ comparisons) are also enriched in the GRE motif (Bonferroni p-value = 0.0047).
Because these inverted genes tend to show high expression in young heterozygous mutant
brains (i.e. up-regulated in the ‘young heterozygous mutant vs. young wild type’ compari-
son) and low expression in aged heterozygous mutant brains (i.e. down-regulated in the
‘aged heterozygous mutant vs. aged wild type’ comparison), this suggests that young hetero-
zygous mutant zebrafish brains may initially exhibit abnormally increased glucocorticoid
signalling, while aged heterozygous mutant brains later exhibit abnormally decreased glu-
cocorticoid signalling. Notably, the inverted genes containing a GRE motif in their promot-
ers include COQ10A (encodes Coenzyme Q10, a key component of the electron transport
chain and free-radical scavenging antioxidant); pik3r3a (encodes regulatory subunit
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gamma of phosphoinositide 3-kinase, an enzyme that interacts with insulin growth factor 1
receptor among other proteins); mmadhc (encodes a protein involved in an early and essen-
tial step of vitamin B12 metabolism), plk3 (polo-like kinase 3, involved in stress response
and double-stranded DNA repair), and fkbp5 (encodes FK506 binding protein, involved in
regulating immune and stress responses, protein trafficking and folding, and glucocorticoid
receptor regulation). A list of zebrafish genes containing the GRE promoter motif is pro-
vided in S7 Table.
Gene expression changes in the heterozygous mutant zebrafish indicate
vast changes to cellular processes and pathways
A gene set is a group of genes that contribute to a known biological function, pathway, or
state. A gene set test is an analysis used to evaluate whether a particular gene set is differen-
tially expressed for a particular comparison. We used the FRY method to test whether
‘Hallmark’ gene sets from the Molecular Signatures Database, MSigDB [38] were associ-
ated with differential expression in each of the four comparisons (Fig 4 and S8 Table).
Using an FDR-adjusted p-value < 0.05 to define a gene set as differentially expressed, we
find:
1. 50 gene sets are differentially expressed during normal brain aging (‘aged wild type vs.
young wild type’) (middle row of heatmap, Fig 4A). This supports that many biological
functions and pathways are altered during normal aging. For some gene sets, the propor-
tion of genes that are up-regulated and down-regulated is similar (e.g. interferon alpha
response, E2F targets, early estrogen response). However, other gene sets contain a predom-
inance of up-regulated genes (e.g. epithelial mesenchymal transition, TNFA signalling via
NFKB) or down-regulated genes (e.g. coagulation, reactive oxygen species pathway).
2. 22 gene sets are differentially expressed in young heterozygous mutant brains (‘young
heterozygous mutant vs. young wild type’) (top row of heatmap, Fig 4A). These 22 gene
sets may represent earlier functional changes in the brain that occur due to this mutation.
The gene sets implicate diverse processes including Wnt/β-catenin signalling, early estro-
gen response, DNA repair, hedgehog signalling and fatty acid metabolism. Similar to the
pattern of accelerated aging observed in Fig 3, we also observe that most of the gene sets
up-regulated in young heterozygous mutant brains are regulated in the same direction
during normal aging. This is consistent with the idea that the biological changes in young
heterozygous mutant brains may partially recapitulate those that occur during normal
brain aging.
3. 44 gene sets are differentially expressed between aged heterozygous mutant and aged
wild type brains (bottom row, Fig 4A). These differentially expressed gene sets may repre-
sent the pathological state of aged zebrafish brains bearing this mutation. Importantly, 21 of
the 22 gene sets that were differentially expressed in young heterozygous mutant brains
(‘young heterozygous mutant vs. young wild type’) remain altered also when these are aged
(‘aged heterozygous mutant vs. aged wild type’). However, the proportions of up- and
down-regulated genes tend to differ; notably, several gene sets containing a predominance
of up-regulated genes in the young heterozygous mutant brains contain a predominance of
down-regulated genes in the old heterozygous mutant brains. These ‘inverted’ gene sets
include biological functions and pathways as diverse as Wnt/β-catenin signalling, early
estrogen response, hedgehog signalling, androgen response, epithelial mesenchymal transi-
tion, DNA repair, apical surface, and TGF-β signalling.
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4. Aging in the heterozygous mutant brains is similar but distinct from aging in wild type
brains. The 50 gene sets differentially expressed during normal brain aging are also differ-
entially expressed during heterozygous mutant brain aging (‘aged heterozygous mutant vs.
young heterozygous mutant’) (Fig 4B). However, proportions of up- and down-regulated
genes differ from those in normal brain aging. This suggests that zebrafish brains bearing
this mutation may not properly regulate certain gene sets during aging (e.g. cholesterol
homeostasis, adipogenesis, DNA repair, hypoxia, Wnt/β-catenin signalling).
Altered protein abundance in the heterozygous mutant zebrafish brains
Despite its high sensitivity, estimating gene expression does not capture regulatory processes
or post-transcriptional modifications that might affect the amount of active protein. Correla-
tion between gene expression and protein abundance in samples from multicellular organisms
has been notoriously low [39], but analysing proteomics data alongside gene expression data
has been shown to be an effective complementary approach [40]. Because of this, we decided
to use LC-MS/MS to compare protein abundance in heterozygous mutant zebrafish brains rel-
ative to wild type siblings. Overall, 323 proteins were reliably quantified across all samples
aged 6 or 24 months. Testing for differential protein abundance was done analogously to
Fig 4. Differential gene set expression in heterozygous mutant (psen1K97fs/+) zebrafish brains compared to wild type siblings.
Values in each cell are the estimated proportions of up- and down-regulated genes for each gene set, for any particular pairwise
comparison shown to the left of the cells. A missing cell indicates that the particular gene set is not differentially expressed for that
particular pairwise comparison. Colours of cells are proportional to the difference between the proportion of up- and down-
regulated genes in a gene set. Differentially expressed gene sets have Mixed FDR below 0.05, indicating genes within the gene set
show statistically significantly altered (up and/or down) expression for a particular comparison. The genes in each gene set are
defined using the “Hallmark” gene set collection at the Molecular Signatures Database (MSigDB). (A) Gene sets showing
differential expression between heterozygous mutant (psen1K97fs/+) and wild type (psen1+/+) zebrafish brains at 6 months
(young) and 24 months (aged). The comparison representing normal aging (aged wild type vs. young wild type) is also shown to
highlight the ‘accelerated aging’ phenomenon in the young heterozygous mutants. (B) Gene sets showing differential expression
during normal aging. The aged K97fs/+ vs. young K97fs/+) comparison is also shown to highlight the phenomenon of aberrant
aging in the heterozygous mutants.
https://doi.org/10.1371/journal.pone.0227258.g004
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testing for differential gene expression, with differences at FDR-adjusted p-value < 0.05 con-
sidered statistically significant. 22 proteins were differentially abundant between 6-month-old
heterozygous mutant and wild type brains, while 65 proteins were differentially abundant
between 24-month-old heterozygous mutant and wild type brains (Fig 5; Fig D in S1 File).
Unexpectedly, three proteins found to be differentially abundant between 6-month-old hetero-
zygous mutant and wild type zebrafish have causative roles in human neurodegenerative dis-
eases: apolipoprotein Eb (encoded by the zebrafish apoeb gene, orthologous to the major
human genetic risk factor for sporadic AD, APOE), superoxide dismutase (encoded by the zeb-
rafish sod1 gene, orthologous to the human SOD1 gene mutated in familial amyotrophic lateral
sclerosis), and protein DJ-1 (encoded by the zebrafish park7 gene, orthologous to the human
PARK7 gene mutated in familial Parkinson’s disease). Overall, correlation between gene
expression and protein abundance was low with rs = 0.4 at 6 months of age and rs = 0.28 at
Fig 5. Protein abundance changes in the brains of heterozygous mutant (psen1K97fs/+) zebrafish compared to wild type (psen1+/+)
siblings at 6 months (young) and 24 months (aged). Protein abundance was quantified at the peptide-level with LC-MS/MS (liquid
chromatography tandem mass spectrometry) and differential abundance was assessed using moderated t-tests (limma). Differentially
abundant proteins are defined as those with FDR-adjusted p-value< 0.05. Protein names were used to retrieve equivalent gene
symbols for display purposes on these heatmaps. (A) Differentially abundant proteins between young heterozygous mutant and
wild type zebrafish brains. (B) Differentially abundant proteins between aged heterozygous mutant and wild type zebrafish
brains. The proteins have been clustered according to their abundance changes across the four comparisons.
https://doi.org/10.1371/journal.pone.0227258.g005
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24 months of age (Figs E and F in S1 File). However, this is overall consistent with previously
reported correlation coefficients in multicellular organisms that range from 0.09 to 0.68 [39]).
Gene expression changes in the heterozygous mutant zebrafish brains can
be compared to those in human AD
Our results indicate that gene expression changes involving diverse cellular processes occur in
aged heterozygous mutant zebrafish brains. The K115fs mutation is a human fAD mutation,
but the majority of human AD cases are sporadic, arise from diverse environmental and
genetic risk factors, and can involve heterogenous pathological changes in the brain. Neverthe-
less, it may be informative to explore the extent to which the changes in aged heterozygous
mutant zebrafish can model those in human AD.
To assess the similarity of these changes to human brains with AD, we compared gene
expression patterns in our zebrafish RNA-seq dataset and an independent human RNA-seq
dataset from the Mayo RNA-seq study. The Mayo RNA-seq dataset includes not only patients
with AD (defined as having dementia symptoms, Braak neurofibrillary tangle stage IV or
greater, and presence of amyloid pathology) and similarly aged controls, but also patients with
other brain afflictions that recapitulate aspects of AD (“pathological aging” patients possessing
amyloid pathology without dementia symptoms, and progressive supranuclear palsy patients
possessing neurofibrillary tangle pathology but no amyloid pathology) [41].
We constructed separate gene co-expression networks from the zebrafish and human
RNA-seq datasets. Each network only included genes that were orthologs in humans and zeb-
rafish. Whilst there are many methods for constructing a co-expression network of gene
expression [42], we used the weighted gene co-expression network analysis (WGCNA) method
[43], which has previously been used to group genes expressed in the brain into “modules”
associated with biological functions or activities [44–48]. The zebrafish brain co-expression
network is shown in Fig 6, and the human brain co-expression network is provided in Fig G
in S1 File.
We identified 30 modules (i.e. groupings of genes) in the zebrafish brain co-expression
network containing between 54 and 1221 genes each and 27 modules in the human brain co-
expression network containing between 62 and 921 genes each. We used two methods to
confirm that most modules represented functional relationships between genes: enrichment
analysis (for identifying enriched biological functions and enriched promoter motifs), and
correlating modules with particular traits of interest (age and/or psen1 genotype). By corre-
lating modules with particular zebrafish traits (age and psen1 genotype), we identified 13
(out of 30) modules showing evidence of altered expression patterns in heterozygous mutant
zebrafish brains (Fig 6B). Using enrichment analysis, we identified the biological relevance
of each module in the zebrafish co-expression network (see Table 1 for a summary, and full
enrichment analysis results are shown in S9–S11 Tables). Overall, the majority of modules in
the zebrafish and human networks show significant enrichment in known functional anno-
tations (e.g. Gene ontology terms, MSigDB gene sets, KEGG pathways, with Bonferroni-
adjusted p-value < 0.05), supporting the idea that these modules are likely to represent bio-
logically relevant groupings of genes. Some of the biological functions represented by differ-
ent modules in the zebrafish brain include: G-protein coupled receptor signalling pathway
(represented by module 13), TGF-β and Wnt/β-catenin signaling (represented by module
15), PI3K/AKT activation (represented by module 18), immune response (represented by
module 20), regulation of MAPK cascade (represented by module 26), and oxidative phos-
phorylation (represented by module 27). The genes in several modules in the zebrafish net-
work were also significantly enriched in promoter motifs including the glucocorticoid
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Fig 6. Zebrafish brain gene co-expression network. (A) Gene co-expression network visualisation. Each node
represents one gene, with node size proportional to the number of connected nodes (co-expressed genes). Edges represent
co-expression between two genes, with edge weight proportional to the strength of co-expression. The co-expression
network is a signed adjacency matrix constructed from RNA-seq data from wild type and heterozygous mutant zebrafish
brains at 6 and 24 months of age. Only nodes with at least four connections are shown. Gene "modules" are groups of
genes with similar expression patterns across heterozygous mutant and wild type zebrafish brains. In this network, 30
gene modules were identified using a hierarchical clustering and branch cutting method. Modules showing no significant
changes in expression are coloured grey, modules showing significantly increased expression during wild-type brain
aging are coloured red, while modules showing significantly decreased expression during wild-type brain aging are
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receptor element (GRE) motif (for genes in module 18), GATA3 motif (for genes in module
23), and numerous ETS transcription factor motifs (for genes in module 20) (Bonferroni-
adjusted p-values < 0.05) (S12 Table).
Several pathological changes in the heterozygous mutant zebrafish brains
are similar to those in human AD brains
There are several methods for assessing whether modules are preserved across two indepen-
dent gene co-expression networks constructed using the same genes [49]. The most easily
interpretable method is to compare directly the assignment of equivalent genes to modules
identified in each network. The resulting overlap in gene co-expression patterns across the two
networks can be visualised using a Sankey diagram (Fig 7). Overall, the gene co-expression
patterns in the zebrafish brain appear to be broadly similar to the gene co-expression patterns
in the human brain, despite differences in RNA-seq platform and brain regions used, which
would be expected to make the networks less comparable. A more sophisticated method of
assessing module preservation involves using permutation-based Z-statistics to test whether
certain properties of modules (e.g. density, connectivity) defined in one co-expression network
are preserved in another network [49]. Z-statistics for each module property can be summa-
rised into a Z-summary score, with Z-summary scores less than 2 indicating no module preser-
vation, scores between 2 and 10 indicating weak to moderate module preservation, and scores
above 10 indicating strong preservation [49]. When comparing zebrafish and human brain co-
expression networks, four of the 30 zebrafish modules (16, 20, 13, 26) have Z-summary scores
between 2 and 10, indicating weak to moderate preservation in the human co-expression net-
work (Table 1, S9 Table). While modules 16 (enriched in functions relating to ribosome and
nonsense mediated decay) and 13 (enriched in G-protein coupled receptor activity) do not
show significant differences between heterozygous mutant and wild-type brains as they age,
modules 20 and 26 display distinct coordinated changes in expression during aging of wild-
type brains. Module 20 genes are enriched in immune response functional terms and tend to
be up-regulated with aging (correlation p-value 0.01), while module 26 genes are enriched in
terms relating to regulation of the MAPK cascade and tend to be down-regulated with aging
(correlation p-value 0.05, Fig 6). Importantly, these coordinated gene expression changes
appear to be lost in aged heterozygous mutant brains (correlation p-values of 0.3 and 0.3
respectively), suggesting the K97fs mutation in psen1 may contribute to alterations in at least
these biological functions. Notably, module 26 which is enriched in immune response func-
tions also displays significant enrichment in ETS and IRF promoter motifs (see Table 1, all
FDR-adjusted p-values < 0.05). The equivalent module in the human co-expression network
also displays enrichment in these particular motifs, suggesting that the regulation of immune
and microglial gene expression responses is likely well conserved between aged zebrafish and
human brains.
coloured blue. Modules with other colours also show signficantly altered expression during heterozygous mutant brain
aging. See B for details. Asterisks indicate zebrafish brain gene modules which are significantly preserved in a co-
expression network constructed from an independent human brain dataset. (B) Gene expression patterns of modules in
the gene co-expression network across heterozygous mutant and wild type zebrafish brains at 6 months and 24
months of age. Values shown in cells are hybrid Pearson-robust correlations between the overall gene expression in a
module (summarised using the first principal component) and experimental condition encoded as a binary variable
(6-month-old heterozygous mutant, 24-month-old heterozygous mutant, 6-month-old wild type, 24-month-old wild
type). Values in parentheses are unadjusted Student correlation p-values. Modules showing potentially altered expression
patterns during heterozygous mutant aging compared to wild-type aging are labelled with coloured text, with colours
corresponding to module colours in (A). Asterisks indicate zebrafish brain gene modules which are significantly
preserved in a co-expression network constructed from an independent human brain dataset.
https://doi.org/10.1371/journal.pone.0227258.g006
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Table 1. Summary of modules in a co-expression gene expression network constructed from zebrafish RNA-seq data and their preservation in an independent







Top Functional Enrichment Terms
(FDR p-value < 0.05)
Promoter Motif Enrichment





Random 1000 -0.450372394 - - -
1 262 0.951510976 Sarcomere, muscle structure
development
- -
2 209 1.967152607 Extracellular matrix organisation EKLF(Zf) -
3 137 0.864232356 Sequence specific DNA binding,
AP2 transcription factors
- -
4 54 0.097738923 - - -
5 133 0.342079228 Homeobox genes - -
6 212 -0.201216548 L27 protein domain - -
7 98 1.004032939 - - -
8 67 0.62219677 Vacuolar membrane - -
9 1493 3.032384176 - - -
10 57 -0.720174553 - - -
11 319 -0.828726101 Mismatch repair - -
12 163 0.101290609 - - -
13 668 3.95602259 G-protein coupled receptor
signalling pathway
- Neuron
14 81 0.842726312 Gland morphogenesis, Notch Hoxb4(Homeobox) -
15 82 1.741071825 Transcription factor binding - -
16 62 5.804071733 Ribosome, nonsense mediated
decay
GFX, ZBTB33(Zf), ERG(ETS) -
17 59 1.92925347 Synapse part, regulation of synaptic
plasticity
- -
18 189 -0.849139273 PI3K/AKT activation GRE(NR) -
19 1221 0.552830789 Cholesterol biosynthesis - -
20 381 5.071793968 Immune response SpiB(ETS), ELF3(ETS), PU.1(ETS), IRF1(IRF), IRF8(IRF), PU.1-IRF
(ETS:IRF), EWS:ERG-fusion(ETS), ELF5(ETS), IRF3(IRF), IRF2(IRF),
ISRE(IRF), EHF(ETS), PU.1:IRF8(ETS:IRF), EBF(EBF), SPDEF(ETS)
Microglia
21 97 -0.689019253 Semaphorin receptor activity,
integral component of membrane
- -
22 127 0.53275753 - - -
23 309 1.081006115 Zinc Finger C2H2 GATA3(Zf) -
24 103 0.322883371 Oxidative phosphorylation, fatty
acid metabolism
- -
25 55 -0.250719822 - - -
26 90 2.432423753 Regulation of MAPK cascade - -
27 69 -0.222869961 Oxidative phosphorylation - -
28 59 0.023104171 Pattern specification process,
cardiovascular system development
- -
29 171 0.553682784 Phototransduction - -
30 549 -0.624680799 Response to DNA damage ETS1 -
The Z-Summary preservation score is a statistic that aggregates various Z-statistics obtained from permutation tests of the coexpression network to test whether network
properties such as density and connectivity in the zebrafish co-expression network are preserved in an independent co-expression network constructed from human
brain gene expression data. In this analysis, 200 permutations were used. Z-summary scores less than 2 indicate no preservation, while scores between 2 and 10 indicate
weak-to-moderate evidence of preservation. The top functional enrichment and cell type marker enrichment terms are used to give insight into possible biological
functions represented within each module. Cell type marker enrichment gene sets are from MSigDB, while functional enrichment terms are from Gene Ontology and
MSigDB gene sets. The “Random” module is a random sample of 1,000 genes in the zebrafish co-expression network expected to show non-significant preservation (Z-
summary < 2) in the human co-expression network. Shaded rows indicate zebrafish gene modules identified as showing significant preservation in the human network.
https://doi.org/10.1371/journal.pone.0227258.t001
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Fig 7. Module overlap between co-expression networks constructed using zebrafish and human brain gene expression data.
Zebrafish and human co-expression networks were constructed using 7,118 genes that were orthologs in zebrafish and humans and
expressed in brain gene expression data. Modules of co-expressed genes were separately identified for both the zebrafish and human co-
expression networks, resulting in 30 modules in the zebrafish network (left) and 27 modules in the human network (right). Several
zebrafish modules (indicated with asterisks) were found to have Z-summary preservation score> 2, indicating statistically significant
weak-to-moderate preservation of these modules (i.e. genes in these modules still tend to be co-expressed) in the human brain co-
expression network. Four out of five of these modules also showed statistically significant functional enrichment. See Table 1 for more
details on the Z-summary preservation scores and functional enrichment for each module in the zebrafish co-expression network.
https://doi.org/10.1371/journal.pone.0227258.g007
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Aged heterozygous mutant brains possess increased abundance of
microglia
The changes we observed in immune-microglia gene co-expression in the aged heterozygous
mutant brains prompted us to ask whether differences might be observable in microglial form
or even abundance. We used immunostaining for the pan-leukocyte marker L-plastin to detect
microglia on sections of fixed brain material from 24-month-old wild type and heterozygous
mutant zebrafish (Fig 8). An increased abundance of cells expressing L-plastin was evident in
psen1K97fs/+ heterozygotes in both ventricular (Fig 8C.i and 8E.i) and parenchymal (Fig 8C.ii
and 8F.i) regions compared to wild type brains (Fig 8D.i and 8D.ii). We observed significant
differences in mean fluorescent intensity (MFI) of the image in the L-plastin channel indicat-
ing increased abundance of cells expressing L-plastin in the forebrain, midbrain and hindbrain
regions of heterozygous mutant and wild type fish (Fig 8G, p = 0.0048, p = 0.0005, p<0.0001
respectively; two-way ANOVA with Sidak’s multiple comparisons test). This immunostaining
was also capable of distinguishing between distinct morphologies of microglia in the ventricu-
lar (amoeboid “activated” morphology) and parenchymal (ramified morphology) regions in
the zebrafish brain (Fig H in S1 File) although there was no obvious variation in morphology
observed between heterozygous mutant and wild type brains.
Molecular changes in the aged heterozygous mutant zebrafish brains occur
without obvious histopathology
Teleosts (bony fish) such as the zebrafish show impressive regenerative ability following tissue
damage that includes repair of nervous tissue. Previous attempts to model neurodegenerative
Fig 8. Cells expressing L-plastin are more abundant across the heterozygous mutant (psen1K97fs/+) zebrafish brain than in wild type siblings at 24
months. Immunostaining for the pan-leukocyte marker L-plastin supports increased numbers of microglia in the forebrain (A-B), midbrain (C-D) and
hindbrain (E-F). Increased microglial abundance is evident in psen1K97fs/+ heterozygotes in both ventricular (D.i, F.i) and parenchymal (D.ii) regions
compared to wild types (C, E). (G) Significant differences in MFI were observed between the forebrain, midbrain and hindbrain of psen1K97fs/+ and
psen1+/+ fish; ��p = 0.0048, ���p = 0.0005, ����p< 0.0001; two-way ANOVA with Sidak’s multiple comparisons test. Data presented as means with
SEM. Scale bar 50 μm in all images.
https://doi.org/10.1371/journal.pone.0227258.g008
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diseases in adult zebrafish have failed to show cellular phenotypes [50]. Also, zebrafish are
thought unlikely to produce the Aβ peptide [51] that many regard as central to AD pathologi-
cal mechanisms [52]. The analyses described in this paper support that a fAD mutation mim-
icking PS2V formation may accelerate aspects of brain aging and promote a shift in aged
heterozygous mutant brains towards an altered, pathological state of gene and protein expres-
sion. We therefore made histopathological comparisons of aged (24 months) wild type and
heterozygous mutant brains equivalent to those used in our ‘omics analyses. Analysis of vari-
ous brain regions using markers of aging, senescence and amyloid accumulation (lipofuscin,
senescence-associated β-galactosidase, and Congo Red staining respectively) revealed no
discernible differences (see Materials and methods and Figs I-K in S1 File). This is consistent
with the lack of neurodegenerative histopathology observed in a heterozygous knock-in model
of a PSEN1 fAD mutation in mice [25].
Discussion
Fig 9 summarises the main molecular changes that occur with aging and heterozygous
mutation.
Evidence of increased stress long preceding AD
We identified a subset of ‘inverted’ genes that are up-regulated in young heterozygous mutant
brains, but down-regulated in aged heterozygous mutant brains. Although this pattern might
be overlooked, similar patterns have been observed in human cases. Patients with Mild Cogni-
tive Impairment, pre-clinical AD, or Down Syndrome (who often develop AD in adulthood)
initially display increased expression of particular genes, which show decreased expression
when AD symptoms become more severe [23, 53–55]. Collectively, results from these studies
and our heterozygous mutant zebrafish suggest that early increases in brain activity likely pre-
cede AD symptoms in both PSEN1-mutation carriers and more general cases of AD. Evidently,
to find strategies for preventing AD progression while patients are still asymptomatic, it is
important to understand the causes of this increased gene activity in the brain.
Our results suggest that stress responses likely contribute to early increases in brain activity
for fAD mutation carriers. In heterozygous mutant zebrafish, the inverted gene expression pat-
tern seems to arise from altered glucocorticoid signalling. In humans, chronically increased
glucocorticoid signalling in the brain can lead to glucocorticoid resistance, whereby the brain
is unable to increase glucocorticoid signalling even during stressful conditions [56, 57]. We
did not confirm whether glucocorticoid signalling and cortisol levels were altered in zebrafish
brains in vivo. However, many of the inverted genes possess glucocorticoid receptor elements
in their promoters, with one particular inverted gene (fkbp5) encoding a protein which is
known to bind directly to the glucocorticoid receptor to negatively regulate its activity. Previ-
ous studies in humans demonstrate that fkbp5 levels are highly responsive to chronic stress
and stress-related diseases (e.g. bipolar disorder; depression in AD [58]), implying that fkbp5
expression is a sensitive marker of glucocorticoid signalling. Our analysis supports this idea,
with fkbp5 mRNAs showing a significant difference in expression between heterozygous
mutant and wild type brains (logFC = 2.1, FDRp = 1.77e-06 in young heterozygous mutant vs
wild type; logFC = -3.9, FDRp = 3.16e-08 in aged heterozygous mutant vs wild type). Aside
from altered glucocorticoid signalling, we also found altered gene expression patterns associ-
ated with diverse biological changes in heterozygous mutant zebrafish brains. If we assume
that these heterozygous mutant zebrafish model some aspects of human AD, then these alter-
ations may offer insight into early changes in the brains of human fAD-mutation carriers and,
potentially, other individuals predisposed to AD. The brains of young heterozygous mutant
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zebrafish exhibit changes relating to developmental signalling pathways (Wnt/β-catenin sig-
nalling, hedgehog signalling, TGF-β signalling), stress and immune responses (DNA repair,
IL2-STAT5 signalling, complement system, IFN-γ response, inflammatory response), hor-
monal changes (early and late estrogen responses, androgen response), and energy metabolism
(glycolysis, oxidative phosphorylation). Appropriate regulation of these biological processes is
critical for brain function, so it is unsurprising that disruption of these processes in the brain
Fig 9. Summary of the molecular changes in the brains of zebrafish due to aging and/or the K115fs-like mutation (psen1K97fs/+). For each of the
four pairwise comparisons shown, the summarised molecular changes (" = overall increased, # = overall decreased, • = significant alterations but not in
an overall direction) were inferred from a combination of the following analyses: functional enrichment analysis of differentially expressed genes and
proteins, promoter motif enrichment analysis of differentially expressed genes, gene set enrichment analysis of differentially expressed genes, and
weighted co-expression network analysis of the gene expression data.
https://doi.org/10.1371/journal.pone.0227258.g009
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has been linked previously to various pathological states, including early stages of neurodegen-
eration [59–62].
Quantifying protein abundance in young heterozygous mutant zebrafish brains revealed
additional sources of early-life stress. In young heterozygous mutant zebrafish brains, proteins
associated with oxidative stress responses and energy metabolism in mitochondria already
demonstrated altered abundance. Overall, stress responses were increased, consistent with the
RNA-seq data, and decreased abundance of metabolic and antioxidant proteins imply mito-
chondrial function was likely already impaired. Both increased oxidative stress and altered
energy metabolism are known to be early events in AD [2, 63–69], consistent with the idea
that these events may contribute to early stress responses in the brain.
Involvement of microglia-mediated immune responses in AD
Our analysis identified two modules with altered gene co-expression patterns in both the aged
heterozygous mutant zebrafish brains and post-mortem human AD brains. These modules
demonstrated significant functional enrichment in immune and microglial responses (module
20 in the zebrafish network) and regulation of the MAPK cascade (module 26 in the zebrafish
network), consistent with their well-established dysfunction in human AD [9, 36, 70, 71].
Gene co-expression changes associated with the immune-microglia responses and the MAPK
cascade were evident in aged but not young heterozygous mutant brains, suggesting that these
changes are likely to occur in later stages of AD pathogenesis. Our results are consistent with
two independent studies involving co-expression analysis of AD brains by Miller et al. [47]
and Zhang et al. [48] which also identified a prominent immune-microglia module demon-
strating similar changes in gene co-expression in AD patients, despite differences in patient
cohorts used, brain regions and tissue types sampled, RNA-seq or microarray platforms,
and methodology used to construct the gene co-expression networks. Collectively, the results
from these studies and our analysis support the involvement of microglia-mediated immune
responses in late stages of AD pathogenesis.
Our analysis reveals additional insights that help explain the involvement of the immune-
microglia module in AD. Promoter enrichment analysis of genes in the immune-microglia
module indicates statistically significant enrichment in several known motifs. Interestingly, all
of these motifs are binding sites for transcription factors from either the ETS (SpiB, ELF3,
ELF5, PU.1, EHF) or IRF (IRF3, IRF8, IRF1) families. This finding is important, because 1)
ETS and IRF transcription factor motifs are also enriched in the promoters of genes that are
up-regulated with brain aging in wild type zebrafish, but not in genes that are up-regulated
with brain aging in heterozygous mutant zebrafish. This suggests that the genes they regulate
are important during normal brain aging and that their dysregulation may contribute to
pathology. 2) ETS and IRF transcription factors are known to mediate critical biological func-
tions, with ETS factors regulating cellular differentiation, proliferation, cell-cycle control, apo-
ptosis, migration and mesenchymal-epithelial interactions [72, 73], and IRF factors mediating
immune and other stress responses. Our results are consistent with those in a previous study
by Gjoneska et al. [74] that analysed RNA-seq and ChIP-seq (chromatin immunoprecipitation
sequencing) data from mouse and human brain tissues, which found that immune response
genes were up-regulated in both the CK-p25 mouse model and in human sporadic AD, that
these genes were enriched in ChIP-seq peaks corresponding to ETS and IRF transcription
factor motifs, and that microglia-specific activation was likely responsible for these gene
expression changes.
Immunohistochemistry on sections from aged brains to identify L-plastin-expressing
cells, (thought to represent microglia), revealed an increased abundance of these cells in
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heterozygous mutant fish compared to wild type fish but no obvious genotype-dependent dif-
ferences in cell morphologies. The concentration of these cells in ventricle-proximal regions
suggests an involvement with neural cell proliferation [75] which might occur in the regenera-
tive zebrafish brain if the rate of cell turnover was increased due to pathological processes and
this deserves future investigation. The increased abundance of L-plastin-expressing cells was
not reflected in a noticeable increase in the mean expression of multiple microglial marker
genes from the RNA-seq data. However, the RNA-seq data was derived from entire zebrafish
brains and this may have obscured region-specific differences in microglial abundance, mor-
phology, and activation.
Heterozygous mutant zebrafish in our study overall appear to recapitulate partially cer-
tain transcriptional and molecular changes that occur in more general cases of sporadic AD.
Although revealing valuable insights, our comparison of the gene co-expression patterns in
the zebrafish and human datasets is limited by inherent differences in species-level gene
expression, differences in the brain regions and tissues sampled in each dataset, and differ-
ence in the RNA-seq platforms used to collect data, which has been previously shown to
affect network properties including connectivity and density of modules [42]. In addition,
the heterogeneity of sporadic AD would likely result in variation in gene expression patterns
which may also confound our ability to identify reliably gene modules showing similar
expression patterns across all samples. All of these differences would likely have contributed
to decreasing our ability to detect preservation of modules between the zebrafish and human
co-expression networks.
AD-like gene expression changes can occur without amyloid pathology
typically associated with AD
Somewhat surprisingly, the gene and protein expression changes observed in our aged hetero-
zygous mutant zebrafish were not reflected in an obvious histopathology. However, this is
consistent with an attempt to model neuronal ceroid lipofuscinosis in adult zebrafish [50]
and with observations from heterozygous fAD mutation knock-in models in mice [25–27]
(although, in general, mouse single heterozygous mutation brain histology phenotypes have
not been reported). It is important to realise that differences in scale between the mass of
a human brain and the brains of mice and zebrafish, (~1,000-fold and ~200,000 fold
respectively) mean that any metabolic or other stresses in the small brains of the genetic mod-
els are likely exacerbated in the huge human brain [76]. Human brains also lack the regenera-
tive ability of zebrafish, while mice and zebrafish both show sequence divergences in the Aβ
regions of their APP orthologous genes greater than seen in most mammals [33, 77, 78]. Nev-
ertheless, the heterozygous fAD-like mutation models of mice and (with this paper) zebrafish
are probably the closest one can come to modelling AD in these organisms without subjec-
tively imposing an opinion of what AD is by addition of further mutations or transgenes.
It is important to remember that the pathological role in AD of Aβ, neuritic plaques, and
neurofibrillary tangles is still debated and that around one quarter of people clinically diag-
nosed with AD lack typical amyloid pathology upon post-mortem examination [79]. By the
current definition, these people do not have AD [80] although this restrictive definition has
been questioned [81, 82]. Many people also have brains containing high levels of Aβ [83] or
Braak stage III to VI neurodegeneration [79] without obvious dementia. Thus the connection
between amyloid pathology, histopathological neurodegeneration and Alzheimer’s disease
dementia is unclear. Our data indicate that the AD cellular pathologies may occur subsequent
to cryptic but dramatic changes in the brain’s molecular state (gene and protein expression)
that are the underlying drivers of AD.
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Finally, it is also important to acknowledge that the specific fAD mutation modelled in this
study (K115fs of PSEN2) is an uncommon fAD mutation which produces novel alternative
transcripts and splice isoforms, and it is unclear how pathogenic effects of this mutation might
compare to other more common fAD mutations [84]. When beginning this research, we ini-
tially hypothesised that the alternative protein product PS2V (exon 6 deletion) produced from
mutant K115fs PSEN2 played a pathogenic role in AD. PS2V has previously been detected in
sAD brains [29], and our previous research suggested dominant-negative effects of the func-
tionally similar PS2V-like protein product produced from zebrafish psen1 [32, 85]. Recent
research suggests that some aberrant transcripts derived from the human K115fs mutant allele
may, in fact, follow the "fAD mutation reading frame preservation rule" that is obeyed by all
other fAD mutations in the PSEN genes [84]. If this is true, then our zebrafish model of K115fs
is best regarded as illuminating the contribution that PS2V-mimicry by the K115fs mutation
can make to its overall fAD phenotype. Nevertheless, our results indicate that the contribution
made by such PS2V-mimicry is likely to be very significant. Our laboratory has been develop-
ing additional heterozygous mutant zebrafish modelling other forms of fAD mutation [86],
and future analysis incorporating these zebrafish to produce a consensus co-expression net-
work should help to identify and refine a “signature” of the transcriptome and proteome
changes that cause fAD.
Materials and methods
Zebrafish husbandry and animal ethics
This study was approved under permits S-2014-108 and S-2017-073 issued by the Animal Eth-
ics Committee of the University of Adelaide. Tübingen strain zebrafish were maintained in a
recirculated water system.
Generation of TALEN coding sequences and single stranded
oligonucleotide
TALEN coding sequences were designed by, and purchased from, Zgenebio (Taipai City,
Taiwan). The DNA binding sites for the TALEN pair targeting psen1 were (5’ to 3’): left site,
CAAATCTGTCAGCTTCT and right site, CCTCACAGCTGCTGTC (Fig A in S1 File). The coding
sequences of the TALENs were provided in the pZGB2 vector for mRNA in-vitro synthesis.
The single stranded oligonucleotide (ssoligo) sequence was designed such that the dinucleotide
‘GA’ deletion was in the centre of the sequence with 26 and 27 nucleotides of homology on
either side of this site (Fig A in S1 File). The ssoligo was synthesized by Sigma-Aldrich
(St. Louis, Missouri, USA) and HPLC purified. The oligo sequence was (5’ to 3’): CCATCAAA
TCTGTCAGCTTCTACACACAAGGACGGACAGCAGCTGTGAGGAGC (Fig A in S1 File).
In-vitro mRNA synthesis
Each TALEN plasmid was linearized with Not I. Purified linearized DNA was used as a tem-
plate for in-vitro mRNA synthesis using the mMESSAGE mMACHINE SP6 transcription kit
(Thermo Fisher, Waltham, USA) as per the manufacturer’s instructions as previously
described [85].
Microinjection of zebrafish embryos
Embryos were collected from natural mating and, at the 1-cell stage, were microinjected with a
~3nl mixture of 250ng/μl of left and right TALEN mRNA and 200ng/μl of the ssoligo.
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Genomic DNA extraction of zebrafish tissue
Embryos. A selection of 10–20 embryos were collected at 24 hpf and placed in 150μl of a
50mM NaOH 1xTE solution and then incubated at 95˚C until noticeably dissolved (10-
20mins). The lysis solution was cooled to 4˚C and 50μl of Tris solution (pH 8) was added. The
mixture was then centrifuged at maximum speed for 2 mins to pellet cellular debris. The
supernatant was transferred into a fresh microfuge tube ready for subsequent PCR.
Adult fin clips. For fin clips, adult fish were first anesthetised in a 0.16 mg/mL tricaine
solution and a small section of the caudal fin was removed with a sharp blade. Fin clips were
placed in 50μl of a 1.7 μg/ml Proteinase K 1xTE solution and then incubated at 55˚C until
noticeably dissolved (2-3hours). The lysis solution was then placed at 95˚C for 5mins to inacti-
vate the Proteinase K.
Genomic DNA PCR and sequencing for mutation detection
To genotype by PCR amplification, 5 μl of the genomic DNA was used with the following
primer pairs as relevant. Primers to detect wild type (WT) sequence at the mutation site:
primer psen1WTF: (5’TCTGTCAGCTTCTACACACAGAAGG3’) (GA nucleotides in italics)
with primer psen1WTR: (5’AGTAGGAGCAGTTTAGGGATGG3’). Primers to detect the pres-
ence of the GA dinucleotide deletion: primer psen1GAdelF: (5’AATCTGTCAGCTTCTACAC
ACAAGG3’) with primer psen1WTR. To confirm the presence of the GA dinucleotide dele-
tion mutation by sequencing of extracted genomic DNA, PCR primers were designed to
amplify a 488 bp region around the GA mutation site: primer psen1GAsiteF: (5’GGCACA
CAAGCAGCACCG3’) with primer psen1GAsiteR: (5’TCCTTTCCTGTCATTCAGACCTG
CGA3’). This amplified fragment was purified and sequenced using the primer psen1seqF:
(5’ AGCCGTAATGAGGTGGAGC 3’). All primers were synthesized by Sigma-Aldrich. PCRs
were performed using GoTaq polymerase (Promega, Madison, USA) for 30 cycles with an
annealing temperature of 65˚C (for the mutation-detecting PCR) or 61˚C (for the WT
sequence-detecting PCR) for 30 s, an extension temperature of 72˚C for 30 s and a denatur-
ation temperature of 95˚C for 30 s. PCR products were assessed on 1% TAE agarose gels run
at 90V for 30 mins and subsequently visualized under UV light.
Whole brain removal from adult zebrafish
Adult fish were euthanized by sudden immersion in an ice water slurry for at least ~30 seconds
before decapitation and removal of the entire brain for immediate RNA or protein extraction.
All fish brains were removed during late morning/noon to minimise any influence of circadian
rhythms.
RNA extraction from whole brain
Total RNA was isolated from heterozygous mutant and WT siblings using the mirVana
miRNA isolation kit (Thermo Fisher). RNA isolation was performed according to the manu-
facturer’s protocol. First a brain was lysed in a denaturing lysis solution. The lysate was then
extracted once with acid-phenol:chloroform leaving a semi-pure RNA sample. The sample was
then purified further over a glass-fiber filter to yield total RNA. This procedure was formulated
specifically for miRNA retention to avoid the loss of small RNAs. Total RNA was then sent to
the ACRF Cancer Genomics Facility (Adelaide, Australia) to assess RNA quality and for subse-
quent RNA sequencing on the Illumina NextSeq platform as paired-end 100bp reads.
RNA extraction and cDNA synthesis from entire brains for digital PCR. Total RNA was
extracted using the QIAGEN RNeasy Mini Kit according to the manufacturer’s protocol. The
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RNA was DNase-treated using RQ1 DNase (Promega) according to the manufacturer’s proto-
col prior to cDNA synthesis. Equal concentrations of total RNA from each brain were used to
synthesise first-strand cDNA by reverse transcription with random priming (Superscript III kit;
Invitrogen). cDNA was RNaseH treated before use in 3D Quant Studio Digital PCR.
Allele-specific digital quantitative PCR. Digital PCR was performed on a QuantStudio™
3D Digital PCR System (Life Technologies, Carlsbad, California, USA). 20μL reaction mixes
were prepared containing 9 μL 1X QuantStudio™3D digital PCR Master Mix (Life Technolo-
gies), 2 μL of 20X Sybr1 dye in TE buffer, 25ng cDNA per total reaction (determined from the
RNA concentration under the assumption that single strand cDNA synthesis from total RNA
was complete), 200nM of specific primers and 6.3 μL of nuclease-free water (Qiagen). 14.5μL
of the reaction mixture was loaded onto a QuantStudio™3D digital PCR 20 K chip (Life Tech-
nologies) using an automatic chip loader (Life Technologies) according to manufacturer’s
instructions. Loaded chips underwent thermo-cycling on the Gene Amp 9700 PCR system
under the following conditions: 96˚C for 10 min; 45 cycles of 60˚C for 2 min and 98˚C for 30
sec; followed by a final extension step at 60˚C for 2 min. After thermo-cycling, the chips were
imaged on a QuantStudio™ 3D instrument [87, 88]. Primers used for psen1 allele detection
were: wild-type allele forward 5’ CTACACACAGAAGGACGGACAGC 3’, K97fs allele forward
5’ TCTGTCAGCTTCTACACACAAGGA 3’ and both were paired with a common reverse
primer 5’ GCCAGGCTTGAATCACCTTGTA 3’.
PCR test for aberrant splicing in the region of the K97fs mutation in zebrafish psen1.
Total RNA was extracted from each 24-month-old zebrafish brain using the QIAGEN RNeasy
mini Kit (QIAGEN, Hilden, Germany). 250ng of total RNA from each brain was then used to
synthesise 20μL of first-strand cDNA by reverse transcription (SuperScript III kit, Invitrogen,
Camarillo, California, USA). 10ng of each cDNA preparation (a quantity calculated from the
RNA concentration on the assumption that reverse transcription of RNA into cDNA was com-
plete) was used to perform PCR using Phusion high-fidelity DNA polymerase (New England
Biolabs, Ipswich, Massachusetts). Each 25μL PCR reaction contained 0.2mM of deoxyribonu-
cleotide triphosphates (dNTPs), 0.4μM of each PCR primer, 1 unit of Phusion polymerase and
10ng of zebrafish brain cDNA template. PCR cycling was performed with 35 cycles of a dena-
turation temperature of 95˚C for 30s, then an annealing temperature of 60˚C for 30s and then
an extension temperature of 72˚C for 2 minutes. PCR products were electrophoresed through
a 1% agarose gel in 1×TAE buffer for separation and identification.
Protein extraction and proteomic analysis of adult brain
Sample preparation. Freshly removed entire adult zebrafish brains were lysed under
denaturing conditions in 7 M urea (Merck, Darmstadt, Germany) plus complete protease
inhibitors (Roche) using a Bioruptor (Diagenode, Seraing, Belgium) in ice cold water. Samples
were quantified using the EZQ protein assay (Life Technologies) and the extracts were trypsin-
digested using the FASP method [89]. Protein samples were then sent to the Adelaide Proteo-
mics Centre (Adelaide, Australia) for quantification and data acquisition.
Data acquisition. Nano-LC-ESI-MS/MS was performed using an Ultimate 3000 RSLC
system (Thermo Fisher Scientific) coupled to an Impact HD™ QTOF mass spectrometer
(Bruker Daltonics, Bremen, Germany) via an Advance Captive Spray source (Bruker Dal-
tonics). Peptide samples were pre-concentrated onto a C18 trapping column (THC164535,
Thermo Fisher) at a flow rate of 5 μL/min in 2% (v/v) ACN 0.1% (v/v) FA for 10 minutes.
Peptide separation was performed using a 75μm ID 50 cm C18 column (THC164540, Thermo
Fisher) at a flow rate of 0.2 μL/minute using a linear gradient from 5 to 45% B (A: 5% (v/v)
ACN 0.1% (v/v) FA, B: 80% (v/v) ACN 0.1% (v/v) FA) over 180 minutes. MS scans were
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acquired in the mass range of 300 to 2,200 m/z in a data-dependent fashion using Bruker’s
Shotgun Instant Expertise™ method (singly charged precursor ions excluded from acquisition,
CID from 23% to 65% as determined by the m/z of the precursor ion).
Data analysis. The acquired peptide spectra were identified and quantified using the mass
spectrometry software MaxQuant with the Andromeda search engine against all entries in the
non-redundant UniProt database (protein and peptide false discovery rate set to 1%). The
MaxQuant software allows for the accurate and robust proteomewide quantification of label-
free mass spectrometry data [90].
RNA-seq analysis
Data processing. We used FastQC [91] to evaluate the quality of the raw paired-end
reads. Using AdapterRemoval [92], we trimmed reads and removed adapter sequences. From
the FastQC reports, some over-represented sequences in the raw and trimmed reads corre-
sponded to ribosomal RNA, possibly from insufficient depletion during library preparation.
We removed ribosomal RNA sequences in silico by aligning all trimmed reads to known zebra-
fish ribosomal RNA sequences and discarding all reads that aligned. Next, we used HISAT2
[93] to align reads to the Ensembl zebrafish genome assembly (GRCz10). Using Picard [94]
and the MarkDuplicates function, we removed optical and PCR duplicates from the aligned
reads. To quantify gene expression, we used FeatureCounts [95], resulting in a matrix of gene
expression counts for 32,266 genes for the 12 RNA-seq libraries.
Differential gene expression analysis. Differential gene analysis was performed in R [96]
using the packages edgeR [97] and limma [98–100]. We retained 18,296 genes with>1.5 cpm
in at least 6 of the 12 RNA-seq libraries. We then calculated TMM-normalisation factors to
account for differences in library sizes and applied the RUVs method from the RUVseq pack-
age [101] to account for a batch effect with one factor of unwanted variation (k = 1). Differen-
tial gene expression analysis was performed using limma. We considered genes differentially
expressed if the FDR-adjusted p-value associated with their moderated t-test was below 0.05.
We used the pheatmap R package [102] to produce all heatmaps.
Gene set testing. We downloaded the Hallmark gene set collection from MSigDB v6.1
[38]. Using biomaRt [103, 104], we converted human Entrezgene identifiers to zebrafish
Entrezgene identifiers. To perform gene set testing, we applied the fast rotation gene set testing
(FRY) method [105] for each comparison. We considered all gene sets with non-directional
(Mixed) FDR< 0.05 as differentially expressed. To obtain estimates of the proportions of up-
regulated and down-regulated genes for each significant gene set, we used the ROAST [106]
method with 9,999 rotations with the ‘set.statistic’ option set to ‘mean’, to maintain consistency
with the results obtained from FRY.
Promoter motif analysis. We performed promoter motif enrichment analysis using
HOMER [107, 108] and downloaded a set of 364 zebrafish promoter motifs from published
ChIP-seq experiments, as collated by HOMER authors, using the command ‘configureHomer.pl
-install zebrafish-p’. We retained default parameters with the findMotifs.pl program with the fol-
lowing modifications: the 18,296 Ensembl genes considered as expressed in the differential gene
expression analysis were specified as the background; and promoter regions were defined as 1500
bp upstream and 200 bp downstream of the transcription start site. We defined motifs as being
significantly enriched in a set of genes if the Bonferroni-adjusted p-value was less than 0.05.
LC-MS/MS analysis
Data processing. Raw MS/MS spectra were analysed using MaxQuant (V. 1.5.3.17). A
False Discovery Rate (FDR) of 0.01 for peptides and a minimum peptide length of 7 amino
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acids was specified. MS/MS spectra were searched against the zebrafish UniProt database.
MaxQuant output files for the 6-month-old and 24-month-old samples were processed in
separate batches with the MSStats R package [109] due to an unresolvable batch effect. Briefly,
peptide intensities were log2-transformed and quantile normalised, followed by using an accel-
erated failure time model to impute censored peptides. Peptide-level intensities were summa-
rised to protein-level intensities using Tukey’s median polish method. This resulted in 2,814
peptides (summarised to 534 proteins) for the 6-month-old data and 3,378 peptides (summa-
rised to 582 proteins) for the 24-month-old data. After summarisation, both sets of protein
intensities were combined, quantile normalised and filtered to retain the 323 proteins that
were detected across all samples.
Differential protein analysis. Differential protein abundance analysis was performed
using limma [110] using moderated t-tests. Proteins were identified as being differentially
abundant if FDR-adjusted p-values were below 0.05. Over-representation analysis using the
‘goana’ and ‘kegga’ functions from limma were used to test for enriched gene ontology terms
and KEGG pathways respectively.
Gene co-expression network analysis
Network construction. We used the WGCNA R package to construct co-expression
networks for our zebrafish RNA-seq data and a processed human RNA-seq dataset from the
Mayo RNAseq study [41]. The human RNA-seq data consists of 101 bp paired-end reads
sequenced with the Illumina HiSeq 2000 platform and derived from cerebellum and temporal
cortex samples from North American Caucasian subjects with either AD (n = 86), progressive
supranuclear palsy (PSP, n = 84), pathological aging (PA, n = 28) or controls lacking neurode-
generation (n = 80). The Mayo RNAseq study authors performed read alignment and counting
using the SNAPR software with the GRCh38 reference human genome and Ensembl v77 gene
models, and provided TMM-normalised gene counts as output by the edgeR package [97, 111].
We matched zebrafish genes to human homologous genes via orthologous Ensembl gene iden-
tifiers and retained genes that were expressed in both the human and zebrafish datasets, leav-
ing 8,396 genes for network construction. To reduce noise during network construction, we
calculated connectivities for each gene in each dataset and retained 7,576 genes with connec-
tivities above the 10th percentile of all connectivities. To construct approximately scale-free
weighted networks, the Pearson correlation was calculated between each pair of genes, and
the resulting correlation matrix was raised to the soft-thresholding power of 14 to produce a
signed adjacency matrix for each dataset [43]. Next, we applied a transformation to obtain a
measure of topological overlap for each pair of genes. Lastly, we hierarchically clustered genes
in each dataset based on the measure 1—Topological Overlap. To identify modules of co-
expressed genes, we used the Hybrid Tree Cut method from the dynamicTreeCut package
[112] with default parameters except for the following modifications: minimum module size
set at 40 genes, 0.90 as the maximum distance to assign previously unassigned genes to mod-
ules during PAM (Partioning Around Medoids) stage, and the deepSplit parameter to 1 for
both the human and zebrafish datasets.
Network analysis. We assessed functional enrichment of each module using default set-
tings in the anRichment R package. We assessed promoter motif enrichment using HOMER
as described earlier. To calculate the correlation between modules and phenotypic traits, we
calculated the hybrid-robust correlation between the first principal component of each module
and four binary variables defining the experimental conditions [113]. We evaluated the preser-
vation of zebrafish modules in the human network and vice versa using the modulePreserva-
tion function from WGCNA, which uses a permutation-based approach to determine whether
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module properties (e.g. density, connectivity) are preserved in another network [49]. We also
used the Sankey diagram functionality in the networkD3 package to visualise overlap between
zebrafish and human modules [114].
Network visualisation. To visualise networks, we imported edges and nodes into Gephi
and applied the OpenOrd algorithm with default settings [115]. We coloured the nodes
(genes) based on their assigned modules from WGCNA.
psen1K97fs/+ vs. wild type L-plastin immunostain
Anti-L-plastin immunostain. Frozen cryosections of adult psen1K97fs/+ (n = 3 fish) or
psen1+/+ (n = 4 fish) brains were dried for >1hr at room temperature, then rehydrated in
1x PBS for >30 min. Sections were then washed twice with 0.3% Triton X-100 in 1x PBS
(PBS-Tx 0.3%) for 15 min at room temperature (RT). Sections were subsequently incubated
with polyclonal rabbit anti-L-plastin primary antibody [116, 117] (a kind gift from Prof. Dr.
Michael Brand, Centre for Regenerative Therapies, Technische Universität Dresden) at
1:2500 concentration in PBS-Tx 0.3%, overnight at 4˚C in a humid chamber. Sections were
then washed 3 x 20 min in PBS-Tx 0.3% at RT, followed by 1 h incubation at RT with goat
anti-rabbit Alexa 488 secondary antibody (Thermo Fisher, 1:750 in PBS-Tx 0.3%) alongside
DAPI at 1:5000 concentration. Sections were subsequently washed once for 10 min with
PBS-Tx 0.3%, then twice for 20 min with 1x PBS at RT, then mounted with 50% glycerol in
1 x PBS.
Imaging. Z-stacks of brain sections were acquired on a Leica TCS SP8 confocal micro-
scope equipped with a HyD detector, and using the Leica LASX software suite. Stacks were
captured at 1024 x 1024 resolution at scanning speed of 600, with bidirectional X scanning
active. No averaging or accumulation was applied to stack acquisitions, and laser power and
gain were kept constant throughout image acquisition. Overview stacks were captured with
either a 10x dry objective (midbrain, hindbrain overviews) or a 20x oil-immersion objective
(forebrain overviews), while higher magnification stacks were acquired with a 40x water-
immersion objective. ~3 stacks were captured per fish (one of each forebrain, midbrain and
hindbrain at approximately equal levels).
Image processing and statistical analysis. Stacks were opened in Fiji 2 (https://imagej.
net/Fiji/Downloads), and split into individual channels. The green channel (corresponding to
L-plastin in all stacks) was max-projected and the MFI of the entire image was recorded using
the Measure function. Statistical analysis was conducted in Prism 7 (GraphPad); MFI between
brain regions in psen1K97fs/+ and psen1+/+ fish was compared via two-way ANOVA with
Sidak’s multiple comparisons test. Statistical significance was defined as p<0.05, with all data
presented as means with SEMs.
Histological analysis
Tissue preparation. Two-year-old adult zebrafish heterozygous for the psen1K97fs
mutation and their wild type siblings were sacrificed by immersion in ice-water, then tails
were nicked to exsanguinate the fish and prevent blood clotting on neural tissue. The dorsal
neurocranium was subsequently resected to expose the brain. Fish were then decapitated
and heads were incubated in a decalcification solution (100 ml 0.5M EDTA, 22 g sucrose, 11
ml 10x phosphate buffered saline solution, PBS) for four hours on a slow shaker at room
temperature. Decalcified heads were then fixed overnight in 4% paraformaldehyde in phos-
phate buffer (PFA in PB), at 4˚C on a slow shaker. Heads were then embedded in a sucrose-
gelatin medium (20% sucrose, 8% cold-water fish gelatin in 1x PBS), frozen on dry ice and
cryosectioned at 16 μm thickness on a Leica CM3050-S cryostat. Serial sections were
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mounted on SuperFrost Plus microscope slides (Menzel-Gläser). Sections were subse-
quently dried at room temperature for four hours, and then stored at -20˚C until staining.
Prior to all stains, sections were retrieved from -20˚C and brought to RT, then rehydrated in
1x PBS.
Senescence-associated β-galactosidase (saβgal) staining. Sections were prefixed with 4%
PFA in PB for one hour in a humid chamber at room temperature, then washed twice for 15
minutes with 0.3% Triton X-100 in 1x PBS (PBS-Tx (0.3%)). The pH of sections was then
equilibrated with two 30 minute washes with 1x PBS at pH 5.5 (all washes were performed in
a humid chamber). Sections were then stained for 16 hours at 37˚C in a humid chamber in
staining solution (2 mM MgCl2, 5 mM K3Fe(CN)6, 5 mM K3Fe(CN)6�3H2O, 1 mg/ml X-gal,
with the remaining volume made up of 1x PBS at pH 5.5). Following incubation, staining was
arrested by a 20-minute wash in 4% PFA in PB at room temperature. Sections were then
washed well in PBS at pH 5.5 and mounted in 50% glycerol. Sections were then imaged on an
Olympus Provis AX70 widefield microscope with an Olympus DP70 camera, with images
acquired at 4080x3072 resolution.
Congo Red staining for amyloid. Following rehydration in 1x PBS, sections were stained
for 20 minutes in Congo Red staining solution (0.5% Congo Red in 50% ethanol). Sections
were then rinsed in distilled water, and quickly differentiated by dipping five times in an alka-
line alcohol solution (1% NaOH in 50% ethanol). Sections were rinsed for 1 minute in distilled
water, then mounted in 50% glycerol. Sections were imaged in both brightfield and birefrin-
gence on a Leica Abrio polarising microscope at 1024x1024 resolution.
Autofluorescent detection of lipofuscin. Following rehydration in 1x PBS, sections were
mounted in 50% glycerol and imaged confocally on a Leica TCS SP8 invert confocal laser scan-
ning microscope with a Leica HyD hybrid detector using 20x and 63x oil-immersion objec-
tives. Lipofuscin has an emission maximum at 590 nm when excited at 488 nm; samples were
thus excited with a 488nm laser at power 5.00, and the detector was gated for emission wave-
lengths between 560–700 nm. Images were acquired at 1024x1024 resolution with gain at
137.8%.
Supporting information
S1 File. Supporting figures and text.
(PDF)
S1 Table. Differential gene expression results for each comparison.
(XLSX)
S2 Table. Differential protein abundance results for each comparison.
(XLSX)
S3 Table. Summary of functional enrichment results for groups of genes identified in dif-
ferential gene expression analysis.
(PDF)
S4 Table. Full gene ontology analysis results for groups of genes identified in differential
gene expression analysis.
(XLSX)
S5 Table. Summary of promoter motif enrichment analysis in groups of genes identified
from differential gene expression analysis.
(PDF)
Accelerated brain aging towards transcriptional inversion in a zebrafish model of a human PSEN2 mutation
PLOS ONE | https://doi.org/10.1371/journal.pone.0227258 January 24, 2020 28 / 36
73
S6 Table. Full enrichment results of known zebrafish promoter motifs in groups of genes
identified from differential gene expression analysis.
(XLSX)
S7 Table. List of zebrafish genes containing the GRE (glucocorticoid receptor element)
motif. These genes have a 90% match for the GRE motif in the region 1500bp upstream to
200bp downstream of the transcription start site.
(XLSX)
S8 Table. Differentially expressed Hallmark MSigDB gene sets for each comparison identi-
fied using the FRY (fast rotation) method. Proportions of up- and downregulated genes in
each set were estimated using ROAST (which FRY approximates). Differentially expressed
gene sets were defined as having “Mixed FDR”< 0.05.
(XLSX)
S9 Table. Zebrafish module functional enrichment results using anRichment R package.
(XLSX)
S10 Table. Zebrafish module promoter motif enrichment results using HOMER soft-
ware.
(XLSX)
S11 Table. Human module functional enrichment results using anRichment R package.
(XLSX)
S12 Table. Promoter motif enrichment analysis of the immune-microglia enriched module
in the zebrafish network.
(XLSX)
S13 Table. Z-score calculation results for preservation of zebrafish co-expression network
properties in human co-expression network.
(XLSX)
Acknowledgments
The authors thank Awais Choudhry for technical assistance. We also thank the Carthew Fam-
ily Foundation and Prof. David Adelson for their encouragement and support.
Author Contributions
Conceptualization: David L. Adelson, Stephen Pederson, Michael Lardelli.
Data curation: Morgan Newman, Seyed Hani Moussavi Nik, Yang Dong, Michael Lardelli.
Formal analysis: Nhi Hin, Morgan Newman, Jan Kaslin, Alon M. Douek, Amanda Lumsden,
Xin-Fu Zhou, Stephen Pederson.
Funding acquisition: Morgan Newman, Michael Lardelli.
Investigation: Nhi Hin, Morgan Newman, Jan Kaslin, Yang Dong, Xin-Fu Zhou, Stephen
Pederson, Michael Lardelli.
Methodology: Nhi Hin, Morgan Newman, Jan Kaslin, Alon M. Douek, Amanda Lumsden,
Seyed Hani Moussavi Nik, Xin-Fu Zhou, Alastair Ludington, Michael Lardelli.
Project administration: Michael Lardelli.
Accelerated brain aging towards transcriptional inversion in a zebrafish model of a human PSEN2 mutation
PLOS ONE | https://doi.org/10.1371/journal.pone.0227258 January 24, 2020 29 / 36
74
Resources: David L. Adelson, Michael Lardelli.
Software: Alastair Ludington, David L. Adelson, Stephen Pederson.
Supervision: David L. Adelson, Stephen Pederson, Michael Lardelli.
Validation: Jan Kaslin, Stephen Pederson.
Visualization: Nhi Hin, Morgan Newman, Jan Kaslin, Michael Lardelli.
Writing – original draft: Nhi Hin, Morgan Newman, Jan Kaslin, Stephen Pederson, Michael
Lardelli.
Writing – review & editing: Nhi Hin, Morgan Newman, Jan Kaslin, Alon M. Douek, Amanda
Lumsden, Seyed Hani Moussavi Nik, Yang Dong, Xin-Fu Zhou, Noralyn B. Mañucat-Tan,
Alastair Ludington, David L. Adelson, Stephen Pederson, Michael Lardelli.
References
1. Cadonic C, Sabbir MG, Albensi BC. Mechanisms of Mitochondrial Dysfunction in Alzheimer’s Disease.
Mol Neurobiol. 2015. https://doi.org/10.1007/s12035-015-9515-5 PMID: 26537901.
2. Castellani R, Hirai K, Aliev G, Drew KL, Nunomura A, Takeda A, et al. Role of mitochondrial dysfunc-
tion in Alzheimer’s disease. J Neurosci Res. 2002; 70(3):357–60. Epub 2002/10/23. https://doi.org/10.
1002/jnr.10389 PMID: 12391597.
3. Fedrizzi L, Carafoli E. Ca2+ dysfunction in neurodegenerative disorders: Alzheimer’s disease. Biofac-
tors. 2011; 37(3):189–96. Epub 2011/06/24. https://doi.org/10.1002/biof.157 PMID: 21698698.
4. Mills E, Dong XP, Wang F, Xu H. Mechanisms of brain iron transport: insight into neurodegeneration
and CNS disorders. Future Med Chem. 2010; 2(1):51–64. https://doi.org/10.4155/fmc.09.140 PMID:
20161623.
5. Moir RD, Atwood CS, Huang X, Tanzi RE, Bush AI. Mounting evidence for the involvement of zinc and
copper in Alzheimer’s disease. Eur J Clin Invest. 1999; 29(7):569–70. Epub 1999/07/20. https://doi.
org/10.1046/j.1365-2362.1999.00472.x PMID: 10411660.
6. Arimon M, Takeda S, Post KL, Svirsky S, Hyman BT, Berezovska O. Oxidative stress and lipid peroxi-
dation are upstream of amyloid pathology. Neurobiol Dis. 2015; 84:109–19. https://doi.org/10.1016/j.
nbd.2015.06.013 PMID: 26102023.
7. Oresic M, Hyotylainen T, Herukka SK, Sysi-Aho M, Mattila I, Seppanan-Laakso T, et al. Metabolome
in progression to Alzheimer’s disease. Transl Psychiatry. 2011; 1:e57. Epub 2011/01/01. https://doi.
org/10.1038/tp.2011.55 PMID: 22832349.
8. Poirier J, Miron J, Picard C, Gormley P, Theroux L, Breitner J, et al. Apolipoprotein E and lipid
homeostasis in the etiology and treatment of sporadic Alzheimer’s disease. Neurobiol Aging. 2014;
35 Suppl 2:S3–10. Epub 2014/06/29. https://doi.org/10.1016/j.neurobiolaging.2014.03.037 PMID:
24973118.
9. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflamma-
tion in Alzheimer’s disease. Lancet Neurol. 2015; 14(4):388–405. Epub 2015/03/21. https://doi.org/10.
1016/S1474-4422(15)70016-5 PMID: 25792098.
10. Zotova E, Nicoll JA, Kalaria R, Holmes C, Boche D. Inflammation in Alzheimer’s disease: relevance to
pathogenesis and therapy. Alzheimers Res Ther. 2010; 2(1):1. Epub 2010/02/04. https://doi.org/10.
1186/alzrt24 PMID: 20122289.
11. Abramsson A, Kettunen P, Banote RK, Lott E, Li M, Arner A, et al. The zebrafish amyloid precursor
protein-b is required for motor neuron guidance and synapse formation. Dev Biol. 2013; 381(2):377–
88. https://doi.org/10.1016/j.ydbio.2013.06.026 PMID: 23850871.
12. De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease
process. Physiol Rev. 2010; 90(2):465–94. https://doi.org/10.1152/physrev.00023.2009 PMID:
20393191.
13. Hipp MS, Park SH, Hartl FU. Proteostasis impairment in protein-misfolding and -aggregation diseases.
Trends Cell Biol. 2014. Epub 2014/06/21. https://doi.org/10.1016/j.tcb.2014.05.003 PMID: 24946960.
14. Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer’s disease. Neuro-
biol Aging. 1997; 18(4 Suppl):S85–8. Epub 1997/07/01. https://doi.org/10.1016/s0197-4580(97)
00062-6 PMID: 9330992.
Accelerated brain aging towards transcriptional inversion in a zebrafish model of a human PSEN2 mutation
PLOS ONE | https://doi.org/10.1371/journal.pone.0227258 January 24, 2020 30 / 36
75
15. Masters CL, Bateman RJ, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer’s disease.
Nature reviews Disease Primers. 2015; 1:1–8. https://doi.org/10.1038/nrdp.2015.56 PMID:
27188934
16. Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer’s disease drugs keep fail-
ing? A discontinued drug perspective for 2010–2015. Expert Opin Investig Drugs. 2017; 26(6):735–9.
https://doi.org/10.1080/13543784.2017.1323868 PMID: 28460541.
17. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition,
neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study.
Lancet Neurol. 2013; 12(4):357–67. Epub 2013/03/13. https://doi.org/10.1016/S1474-4422(13)70044-
9 PMID: 23477989.
18. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker
changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012; 367(9):795–804. https://
doi.org/10.1056/NEJMoa1202753 PMID: 22784036.
19. Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Perez JM, Evans AC, Alzheimer’s Disease Neuro-
imaging I. Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifacto-
rial data-driven analysis. Nat Commun. 2016; 7:11934. https://doi.org/10.1038/ncomms11934 PMID:
27327500.
20. Quiroz YT, Schultz AP, Chen K, Protas HD, Brickhouse M, Fleisher AS, et al. Brain Imaging and Blood
Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional
Study. JAMA Neurol. 2015; 72(8):912–9. https://doi.org/10.1001/jamaneurol.2015.1099 PMID:
26121081.
21. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, et al. Brain imaging
and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer’s dis-
ease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012; 11(12):1048–56.
https://doi.org/10.1016/S1474-4422(12)70228-4 PMID: 23137948.
22. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, et al. Functional brain abnor-
malities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc Natl Acad Sci U S
A. 2004; 101(1):284–9. Epub 2003/12/23. https://doi.org/10.1073/pnas.2635903100 PMID:
14688411
23. Berchtold NC, Sabbagh MN, Beach TG, Kim RC, Cribbs DH, Cotman CW. Brain gene expression pat-
terns differentiate mild cognitive impairment from normal aged and Alzheimer’s disease. Neurobiol
Aging. 2014; 35(9):1961–72. https://doi.org/10.1016/j.neurobiolaging.2014.03.031 PMID: 24786631.
24. Antonell A, Llado A, Altirriba J, Botta-Orfila T, Balasa M, Fernandez M, et al. A preliminary study of the
whole-genome expression profile of sporadic and monogenic early-onset Alzheimer’s disease. Neuro-
biol Aging. 2013; 34(7):1772–8. Epub 2013/02/02. https://doi.org/10.1016/j.neurobiolaging.2012.12.
026 PMID: 23369545.
25. Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, et al. Increased vulnerability of hippocam-
pal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med. 1999; 5(1):101–6.
https://doi.org/10.1038/4789 PMID: 9883847.
26. Kawasumi M, Chiba T, Yamada M, Miyamae-Kaneko M, Matsuoka M, Nakahara J, et al. Targeted
introduction of V642I mutation in amyloid precursor protein gene causes functional abnormality resem-
bling early stage of Alzheimer’s disease in aged mice. Eur J Neurosci. 2004; 19(10):2826–38. https://
doi.org/10.1111/j.0953-816X.2004.03397.x PMID: 15147316.
27. Siman R, Reaume AG, Savage MJ, Trusko S, Lin YG, Scott RW, et al. Presenilin-1 P264L knock-in
mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability. J
Neurosci. 2000; 20(23):8717–26. https://doi.org/10.1523/JNEUROSCI.20-23-08717.2000 PMID:
11102478.
28. Hargis KE, Blalock EM. Transcriptional signatures of brain aging and Alzheimer’s disease: What are
our rodent models telling us? Behav Brain Res. 2017; 322(Pt B):311–28. Epub 2016/05/04. https://doi.
org/10.1016/j.bbr.2016.05.007 PMID: 27155503.
29. Sato N, Hori O, Yamaguchi A, Lambert JC, Chartier-Harlin MC, Robinson PA, et al. A novel presenilin-
2 splice variant in human Alzheimer’s disease brain tissue. Journal of Neurochemistry. 1999; 72
(6):2498–505. https://doi.org/10.1046/j.1471-4159.1999.0722498.x PMID: 10349860
30. Jayadev S, Leverenz JB, Steinbart E, Stahl J, Klunk W, Yu CE, et al. Alzheimer’s disease phenotypes
and genotypes associated with mutations in presenilin 2. Brain. 2010; 133:1143–54. https://doi.org/10.
1093/brain/awq033 PMID: 20375137
31. Newman M, Wilson L, Verdile G, Lim A, Khan I, Moussavi Nik SH, et al. Differential, dominant activa-
tion and inhibition of Notch signalling and APP cleavage by truncations of PSEN1 in human disease.
Hum Mol Genet. 2014; 23(3):602–17. Epub 2013/10/09. https://doi.org/10.1093/hmg/ddt448 PMID:
24101600.
Accelerated brain aging towards transcriptional inversion in a zebrafish model of a human PSEN2 mutation
PLOS ONE | https://doi.org/10.1371/journal.pone.0227258 January 24, 2020 31 / 36
76
32. Moussavi Nik SH, Newman M, Wilson L, Ebrahimie E, Wells S, Musgrave I, et al. Alzheimer’s disease-
related peptide PS2V plays ancient, conserved roles in suppression of the unfolded protein response
under hypoxia and stimulation of gamma-secretase activity. Hum Mol Genet. 2015. Epub 2015/03/31.
https://doi.org/10.1093/hmg/ddv110 PMID: 25814654.
33. Sharman MJ, Moussavi Nik SH, Chen MM, Ong D, Wijaya L, Laws SM, et al. The Guinea Pig as a
Model for Sporadic Alzheimer’s Disease (AD): The Impact of Cholesterol Intake on Expression of AD-
Related Genes. PLoS One. 2013; 8(6):e66235. https://doi.org/10.1371/journal.pone.0066235 PMID:
23805206.
34. Seshadri S, Wolf PA, Beiser A, Au R, McNulty K, White R, et al. Lifetime risk of dementia and Alzhei-
mer’s disease. The impact of mortality on risk estimates in the Framingham Study. Neurology. 1997;
49(6):1498–504. https://doi.org/10.1212/wnl.49.6.1498 PMID: 9409336.
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Abstract
To prevent or ameliorate Alzheimer’s disease (AD) we must understand its molecular basis. AD develops over
decades but detailed molecular analysis of AD brains is limited to postmortem tissue where the stresses initiating
the disease may be obscured by compensatory responses and neurodegenerative processes. Rare, dominant
mutations in a small number of genes, but particularly the gene PRESENILIN 1 (PSEN1), drive early onset of familial
AD (EOfAD). Numerous transgenic models of AD have been constructed in mouse and other organisms, but
transcriptomic analysis of these models has raised serious doubts regarding their representation of the disease
state. Since we lack clarity regarding the molecular mechanism(s) underlying AD, we posit that the most valid
approach is to model the human EOfAD genetic state as closely as possible. Therefore, we sought to analyse brains
from zebrafish heterozygous for a single, EOfAD-like mutation in their PSEN1-orthologous gene, psen1. We
previously introduced an EOfAD-like mutation (Q96_K97del) into the endogenous psen1 gene of zebrafish. Here, we
analysed transcriptomes of young adult (6-month-old) entire brains from a family of heterozygous mutant and wild
type sibling fish. Gene ontology (GO) analysis implies effects on mitochondria, particularly ATP synthesis, and on
ATP-dependent processes including vacuolar acidification.
Keywords: Alzheimer’s disease, Presenilin 1, Mutation, Transcriptome, Brain, ATP synthesis, Mitochondria, Vacuolar
acidification, Zebrafish, Genome editing
Background
AD is the most common form of dementia with severe
personal, social, and economic impacts. Rare, familial
forms of AD exist caused by autosomal dominant muta-
tions in single genes (reviewed by [1]). The majority of
these mutations occur in the gene PRESENILIN 1
(PSEN1) that encodes a multipass integral membrane
protein involved in intra-membrane cleavage of numer-
ous proteins [1].
A wide variety of transgenic models of AD have been
created and studied. These are aimed at reproducing
histopathologies posited to be central to the disease
process, i.e. amyloid plaques and neurofibrillary tangles
of the protein MAPT [2]. However, analysis of the ef-
fects on the brain transcriptome of the transgenes driv-
ing a number of these mouse models showed little
concordance with transcriptomic differences between
human AD brains and age-matched controls [3] (al-
though a recent study asserts that this lack of concord-
ance for the popular “5XFAD” transgenic mouse model
is due to previous failure to analyse the effects of its
transgenes in a variety of genetic backgrounds [4]). We
posit that, in the absence of an understanding of the mo-
lecular mechanism(s) underlying AD, the most objective
approach to modeling this disease (or, at least, modeling
its genetic form, EOfAD) is to create a genetic state as
similar as possible to the EOfAD state in humans.
Mouse “knock-in” models of EOfAD mutations were
created over a decade ago and showed subtle phenotypic
effects but not the desired histopathologies (e.g. [5, 6]).
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Table 1 GOs enriched for genes differentially expressed between heterozygous mutant and wild type sibling fish brains
Gene Ontology Term Ontology Total Genes DE Genes p-value FDR p-value
ATP biosynthetic process BP 29 7 3.48987E-08 0.00041
ribonucleoside triphosphate biosynthetic process BP 49 8 9.41317E-08 0.00045
nucleoside triphosphate biosynthetic process BP 54 8 2.06555E-07 0.00060
purine nucleoside triphosphate biosynthetic process BP 41 7 4.46237E-07 0.00060
purine ribonucleoside triphosphate biosynthetic process BP 41 7 4.46237E-07 0.00060
hydrogen transport BP 60 8 4.783E-07 0.00060
proton transport BP 60 8 4.783E-07 0.00060
energy coupled proton transport, down electrochemical gradient BP 27 6 5.89038E-07 0.00060
ATP synthesis coupled proton transport BP 27 6 5.89038E-07 0.00060
transport BP 2072 48 2.11748E-06 0.00165
purine nucleoside monophosphate biosynthetic process BP 54 7 3.09019E-06 0.00172
purine ribonucleoside monophosphate biosynthetic process BP 54 7 3.09019E-06 0.00172
hydrogen ion transmembrane transport BP 54 7 3.09019E-06 0.00172
ribonucleoside triphosphate metabolic process BP 133 10 3.8448E-06 0.00178
establishment of localization BP 2123 48 4.20295E-06 0.00182
ATP metabolic process BP 109 9 5.50772E-06 0.00230
nucleoside triphosphate metabolic process BP 140 10 6.08925E-06 0.00245
cation transport BP 452 18 6.61154E-06 0.00258
monovalent inorganic cation transport BP 219 12 1.10729E-05 0.00392
ribonucleoside monophosphate biosynthetic process BP 65 7 1.08944E-05 0.00392
nucleoside monophosphate biosynthetic process BP 68 7 1.47269E-05 0.00492
purine ribonucleoside triphosphate metabolic process BP 125 9 1.68142E-05 0.00546
purine nucleoside triphosphate metabolic process BP 126 9 1.79263E-05 0.00552
transmembrane transport BP 654 21 2.93288E-05 0.00797
purine nucleoside monophosphate metabolic process BP 136 9 3.2951E-05 0.00837
purine ribonucleoside monophosphate metabolic process BP 136 9 3.2951E-05 0.00837
energy coupled proton transmembrane transport, against electrochemical gradient BP 35 5 5.20342E-05 0.01106
ATP hydrolysis coupled proton transport BP 35 5 5.20342E-05 0.01106
ATP hydrolysis coupled transmembrane transport BP 35 5 5.20342E-05 0.01106
ATP hydrolysis coupled ion transmembrane transport BP 35 5 5.20342E-05 0.01106
ATP hydrolysis coupled cation transmembrane transport BP 35 5 5.20342E-05 0.01106
ion transport BP 737 22 5.61478E-05 0.01152
localization BP 2621 52 6.0913E-05 0.01207
ribonucleoside monophosphate metabolic process BP 147 9 6.06496E-05 0.01207
nucleoside monophosphate metabolic process BP 150 9 7.09445E-05 0.01360
single-organism localization BP 819 23 9.51294E-05 0.01738
single-organism transport BP 776 22 0.000119082 0.02109
ribonucleotide biosynthetic process BP 129 8 0.000143028 0.02423
ribose phosphate biosynthetic process BP 129 8 0.000143028 0.02423
vacuolar acidification BP 11 3 0.000246582 0.04101
ribonucleotide metabolic process BP 220 10 0.000281352 0.04506
proton-transporting two-sector ATPase complex, proton-transporting domain CC 25 6 3.59375E-07 0.00060
proton-transporting two-sector ATPase complex CC 45 7 8.65692E-07 0.00078
mitochondrial membrane CC 285 15 1.42199E-06 0.00119
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However, at that time, researchers did not have access to
RNA-Seq technology. To the best of our knowledge,
transcriptome analysis of the EOfAD mutation knock-in
mouse models was never performed.
In humans, AD is thought to develop over decades
and the median survival to onset age for EOfAD muta-
tions in human PSEN1 considered collectively is 45 years
[7]. Functional MRI of human children carrying EOfAD
mutations in PSEN1 has revealed differences in brain
activity compared to non-carriers in individuals as young
as 9 years of age [8]. Presumably therefore, heterozygos-
ity for EOfAD mutations in PSEN1 causes early molecu-
lar changes/stresses that eventually lead to AD.
Transcriptome analysis is currently the most detailed
molecular phenotypic analysis possible on cells or tissues.
Here we present an initial analysis of the transcriptomic
differences caused in young adult (6-month-old) zebrafish
brains by the presence of an EOfAD-like mutation in the
Table 1 GOs enriched for genes differentially expressed between heterozygous mutant and wild type sibling fish brains (Continued)
Gene Ontology Term Ontology Total Genes DE Genes p-value FDR p-value
mitochondrial envelope CC 303 15 3.0322E-06 0.00172
membrane part CC 4868 85 1.1722E-05 0.00403
organelle membrane CC 789 24 1.84982E-05 0.00555
mitochondrial inner membrane CC 195 11 1.97958E-05 0.00579
integral component of membrane CC 4419 78 2.52479E-05 0.00720
intrinsic component of membrane CC 4453 78 3.37749E-05 0.00840
organelle envelope CC 420 16 3.76291E-05 0.00917
envelope CC 422 16 3.98337E-05 0.00950
organelle inner membrane CC 215 11 4.86028E-05 0.01106
Cul2-RING ubiquitin ligase complex CC 7 3 5.4156E-05 0.01131
proton-transporting ATP synthase complex CC 19 4 6.25883E-05 0.01220
mitochondrial membrane part CC 117 8 7.21148E-05 0.01360
mitochondrial part CC 404 15 8.83156E-05 0.01639
membrane CC 5379 88 0.000106964 0.01924
vacuolar proton-transporting V-type ATPase, V0 domain CC 9 3 0.000127733 0.02229
mitochondrial proton-transporting ATP synthase complex, coupling factor F(o) CC 12 3 0.000325933 0.04885
proton-transporting V-type ATPase, V0 domain CC 12 3 0.000325933 0.04885
ATPase activity, coupled to transmembrane movement of ions, rotational mechanism MF 34 7 1.1446E-07 0.00045
hydrogen ion transmembrane transporter activity MF 84 9 6.11883E-07 0.00060
ATPase activity, coupled to transmembrane movement of substances MF 98 9 2.27123E-06 0.00166
hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement
of substances
MF 101 9 2.92425E-06 0.00172
primary active transmembrane transporter activity MF 104 9 3.73269E-06 0.00178
P-P-bond-hydrolysis-driven transmembrane transporter activity MF 104 9 3.73269E-06 0.00178
cation-transporting ATPase activity MF 56 7 3.96731E-06 0.00178
ATPase coupled ion transmembrane transporter activity MF 56 7 3.96731E-06 0.00178
ATPase activity, coupled to movement of substances MF 112 9 6.88692E-06 0.00260
active ion transmembrane transporter activity MF 96 8 1.72916E-05 0.00546
active transmembrane transporter activity MF 281 13 2.87859E-05 0.00797
proton-transporting ATP synthase activity, rotational mechanism MF 16 4 3.02121E-05 0.00803
transporter activity MF 991 25 0.000249051 0.04101
substrate-specific transmembrane transporter activity MF 709 20 0.000263528 0.04279
ion transmembrane transporter activity MF 660 19 0.000293184 0.04572
substrate-specific transporter activity MF 828 22 0.000297009 0.04572
monovalent inorganic cation transmembrane transporter activity MF 264 11 0.000297217 0.04572
GOs are grouped by ontology (BP, CC or MF) and ranked by FDR-corrected p-value
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gene psen1 that is orthologous to the human PSEN1 gene.
GO analysis supports very significant effects on mitochon-
drial function, especially synthesis of ATP, and on
ATP-dependent functions such as the acidification of lyso-
somes that are critical for autophagy.
Materials and methods
The mutant allele, Q96_K97del, of psen1 was a bypro-
duct identified during our introduction of the K97fs mu-
tation into psen1 (that models the K115fs mutation of
human PSEN2 – see [9] for an explanation).
Q96_K97del is a deletion of 6 nucleotides from the
coding sequence of the psen1 gene. This is predicted to
distort the first lumenal loop of the Psen1 protein. In
this sense, it is similar to a number of EOfAD mutations
of human PSEN1 [10]. Also, in common with all the
widely distributed EOfAD mutations in PSEN1, (and
consistent with the PRESENILIN EOfAD mutation
“reading frame preservation rule” [1]), the Q96_K97del
allele is predicted to encode a transcript that includes
the C-terminal sequences of the wild type protein.
Therefore, as a model of an EOfAD mutation, it is su-
perior to the K97fs mutation in psen1 [9].
To generate a family of heterozygous Q96_K97del al-
lele (i.e. psen1Q96_K97del/+) and wild type (+/+) sibling
fish, we mated a psen1Q96_K97del/+ individual with a +/+
individual and raised the progeny from a single spawn-
ing event together in one tank. Zebrafish can live for up
to 5 years but, in our laboratory, typically show greatly
reduced fertility after 18 months. The fish become fertile
after around 3 months of age, so we regard 6-month-old
fish as equivalent to young adult humans. Therefore we
analysed the transcriptomes of entire young adult,
6-month-old fish brains using poly-A enriched RNA-seq
technology, and estimated gene expression from the
resulting single-end 75 bp reads using the reference
GRCz11 zebrafish assembly transcriptome [11, 12]. Each
zebrafish brain has a mass of approximately 7 mg. Since
AD is more prevalent in human females than males, and
to further reduce gene expression “noise” in our ana-
lyses, we obtained brain transcriptome data from four fe-
male wild type fish and four female heterozygous
mutant fish. This data has been made publicly available
at the Gene Expression Omnibus (GEO, see under Avail-
ability of data and materials below).
Results
Differentially expressed genes (DE genes)
Genes differentially expressed between wild type and het-
erozygous mutant sibling fish were identified using moder-
ated t-tests and a false discovery rate (FDR)-adjusted
p-value cutoff of 0.05 as previously described [9, 13, 14]. In
total, 251 genes were identified as differentially expressed
(see Additional file 1). Of these, 105 genes showed
increased expression in heterozygous mutant brains relative
to wild type sibling brains while 146 genes showed de-
creased expression.
GO analysis
To understand the significance for brain cellular function
of the differential gene expression identified in young adult
heterozygous mutant brains we used the goana function
[15] of the limma package of Bioconductor software [14] to
identify GOs in which the DE genes were enriched at an
FDR-corrected p-value of less than 0.05. Seventy-eight GOs
were identified (Table 1) of which 20 addressed cellular
components (CC). Remarkably, most of these CCs con-
cerned the mitochondrion, membranes, or ATPases. Seven-
teen GOs addressed molecular functions (MF) and largely
involved membrane transporter activity, particularly ion
transport and ATPase activity coupled to such transport.
Forty-one GOs addressed biological processes (BP) and in-
volved ATP metabolism, ribonucleoside metabolism, and
transmembrane transport processes including vacuolar
acidification (that has previously been identified as affected
by EOfAD mutations in PSEN1 [16]). Overall, our GO ana-
lysis indicates that this EOfAD-like mutation of zebrafish
psen1 has very significant impacts on cellular energy metab-
olism and transmembrane transport processes.
Additional file
Additional file 1: Genes differentially expressed between heterozygous
mutant and wild type brains at 6 months. Lists the genes identified as
differentially expressed between the brains of heterozygous psen1Q96_K97del
mutant fish and the brains of their wild type siblings at an age of 6months.
Genes are ranked according to FDR-corrected p-value. Only genes with a
FDR-corrected p-value less than 0.05 are shown. “FC” denotes fold change.
“DE” denotes differential expression. For DE_Direction, “1” denotes increased
expression in the mutant and “-1” denotes decreased expression in the mu-
tant. (XLSX 39 kb)
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Abstract 
Background: Iron trafficking and accumulation has been associated with 
Alzheimer’s disease (AD) pathogenesis. However, the role of iron dyshomeostasis in 
early disease stages is uncertain. Currently, gene expression changes indicative of 
iron dyshomeostasis are not well characterised, making it difficult to explore these in 
existing datasets.  
Methods: We identified sets of genes predicted to contain Iron Responsive 
Elements (IREs) and used these to explore iron dyshomeostasis responses in gene 
expression datasets. 
Results: IRE gene sets were sufficiently sensitive to distinguish not only between 
iron overload and deficiency in cultured cells, but also between AD and other 
pathological brain conditions in different brain regions. Notably, we see changes in 
IRE transcript abundance as amongst the earliest observable changes in zebrafish 
familial AD (fAD)-like brains, preceding other AD-typical pathologies such as 
inflammatory changes. Unexpectedly, while some IREs in the 3’ untranslated regions 
of transcripts show significantly increased stability under iron deficiency in line with 
current assumptions, many such transcripts instead show decreased stability, 
indicating that this is not a generalizable paradigm.  
Conclusions: Our results reveal iron dyshomeostasis as a likely early driver of fAD 
and as able to distinguish AD from other brain pathologies. Our work demonstrates 
how differences in the stability of IRE-containing transcripts can be used to explore 
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Iron responsive element, iron homeostasis, Alzheimer’s disease, gene expression, 
RNA-seq, gene set enrichment analysis, familial Alzheimer’s disease 
 
Background 
The pathological processes underlying Alzheimer’s Disease (AD) commence 
decades before symptoms become evident [1,2].  Since the early days of AD 
research, iron trafficking and accumulation has been observed to be altered in AD 
[3–7]. However, it is still unclear whether iron dyshomeostasis represents a late 
symptom or an early pathological driver of AD. Iron homeostasis is closely linked to 
many critical biological processes including cellular respiration, hypoxia, and immune 
responses, all of which are disrupted in AD. Consistent with this, discoveries over the 
past decade have shown that disruptions to iron homeostasis can drive feedback 
loops that worsen AD pathology [8,9]. However, evidence for iron dyshomeostasis as 
an early driver of the disease is only just emerging. Recently, amyloidogenic 
processing of the Amyloid Precursor Protein (APP) was shown to impair the export 
of iron from cells, potentially disrupting iron homoeostasis to drive excessive iron 
accumulation during aging with pathological consequences[10]. While iron 
accumulation associated with amyloid plaque formation has been observed in 
93
various transgenic mouse models of AD [11–14], the age at which iron 
dyshomeostasis first occurs is uncertain [15].  
 
Currently, gene expression patterns representing responses to iron dyshomeostasis 
are not well-characterised. Cellular responses to iron dyshomeostasis are complex 
and involve several systems and layers of regulation. The stability of the transcription 
factor HIF1a, (a component of HIF1, a master regulator of responses to hypoxia) is 
regulated by an iron-dependent mechanism so that transcriptional responses to iron 
deficiency can resemble hypoxia responses [16]. However, cellular iron homeostasis 
is also regulated at the post-transcriptional level by the IRP/IRE system [17–19]. In 
this system, altered levels of available ferrous iron (Fe2+) cause Iron Responsive 
Proteins (IRP1 or IRP2) to change conformation or stability respectively [20,21]. This 
alters their ability to bind cis-regulatory Iron Responsive Element (IRE) stem-loop 
motifs in the 3’ or 5’ untranslated regions (UTRs) of genes encoding products related 
to iron metabolism. Only a few IRE-containing genes have been characterised in 
detail, including TfR1 (transferrin receptor 1; 3’ UTR IRE), DMT1 (divalent metal 
transporter 1; 3’ UTR IRE), H- and L-ferritin (both 5’ UTR IRE), and ferroportin (5’ 
UTR IRE) [19]. In general, these well-characterised IRE-containing genes suggest 
that IRPs binding to 3’ IREs tend to stabilise transcripts to increase protein 
translation, while binding to 5’ IREs suppresses translation [18]. Currently however, 
global gene expression changes mediated by the IRP/IRE system have not been 
well-defined, and the overall expression patterns of IRE-containing genes have not 
been explored in the context of AD. In addition, it is unclear how expression of these 
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genes might differ between AD and other neurodegenerative diseases, or how AD 
risk factors such as aging and hypoxia might contribute.  
 
In this study, we utilised the SIREs (Searching for Iron Responsive Elements) tool 
[22] to predict and identify sets of IRE-containing genes in human, mouse, and 
zebrafish. We then applied these gene sets to explore overall IRP/IRE-mediated iron 
dyshomeostasis responses in datasets involving: (1) a cultured cell line subjected to 
iron overload and deficiency treatments, (2) a cohort of AD patients, healthy controls, 
and two other pathological conditions affecting the brain, (3) 5XFAD mice used to 
model the amyloid and tau pathology seen in AD, and (4) a zebrafish knock-in model 
possessing a familial AD (fAD)-like mutation.  
 
Our IRE gene sets displayed significant enrichment in AD, the 5XFAD mouse model, 
and an fAD-like zebrafish model, demonstrating for the first time the early and 
extensive involvement of IRP/IRE-mediated iron dyshomeostasis responses in the 
context of AD. IRE gene sets were sufficiently sensitive to distinguish not only 
between iron overload and deficiency in a cultured cell line dataset, but also between 
AD and other pathological conditions affecting the brain (pathological aging and 
progressive supranuclear palsy), implying that the dysregulation of IRE-containing 
genes and iron dyshomeostasis responses in AD could differ from other conditions. 
Iron dyshomeostasis was already evident in young adult brains (3 month old FXFAD 
mice, 6 month old fAD-like zebrafish). Overall, our observations do not support the 
current assumption that IRP binding to 3’IREs generally stabilizes transcripts as we 
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observed both increases and decreases in abundance of transcripts with either 3’ or 




Defining sets of genes containing Iron Responsive Elements (IREs) 
We utilised the SIREs (Searching for Iron Responsive Elements) tool, to define 
species-specific IRE gene sets by searching for IRE and IRE-like motifs in the 3’ and 
5’ untranslated regions (UTRs) of the reference transcriptomes of human (hg38), 
mouse (mm10), and zebrafish (z11). SIREs assigns a quality-score to all detected 
IREs, with “high-quality” scores corresponding to canonical IREs and “medium-
quality” or “low-quality” scores reflecting deviations from the canonical IRE 
(alternative nucleotide composition in the apical loop, one bulge at the 3’ or one 
mismatch in the upper stem) that would still produce an IRE-like motif with the 
potential to be functional [22–26]. Figure 1 summarises the IRP/IRE interaction 
effects on transcripts and gives examples of canonical and non-canonical IREs.  
 
We defined four gene sets for each species as follows: HQ 3’ IREs (high-quality 
predicted 3’ IRE genes), HQ 5’ IREs (high-quality predicted 5’ IRE genes), all 3’ 
IREs (including all low, medium, and high-quality predicted 3’ IRE genes), and all 5’ 
IREs (including all low, medium, and high-quality predicted 5’ IRE genes). The size 
of these gene sets for each species and the overlap present is shown in Figure 2 
and the gene sets are provided in Supplementary Table 1. Overall, searching 
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through human UTRs uncovered the largest number of predicted IRE genes, 
followed by mouse, and then zebrafish. Overlap between homologous genes from 
the IRE gene sets of different species was generally poor. The largest sets of genes 
shared between species were consistently found between human and mouse, which 
is reflective of their closer evolutionary divergence. While not many high-quality IRE 
genes were identified across all three species, the few we identified are consistent 
with known and well-characterised IREs in the literature [27,28]. For example, the 
single shared HQ 3’ IRE gene between the three species was TFRC (transferrin 
receptor), while the shared HQ 5’ IRE genes between the three species included 
FTH1 (ferritin heavy chain 1) and ALAS2 (5'-aminolevulinate synthase 2).  
 
IRE gene sets are over-represented within up-regulated AD genes, but 
overall not well-represented in existing gene sets 
We explored the biological relevance of the predicted IRE gene sets described 
above by testing whether genes within them were over-represented in existing gene 
sets from the Molecular Signatures Database (MSigDB; available at 
https://www.gsea-msigdb.org/gsea/msigdb). MSigDB represents one of the largest 
publically-available collection of gene sets collated from existing studies and other 
biological databases [29]. We limited our analysis to gene sets from the following 
collections: Hallmark (non-redundant sets of ~200 genes each representing various 
biological activities), C2 (gene sets from databases including KEGG and Reactome 
and published studies), C3 (gene sets containing genes with motif elements), and C5 
(gene sets based on gene ontology terms) (see Methods). We performed over-
representation analysis for the predicted IRE gene sets (all 3’ IREs and all 5’ IREs) 
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separately for each species (human, mouse, zebrafish), and used Wilkinson’s meta-
analytic approach to determine gene sets that were significantly over-represented 
across the three species’ IRE gene sets. Our results indicated that 1,148 of 10,427 
tested gene sets displayed over-representation of IRE gene sets across all three 
species (Bonferroni-adjusted Wilkinson’s p-value < 0.05) (Supplementary Table 2). 
Remarkably, the “Blalock Alzheimer’s Disease Up” gene set from the C2 collection 
was significantly over-represented in both the sets of all 3’ IREs (Bonferroni-
adjusted Wilkinson’s p-value = 3.9e-14) and all 5’ IREs (Bonferroni-adjusted 
Wilkinson’s p-value = 2.1e-26) in the meta-analysis, and was also the gene set with 
the most significant over-representation of the human all 3’ IREs set (Bonferroni-
adjusted Fisher’s exact test p-value = 7.8e-58) (Supplementary Table 2). This 
supports that disturbance of iron homeostasis particularly distinguishes Alzheimer’s 
disease from other disease conditions and pathways represented within the C2 
collection. In addition, the top 15 MSigDB gene sets showing the most significant 
over-representation generally differed between species. However, in all cases, a 
large proportion of IRE genes from the predicted IRE gene sets were not contained 
within any of these top-ranked MSigDB gene sets or within the Heme Metabolism 
geneset belonging to the Hallmark collection (Figure 3). This demonstrates that the 
predicted IRE genes we defined are not fully captured by existing gene sets and so 
may be uniquely useful for investigating gene expression changes during the IRE-
IRP response to iron dyshomeostasis.  
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Involvement of transcription factor regulation within IRE gene sets 
To be confident that IRE gene sets accurately capture information about the 
IRP/IRE-mediated responses, we needed to investigate possible co-ordinate 
regulation by other factors. As a starting point, we examined whether known binding 
motifs for transcription factors were significantly over-represented in the promoter 
regions of genes within each IRE gene set (all 3’ IREs, all 5’ IREs, HQ 3’ IREs, and 
HQ 5’ IREs) for each species. We detected significant over-representation of several 
transcription factors including the Klf14 motif in the zebrafish all 3’ IREs set (FDR-
adjusted p-value = 0.049), the E2F motif in the human all 5’ IREs set (FDR-adjusted 
p-value = 0.049) and the Bach1 (FDR-adjusted p-value = 0.012), Nrf2 (FDR-adjusted 
p-value = 0.013),  and NF-E2 (FDR-adjusted p-value = 0.019) motifs in the zebrafish 
HQ 5’ IREs set (Supplementary Table 3). This suggests that the expression of 
subsets of genes in some of the IRE gene sets may be influenced by other factors. 
 
Gene set enrichment testing approach 
Our predicted IRE gene sets can be used in any standard gene set enrichment 
testing approach to detect potential changes in iron homeostasis between 
conditions. Our workflow, which we later successfully apply on human, mouse, and 
zebrafish datasets, is shown in Figure 4. Due to variability in the results produced by 
different gene set enrichment testing methods, we were inspired by the EGSEA 
framework [30] to combine the results from different methods. Based on an initial 
analysis using EGSEA, we chose fry/mroast [31,32], camera [33], and fgsea [34,35] 
as the representative methods to use. (See Supplementary Figure 1 for a principal 
component analysis of results from different gene set enrichment analysis 
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approaches.) A summary of the different characteristics of the three methods is 
shown in Table 1. The raw enrichment p-values from these approaches can be 
combined to obtain an overall enrichment p-value for each gene set. In accordance 
with EGSEA default parameters, we used Wilkinson’s method to combine raw p-
values, and then applied adjustment for multiple testing on all combined p-values. 
Along with performing this gene set enrichment testing on our IRE gene sets, we 
also recommend using the same method to test for enrichment for the MSigDB 
Hallmark gene sets as the diverse biological activities they represent help to provide 
context for interpreting the IRE enrichment results. To explore further the results of 
IRE gene set enrichment analysis, we use UpSet plots to display the overlap 
between sets of “leading-edge” genes in the all 3’ IREs and all 5’ IREs gene sets. 
The leading-edge genes can be interpreted as the core (often biologically important) 
genes of a gene set that account for the significant enrichment as calculated by 
GSEA [35]. 
 
Differences in IRE gene set enrichment during iron deficiency and iron 
overload in a cultured cell line 
We first tested how our enrichment approach illuminated the effects of iron overload 
and deficiency in a cultured cell line microarray dataset from Caco-2 cells (GEO 
accession: GSE3573). As only one cell type contributed to this dataset, interpretation 
of the IRE enrichment results is simplified by not having to consider the differing iron 
requirements of different cell types. This allowed us to focus on whether the iron 
dyshomeostasis treatments (iron overload and iron deficiency) could be detected 
and distinguished in terms of their IRP/IRE system-driven transcript abundance 
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response. Because the dataset was from a microarray experiment, we performed 
only the differential gene expression and gene set enrichment testing portions of our 
workflow. The results of Principal Component Analysis and differential gene 
expression analysis are provided in Supplementary Figure 2.  
 
In general, we found iron deficiency and iron overload treatments resulted in different 
gene expression responses. In terms of differential gene expression, iron deficiency 
was associated with 96 differentially expressed genes of which 10 possess predicted 
IREs while iron overload was associated with 212 differentially expressed genes 
(FDR-adjusted p-value from limma < 0.05) of which 33 possess predicted IREs 
(Supplementary Figure 2). There were 17 differentially expressed genes in 
common between iron deficiency and iron overload treatments, and all moved in 
opposite directions according to the treatment (i.e. increased abundance under iron 
deficiency and decreased abundance under iron overload, or vice versa). These 
differences between iron deficiency and iron overload were reflected in gene set 
enrichment analyses using the MSigDB Hallmark gene sets, where the gene sets 
involved and the proportions of gene transcripts with increased or decreased 
abundance differed (Figure 5A). As expected, IRE gene sets also showed significant 
enrichment under iron deficiency and overload conditions (Figure 5B) (Bonferroni 
adjusted p-value < 0.05).  
 
We expected that iron deficiency would result in increased expression of genes with 
3’ IREs under the IRP/IRE paradigm. However, both the 3’ and 5’ IRE gene sets 
displayed mixed patterns of increased and decreased expression under both the iron 
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deficiency and iron overload treatments (Figure 5B). This indicates it would be 
difficult to distinguish between these conditions based purely on overall increases or 
decreases in the expression of IRE gene sets. Despite this, we see that the iron 
deficiency and iron overload treatments can be distinguished by their “leading-edge” 
genes (those genes contributing most to the enrichment signal for the predicted IRE 
gene sets (all 3’ IREs and all 5’ IREs) (Figure 5C). This supports that gene set 
enrichment using our predicted IRE gene sets is sufficiently sensitive to detect 
whether iron dyshomeostasis is present and to distinguish between different IRE-
mediated gene expression responses in iron deficiency and iron overload 
treatments.  
 
A distinct iron homeostasis response in human AD patients compared to 
other neuropathologies 
Given that IRE gene sets could distinguish between iron overload and deficiency in a 
cultured cell line, we next tested our gene sets on a more complex data set including 
cerebellum and temporal cortex tissue samples from post-mortem human brains. 
The brains originated from either healthy controls or patients with one of three 
conditions: AD; pathological aging (PA), a condition involving amyloid pathology but 
no significant dementia symptoms; or progressive supranuclear palsy (PSP), a 
tauopathy without amyloid pathology [36]. An important characteristic of the dataset 
is that both cerebellum and temporal cortex tissue samples were available from each 
patient. A summary of the 236 patients whose data we included in this analysis is 
shown in Table 2 and the results of differential gene expression analysis and IRE 
gene set enrichment analysis are shown in Table 3 and Figure 6A. In our analyses, 
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we focus mainly on comparing conditions within each tissue rather than between 
tissues. This is because we found significant differences in the AD vs. control 
comparison in the temporal cortex compared to the cerebellum (see Supplementary 
Figure 3).  
 
Overall, our IRE enrichment analyses indicate significant enrichment of IRE gene 
sets in all pathological conditions (AD, PA or PSP) compared to healthy controls 
within the cerebellum and temporal cortex (Figure 6A). In all pathological conditions, 
3’ and 5’ IRE gene transcripts show overall mixed patterns of abundance (e.g. 
increased and decreased). Further examination of the leading-edge genes from 
these IRE gene sets gives more insight regarding potential differences and 
similarities between AD, PA, and PSP (Figure 6B). Overall, AD, PSP, and PA 
appear to involve distinct yet partially overlapping IRE gene expression responses in 
a tissue-specific manner. Within the temporal cortex, there are 435 3’ IRE leading-
edge genes and 178 5’ IRE leading-edge genes exclusively present in the “AD vs. 
control” comparison. These are greater numbers than for the other two conditions. 
Interestingly, AD and PA share only relatively small numbers of leading-edge genes 
despite the fact that many regard PA as a prodrome of AD [37]. These observations 
suggest that iron dyshomeostasis may be an essential component of AD cognitive 
change. Interestingly, in the cerebellum, while AD and PSP share many 3’ and 5’ 
IRE leading-edge genes, PA is associated with a large number of unique leading-
edge 3’ and 5’ IRE genes, further emphasising its difference from AD and also PSP. 
In general, our IRE gene sets appear sufficiently sensitive to discern and identify 
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potentially interesting biological differences between these different pathological 
conditions affecting the brain.  
 
Age-dependent disruption of IRE-driven iron homeostasis in the 5XFAD 
mouse model  
Alzheimer’s disease is thought to develop over decades [38–40]. However, detailed 
molecular studies of AD brains can only be based on post-mortem tissues. To reveal 
the early molecular changes that initiate the progression to AD we must study the 
brains of animal disease models. Given that the IRE gene sets appear to work well in 
human datasets, we then tested our mouse IRE gene sets on an RNA-seq dataset 
derived from brain cortex tissue of the 5XFAD transgenic mouse AD model (GEO: 
GSE140286). The 5XFAD mouse is one of the most common systems used to 
model the amyloid beta and tau histopathologies of AD brains. It possesses two 
transgenes that include a total of five different mutations, each of which individually 
causes fAD in humans. In this dataset, the mice analysed were either 3, 6 or 12 
months of age. 
 
Using gene set enrichment testing methods as before, we observed significant 
enrichment of the all 3’ IREs and all 5’ IREs gene sets in several comparisons. 
These included 5XFAD vs. wild type comparisons and wild type aging comparisons 
(Bonferroni-adjusted enrichment p-value < 0.05) (Figure 7A). Notably, even the 
youngest age group of 5XFAD mutant mice (3 months) displayed significant 
enrichment of genes containing 3’ or 5’ IREs compared to age-matched wild types. 
This is consistent with an enrichment of immune-related Hallmark gene sets that we 
104
observed in this age group (see Figure 7B) and with a previous transcriptome 
analysis suggesting immune activation in 5XFAD mice as early as 2-4 months [41]. 
UpSet plots of overlapping leading-edge genes suggest that the IRE responses due 
to aging and due to the 5XFAD transgenes may involve partially overlapping gene 
expression changes (Figure 7C). In addition, the UpSet plots reveal subsets 
containing large numbers of IRE-containing genes which uniquely contribute to 
enrichment of IRE gene sets in only one comparison (e.g. 256 3’ IRE genes only 
contribute to enrichment in the “5xFAD vs WT at 6 months” comparison). Notably, 
there are 126 shared 3’ IRE genes contributing to enrichment in the “5xFAD vs WT 
at 6 months” and “5xFAD vs WT at 3 months” comparisons, but no genes shared 
between these comparisons and the “5xFAD vs WT at 12 months” comparison. 
These 126 genes were found to show over-representation of Gene Ontology terms 
including “Hsp70 protein binding” and “nuclear import signal receptor” (FDR-adj. p-
value < 0.05) (Supplementary Table 4), suggesting that subsets of leading-edge 
genes may have biological relevance, and that these may give clues into the 
biologically distinct age-dependent iron dyshomeostasis responses caused by the 
5XFAD transgenes. Although beyond the scope of our current analysis, further 
investigation into these subsets of genes may further help to define differences in 
iron dyshomeostasis responses under different biological conditions of interest.  
 
Similarities in IRE-driven iron homeostasis responses during hypoxia 
and a familial AD-like mutation in a zebrafish model 
Concerns have been raised over the relevance of transgenic mouse models in 
modelling the early stages of AD (reviewed by [42]). In contrast, knock-in models of 
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familial AD (fAD) only exhibit subtle pathological changes with little to no visible 
amyloid or tau pathology present [43]. However, because they more closely mimic 
the genetic state of fAD, knock-in models may reveal the early molecular changes 
that drive later fAD pathology. We had access to whole-brain RNA-seq data from a 
knock-in zebrafish model of fAD possessing a single fAD-like mutation in its 
endogenous psen1 gene (psen1Q96_K97del/+). Previous analysis of a subset of this 
dataset involving young adults (6-month-old brains) revealed gene expression 
changes related to altered energy metabolism [44]. (In contrast, the 3-month-old 
young adult 5XFAD mouse brain dataset is dominated by immune/inflammation 
responses, Figure 7B). Considering the critical role of iron homeostasis in energy 
metabolism, we decided to revisit this zebrafish dataset. We performed IRE gene set 
enrichment on the entire dataset in order to include exploration of the effects of aging 
and acute hypoxia (two important risk factors for sporadic late onset AD) and to 
analyse how these effects interact with the fAD-like psen1Q96_K97del/+ mutant 
genotype. The experimental design and the results of the differential gene 
expression analyses and gene set enrichment tests are summarised in Figure 8.  
 
We first turned our attention to the comparison between young adult (6-month-old) 
psen1Q96_K97del/+ mutant zebrafish and their wild-type siblings. At this age, gene 
expression changes in the mutant fish likely represent early stresses driving the 
development of fAD in humans. Gene set enrichment tests in this comparison 
identify alteration of energy metabolism-related Hallmark gene sets (e.g. OXIDATIVE 
PHOSPHORYLATION, GLYCOLYSIS) (Figure 8B) which is consistent with a 
previous analysis of gene ontology terms with this dataset [44]. In addition, we see 
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enrichment of other gene sets including FATTY ACID METABOLISM, PI3K AKT 
MTOR SIGNALLING, MTORC1 SIGNALLING, and HEME METABOLISM. All of 
these gene sets which show enrichment in 6-month-old psen1Q96_K97del/+ mutants 
relative to wild-type siblings are also enriched in 24-month-old psen1Q96_K97del/+ 
mutants relative to their wild-type siblings (Figure 8B). This supports that the 
biological activities represented in these gene sets are amongst the earliest altered 
in this particular fAD mutation model. 
 
In Lumsden et al. [15] we predicted that fAD mutations in the major locus PSEN1 
would cause an early cellular deficiency of ferrous iron due to the observation of 
insufficient acidification of the endolysosomal pathway in in-vitro PSEN1 mutation 
studies [45,46]. In Newman et al. [44] we saw that GO analysis of 6 month old 
psen1Q96_K97del/+  zebrafish brain supported that lysosomal acidification was affected. 
Therefore, we decided to apply our IRE enrichment analysis to test for evidence of 
iron dyshomeostasis in these fish. The enrichment of the all 3’ IREs set in 6 month 
old psen1Q96_K97del/+  zebrafish brains supports that iron dyshomeostasis is an 
important stress in the early stages of fAD (Figure 8C). 
 
While almost all pairwise comparisons in the zebrafish dataset show significant 
enrichment of at least one IRE gene set (Figure 8C), the expression of IRE genes 
appears to differ in terms of the proportions of IRE-containing transcripts which show 
increased versus decreased abundance (Figure 8D). In addition, the Principal 
Component Analysis plot of expression of the all 3’ IREs set over all samples shown 
in Figure 8E suggests that different conditions appear to have distinct expression 
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patterns of these genes. Across the first principal component, different age groups 
(6- and 24-month-old brains) differ in their expression of predicted 3’ IRE genes, 
while the second principal component appears to separate psen1Q96_K97del/+ mutants 
from their wild-type siblings. This separation between psen1Q96_K97del/+ mutants and 
wild type siblings is even more pronounced when both are exposed to hypoxia.   
 
To gain more insight into the similarities and differences between the IRE responses 
in the psen1Q96_K97del/+ vs. wild type comparison, we plotted UpSet plots of 
overlapping leading-edge genes (Figure 8F). These plots suggest that the IRE 
responses during hypoxia, aging, and due to this fAD-like mutation are mostly 
distinct from each other with unique leading-edge genes. However, similarities in the 
IRE response between different conditions are suggested by the existence of some 
shared leading-edge genes. For example, for the set of all 3’ IREs, the “6-month-old 
psen1Q96_K97del/+  vs. wild type” comparison shares 19 leading-edge genes with the 
“24-month-old psen1Q96_K97del/+  vs. wild type” comparison. As an initial exploration of 
the biological relevance of these genes, we submitted them to the STRINGR tool. 
This indicated that the proteins products of these genes were significantly associated 
with each other (e.g. in terms of text-mining from Pubmed articles, experimentally 
determined interactions, and co-expression). These proteins were significantly over-
represented in the sets “MAPK pathway”, “AP-1 transcription factor”, “Jun-like 
transcription factor”, and “signaling by TGF-beta family members” (FDR-adjusted 
over-representation p-value < 0.05; Supplementary Figure 4). The AP-1 and MAPK 
pathways have previously been shown to be stimulated by iron depletion [47,48]. 
Therefore, mechanistically, it is possible that the IRE-IRP response to iron 
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dyshomeostasis in the fAD-like zebrafish mutant might involve these pathways, 
although this requires confirmation in vivo.  
 
The fact that aging, hypoxia, and a fAD-like mutation all cause changes in the 
abundance of IRE-containing transcripts in zebrafish raised concerns regarding the 
specificity of such changes. Therefore, as a negative control, we examined changes 
in IRE transcript abundance in a brain transcriptome dataset derived from zebrafish 
heterozygous for a psen1 mutation now thought not to be fAD-like, psen1K97fs [49]. In 
this dataset, psen1K97fs/+ zebrafish are compared to their wild type siblings at 6 and 
24 months. We tested this dataset for enrichment using our zebrafish 3’ and 5’ IRE 
gene sets but found no significant enrichment of any of our predicted IRE gene sets 
in psen1K97fs/+ vs. wild type comparisons at any age (Table 4; Supplementary 
Figure 5). Reassuringly, we still observed significant enrichment of both 3’ and 5’ 
IRE gene sets during wild type aging (24-month-old wild types vs. 6-month-old wild 
types), consistent with the equivalent comparison in the psen1Q96_K97del/+ dataset. 
These results support that IRE-containing transcript abundance changes are 
sufficiently sensitive to reflect differences in iron homeostasis between different 
mutation models. 
 
Simultaneous stabilisation of some 3’ IRE transcripts and destabilisation 
of others 
In the cultured cell line dataset analysed above, we noticed that even a 
straightforward iron deficiency treatment resulted in the simultaneous increase and 
decrease in expression of 3’ IRE-containing genes. These findings are difficult to 
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reconcile with the current paradigm that stabilisation of 3’ IRE-containing genes 
occurs under iron deficiency and suggest that the current model of the IRP/IRE 
system may be incomplete or insufficient for describing the regulation of non-
canonical IREs. Given that many predicted 3’ IRE genes with non-canonical IREs 
(e.g. in the all 3’ IREs set) displayed enrichment and different gene expression 
patterns in the fAD-like zebrafish dataset, we decided to explore further the stability 
changes of these genes by comparing the expression of spliced and unspliced 
transcripts for each gene (Supplementary Text 1). We found that transcripts of 
some predicted 3’ IRE genes were significantly increased in stability while others 
were significantly decreased in stability (Supplementary Figure 6; Supplementary 
Table 5).  
 
Discussion 
In this study we successfully identified sets of genes predicted to contain IREs in 
human, mouse, and zebrafish. We found that IRE genes were generally not well-
represented in the existing gene sets in MSigDB. Importantly, these genes were 
most significantly over-represented in an existing gene set previously shown to be 
up-regulated in AD brains (the “Blalock Alzheimer’s Disease Up” gene set from 
MSigDB). This supports the importance of iron dyshomeostasis in sporadic late 
onset Alzheimer’s disease. Furthermore, our IRE gene sets displayed significant 
enrichment in postmortem brains from a human AD cohort, from the 5XFAD mouse 
model, and from a zebrafish model of a fAD-like mutation. This demonstrates for the 
first time the involvement of a coordinated IRE-containing gene expression response 
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to iron dyshomeostasis in the context of AD. 
 
Overall, IRE-containing gene sets were sensitive enough to capture several 
interesting phenomena. The relatively tightly controlled conditions in the mouse and 
zebrafish model datasets revealed a strong age-dependent effect on the transcript 
abundances of these predicted IRE-containing genes. Notably, 3’ IRE gene 
expression changes were amongst the earliest changes observable in the zebrafish 
fAD-like mutation model alongside changes in energy metabolism. These 3’ IRE 
gene expression changes preceded other signals of pathological change in the 
transcriptome (such as altered expression of inflammatory response pathways) 
commonly associated with AD. In addition, IRE gene sets were sufficiently sensitive 
to distinguish not only between iron overload and deficiency in a cultured cell line 
dataset, but also between AD and other pathological conditions affecting the brain 
(i.e. pathological aging and progressive supranuclear palsy). This suggests that the 
dysregulation of IRE-containing genes and iron homeostasis in AD may differ from 
other conditions.  
 
Whether iron deficiency or iron overload was present in the AD brain tissue samples 
(taken from either temporal cortex or cerebellum) was unclear. Most previous work 
has assumed that accumulation of iron in the brain with age (a phenomenon 
observed broadly across animal phyla [50,51]) is indicative of cellular iron overload 
driving oxidative stress[52]. Indeed, iron accumulation and oxidative stress 
apparently contribute to the insolubility of amyloid plaques and neurofibrillary tangles 
in AD brains [53]. However, a recent publication by [54] showed that disturbed 
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lysosomal function leading to increased lysosomal pH causes a deficiency of 
functional ferrous iron (Fe2+) while non-functional ferric iron (Fe3+) accumulated in 
lysosomes. The deleterious effects of this on the brains of mice (defective 
mitochondrial biogenesis and function and stimulation of inflammatory responses) 
could be alleviated by increasing the levels of iron in their diet. The observations of 
Nixon and colleagues that acidification of the endolysomal pathway is affected both 
by fAD mutations in PSEN1 [45] and excessive dosage of the APP gene [55], 
together with our observations from our fAD-like psen1Q96_K97del/+ mutant zebrafish, 
support the possibility that fAD brains may suffer a ferrous iron deficiency in a 
background of ferric iron overload. Intriguingly, the greatest genetic risk factor for late 
onset AD, the e4 allele of the gene APOE, appears to increase lysosomal pH [56] but 
e4’s increased risk of AD is alleviated in individuals who possess the HFE 282Y 
allele that predisposes to the iron overload disease hemochromatosis [57]. Given 
that many other risk loci for sporadic late onset AD also affect endolysosomal 
pathway function (reviewed in [58]) it is reasonable to suggest that disturbed of iron 
homeostasis may afflict brains with this disease. 
 
Outside our interest in AD, our analyses also revealed the surprising finding that 3’ 
IRE-containing genes could be both upregulated and downregulated by iron 
deficiency (at least in a cultured cell line). We also observed simultaneous 
stabilisation of some 3’IRE transcripts and destabilisation of others in our analysis of 
zebrafish brains. This challenges the simplistic paradigm of stabilisation of 3’ IRE-
containing transcripts under ferrous iron deficiency. Previous research holds that 
under iron deficiency, 3’ IRE-containing genes such as DMT1 (divalent metal 
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transporter 1) and TFRC (transferrin receptor protein) are stabilised and hence 
increased in expression [21] in order to increase ferrous iron availability. However, 
our findings reveal that this same principle may not apply to other, less-characterised 
3’ IRE-containing genes, including IREs deviating from the canonical IRE sequence. 
Many of these IRE-like sequences are likely to have some functionality [24–26], and 
their expression and stability changes in our analyses indicate that they are likely to 
be important in iron dyshomeostasis responses in AD. We emphasise the need to 
characterise further the stability of these predicted 3’ IRE-containing transcripts 
under conditions of altered iron availability to better understand iron dyshomeostasis 
responses at the gene expression level.  
The limitations of our study, the conservation of IRE gene sets between species, and 




Our results demonstrate for the first time the involvement of a coordinated IRE-
containing gene expression response to iron dyshomeostasis in the context of AD. 
By searching entire human, mouse, and zebrafish transcriptomes for all genes 
containing potential IREs, we formed comprehensive gene sets effective for 
exploring iron homeostasis in any human, mouse, or zebrafish gene expression 
dataset. While, for the first time, our work suggests the existence of iron 
dyshomeostasis in the young, pre-pathology brains of PSEN1 fAD mutation carriers, 
it also reinforces the critical importance of iron dyshomeostasis in the development 
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of the late onset, sporadic form of AD. More broadly, our approach highlights how 
changes in the stability and abundance of IRE-containing transcripts can be used to 





Defining IRE gene sets for human, mouse, and zebrafish 
We extracted all 3’ and 5’ UTR sequences from the human, mouse and zebrafish 
genome assemblies using the Bioconductor packages 
BSgenome.Hsapiens.UCSC.hg38, BSgenome.Mmusculus.UCSC.mm10 and 
BSgenome.Drerio.UCSC.danRer11, and gene definitions from the Ensembl 94 
release. Each set of UTR sequences was then submitted input into the SIREs web 
server (v.2.0 [22]). The SIREs algorithm assigns quality scores to predicted IREs 
taking into account whether the sequence is canonical, whether it contains any 
mismatches and bulges, and the free energy of the secondary structure. Canonical 
sequences are tagged by SIREs as being high-quality, while IRE-like sequences are 
tagged as low or medium quality. Given that High-quality IRE predictions miss the 
majority of true IREs, this enables a more comprehensive sampling of IRE motifs. 
For human, mouse, and zebrafish, we separately defined the following four gene 
sets: HQ 3’ IREs and HQ 5’ IREs (representing genes with high-quality predicted 
IREs), along with all 3’ IREs and all 5’ IREs, which included genes containing any 
predicted IRE in the respective UTR. Comparisons between gene sets were 
performed using the UpSetR package (v.1.4.0 [59]) with mappings between species 
obtained by BioMart [60].  
 
Over-representation of IRE gene sets in existing MSigDB gene sets 
We downloaded the following gene set collections from MSigDB (v.6.0 [29]): 
Hallmark, C2 (gene sets from online pathway databases and biomedical literature, 
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including KEGG and the REACTOME databases), C3 (motif gene sets based on 
regulatory targets), and C5 (gene sets defined by Gene Ontology terms). We 
excluded the following collections from analysis: C1 (specific to human 
chromosomes and cytogenetic bands, while our analysis involves different species), 
C4 (computationally-defined cancer-focused gene sets), C6 (oncogenic signatures) 
and C7 (immunologic signatures). C4, C6, and C7 were not included as the level of 
detail in the gene sets in these specific collections is more domain-specific rather 
than broad-level.  We used Fisher’s exact test to determine whether any IRE 
geneset was significantly over-represented in each MSigDB gene set. Gene sets 
were defined as having significant enrichment for IRE gene sets if the FDR-adjusted 
p-value from Fisher’s exact test was below 0.05. UpSet plots were produced using 
the UpSetR package (v.1.4.0 [59]) while network representations were produced in 
Gephi (v.0.9.3 [61]). To produce network visualisations, we exported node and edge 
tables from R. The nodes table contained the following gene sets: top 15 gene sets 
(ranked by Fisher’s exact test p-value), Hallmark Heme Metabolism gene set, all 3’ 
IREs, all 5’ IREs, and all genes contained within these gene sets. The edges table 
contained gene – gene set edges which indicated the gene set(s) that genes 
belonged to. To create the network plots, we used “Force Atlas 2” as the initial layout 
algorithm, followed by the “Yifan Hu” [62] layout algorithm to improve the separation 
between groups of genes.  
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Over-representation analysis of transcription factor motifs in IRE gene 
promoters 
Defining promoter regions as being 1500 bp upstream and 200 bp downstream of 
the transcription start site for each gene, we used the findMotifs.pl script from 
HOMER (v.4.11) [63,64] to search for known transcription factor binding site (TFBS) 
motifs in the promoters of each IRE gene set. The HOMER Motif database contains 
363 vertebrate transcription factor binding motifs based on analysis of high-quality 
public ChIP-seq datasets 
(http://homer.ucsd.edu/homer/motif/HomerMotifDB/homerResults.html). We 
considered TFBS motifs as being significantly enriched in a gene set if the FDR-
adjusted p-value was less than 0.05.  
 
Gene set enrichment testing 
We performed all gene set enrichment tests in R v3.6.1 [65] using fry [31,32], 
camera [33], and fgsea [34,35]. For fry, and camera, we used model fits obtained 
using limma [66,67], whilst for fgsea, a ranked list was obtained using moderated t-
statistics taken from limma. All genes were used in gene set enrichment tests (i.e. 
not just DE genes). We combined the raw p-values from fry, camera, and fgsea 
using Wilkinson’s method [68] with default parameters, followed by FDR-adjustment. 
When performing gene set enrichment testing on the MSigDB Hallmark gene sets, 
we applied FDR-adjustment to combined p-values and defined significant enrichment 
as gene sets having an adjusted p-value < 0.05. When performing gene set 
enrichment on the four IRE gene sets (all 3’ IREs, all 5’ IREs, HQ 3’ IREs, HQ 5’ 
IREs), we applied Bonferroni-adjustment to combined p-values to further protect 
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against Type I errors and defined significant enrichment as gene sets having an 
adjusted p-value < 0.05. Depending on the species in the dataset being analysed, 
we used the respective IRE gene sets defined for human, mouse, or zebrafish.  
 
Analysis of the Caco-2 cultured cell line dataset 
We downloaded processed microarray data from the GEO dataset GSE3573. This 
study investigated gene expression responses to iron treatments, including iron 
deficiency (cells treated with ferric ammonium citrate), and iron overload (cells grown 
in DMEM-FBS medium with hemin) [69]. We performed differential gene expression 
analysis using the “lmFit” and eBayes” functions in limma [66]. Genes were defined 
as differentially expressed when their FDR-adjusted p-value < 0.05.  
 
Analysis of the Mayo Clinic RNA-seq dataset 
We downloaded processed CPM count data from Synapse 
(https://www.synapse.org/#!Synapse:syn5550404). We matched cerebellum and 
temporal cortex samples by their patient ID, and only retained genes which were 
present across all samples and patients for which there were both cerebellum and 
temporal cortex samples (n=236 patients with measurements for cerebellum and 
temporal cortex, 472 samples in total). We performed analysis using limma [66,67] 
and determined differentially expressed genes between conditions. In addition, we 
used the “duplicateCorrelation” function in limma, setting the “block” parameter to the 
patient ID. Genes were considered differentially expressed if their FDR-adjusted p-
value < 0.05.  
 
118
fAD-like psen1Q96_K97del/+ zebrafish 
The isolation of the psen1Q96_K97del mutation has previously been described [44]. 
Mutations were only analysed in the heterozygous state in this study. 
 
Zebrafish husbandry and animal ethics 
This study was approved under permits S-2014-108 and S-2017-073 issued by the 
Animal Ethics Committee of the University of Adelaide. Tübingen strain zebrafish 
were maintained in a recirculated water system. 
 
Hypoxia treatment of female adult zebrafish 
psen1Q96_K97del/+ mutants and their wild-type siblings were treated in low oxygen 
levels by placing zebrafish in oxygen-depleted water for 3 hours (oxygen 
concentration of 6.6 ± 0.2 mg/L in normoxia and 0.6 ± 0.2 mg/L in hypoxia.  
 
Whole brain removal from adult zebrafish 
After normoxia or hypoxia treatment adult fish were euthanized by sudden immersion 
in an ice water slurry for at least ~30 seconds before decapitation and removal of the 
entire brain for immediate RNA or protein extraction. All fish brains were removed 
during late morning/noon to minimise any influence of circadian rhythms. 
RNA extraction from whole brain 
Total RNA was isolated from heterozygous mutant and WT siblings using the 
mirVana miRNA isolation kit (Thermo Fisher). RNA isolation was performed 
according to the manufacturer’s protocol. First a brain was lysed in a denaturing lysis 
119
solution. The lysate was then extracted once with acid-phenol:chloroform leaving a 
semi-pure RNA sample. The sample was then purified further over a glass-fiber filter 
to yield total RNA. Total RNA was DNase treated using the DNA-free™ Kit from 
Ambion, Life Technologies according to the manufacturer’s instructions. Total RNA 
was then sent to the Genomics Facility at the South Australian Health and Medical 
Research Institute (Adelaide, Australia) to assess RNA quality and for subsequent 
RNA sequencing (using poly-A enriched RNA-seq technology, and estimated gene 
expression from the resulting single-end 75 bp reads using the reference GRCz11 
zebrafish assembly transcriptome) 
 
Pre-processing of the fAD-like psen1Q96_K97del/+ zebrafish dataset: 
RNA-seq libraries contained single-end 75bp Illumina NextSeq reads. We performed 
quality trimming with AdapterRemoval using default parameters, followed by quality 
assessment with FastQC and ngsReports. Trimmed reads were pseudo-aligned to 
the reference zebrafish transcriptome using Kallisto (v.0.45) [70] and transcript 
descriptions from Ensembl release 94. The “catchKallisto” function from edgeR [71] 
was used to import and summarise counts from transcript-level to gene-level, with all 
subsequent analyses performed at the gene-level.  
Differential gene expression analysis for fAD-like zebrafish dataset 
For differential gene expression analysis, we retained all genes with expression of at 
least 1 cpm in 4 or more samples, and used voomWithQualityWeights to downweight 
lower quality samples [67]. Contrasts were defined to include all relevant pairwise 
comparisons between conditions, and genes were considered as differentially 
expressed using an FDR-adjusted p-value < 0.05.  
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Estimation of spliced and unspliced gene expression in fAD-like zebrafish dataset 
For spliced transcripts in Ensembl release 94, we additionally defined unspliced 
genes including intronic regions. Unspliced transcripts were appended to the end of 
the reference transcriptome and used to build a new Kallisto [70] index. Estimated 
counts for spliced transcripts and unspliced genes were imported into R using the 
“catchKallisto” function from edgeR [71].  
 
Gene set enrichment tests for non-fAD-like (K97fs/+) zebrafish dataset 
Please refer to [44] for details on RNA-seq data processing and analysis of the non-
fAD-like dataset. In the current work, we used the gene expression counts matrix 
with limma. The voom, design, and contrasts objects produced as part of the limma 
analysis were used for gene set enrichment analysis with the zebrafish IRE gene 
sets we defined as well as the MSigDB Hallmark gene sets. Significantly enriched 
Hallmark gene sets had FDR-adjusted p-value < 0.05 while IRE gene sets were 
considered significantly enriched if the Bonferroni-adjusted p-value < 0.05.  
 
Gene set enrichment tests for 7-day-old Q96_K97del/+ dataset 
Please refer to Dong et al. (GEO accession: GSE148631, manuscript in preparation) 
for details on RNA-seq data processing and analysis. In the current work, we used 
the gene expression counts matrix with limma to perform gene set enrichment 
analysis. IRE gene sets we defined as well as the MSigDB Hallmark gene sets. 
Significantly enriched Hallmark gene sets had FDR-adjusted p-value < 0.05 while 
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IRE gene sets were considered significantly enriched if the Bonferroni-adjusted p-
value < 0.05. 
 
Differential transcript stability analysis 
The estimated spliced and unspliced transcript count estimates from kallisto [70] 
were imported into R using the catchKallisto function from edgeR [71]. We used 
limma [66] to determine the logFC of spliced transcripts and unspliced transcripts for 
each comparison. To test for whether there was a significant difference in the logFC 
of the spliced and unspliced transcripts, we used Welch’s t-test with the s2.prior 
values from limma as the variances of the spliced and unspliced transcripts. We 
defined the null (no stabilisation of transcript) and alternate (stabilisation of 
transcript) hypotheses for each gene as follows, where s and u refer to the spliced 
and unspliced versions of a particular gene:  
 
𝐻!:			logFC" = logFC#	
𝐻$:			logFC" ≠ logFC# 
 
We defined genes with FDR-adjusted p-values < 0.05 as having differential stability.   
Checks that observed gene expression differences are not artifacts of 
differences in proportions of cell types 
The Mayo Clinic RNA-seq study, 5XFAD mice, and fAD-like zebrafish datasets are 
bulk RNA-seq datasets. To confirm that any gene expression changes were likely 
due to altered transcriptional programs rather than changes in cell type proportions, 
we compared expression of marker genes for four common neural cell types 
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(astrocytes, neurons, oligodendrocytes, microglia) in conditions within each dataset.  
The marker genes for astrocytes, neurons, and oligodendrocytes were obtained from 
MSigDB gene sets from [72] which were based on studies in mice. The marker 
genes for microglia were derived from [73] which was based on studies in human 
and mouse. All gene IDs were converted to human, mouse, or zebrafish Ensembl 
IDs using BioMart [60] for each dataset. Please refer to Supplementary Text 3 and 




AD: Alzheimer’s disease 
fAD: familial Alzheimer’s disease 
sAD: sporadic Alzheimer’s disease 
FDR: False discovery rate 
GSEA: Gene set enrichment analysis 
IRE: Iron responsive element 
IRP: Iron responsive protein 
MSigDB: Molecular Signatures Database 
PA: Pathological aging 
PSP: Progressive supranuclear palsy 
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Table 1. Summary of gene set testing approaches used in our analyses.   
 




















gene set is 
tested on its 









fry() and mroast() 
functions in the 
limma 
Bioconductor 
package (Wu et 
al. 2010) 
Camera Competitive null 
hypothesis (genes 
within a set do not 
have a stronger 
association with 
experimental condition 




gene set is 
tested on its 





Yes camera() function 
in the limma 
Bioconductor 




of GSEA in R) 
Self-contained null 
hypothesis (genes 









ones are more 
significantly 
enriched) 










Table 2. Samples analysed from Mayo Clinic RNA-seq study. 
 
Group Total number % Female 
Mean age ± 
s.d (years) Diagnosis 
Alzheimer's disease 
(AD) 134 56.7 82.6 ± 7.3 
Braak Stage ≥ 4, diagnosis 
according to NINCDS-ADRDA 
criteria 
Control 130 46.2 82.9 ± 8.3 
Braak Stage ≤ 3, No or sparse 
CERAD neuritic and cortical 
plaque density, no diagnoses 
for any neurodegenerative 
disease 
Pathological Aging 
(PA) 44 54.5 84.5 ± 4.3 
Braak Stage ≤ 3, CERAD 
neuritic and cortical plaque 
density of 2 or more, no 
diagnoses for any 
neurodegenerative disease or 




164 40.2 73.8 ± 6.5 
Braak Stage ≤ 3, no or sparse 






Table 3. Differential gene expression and IRE gene set enrichment results from 
Mayo Clinic RNA-seq study. Asterisks (*) indicate significant enrichment 
(Bonferroni-adjusted Wilkinson’s p-value from fry, camera, and fgsea < 0.05). 
  Comparison 
No. of DE 
genes (FDR p-




All 3’ IREs 
enrichment p-
value 
All 5’ IREs 
enrichment p-
value 
HQ 3’ IREs 
enrichment 
p-value 






AD vs. control 
(cerebellum) 
Down: 1,422 
Up: 1,308 0.0109* 0.128 0.770 0.770 
  











PA vs. control 
(cerebellum) 
Down: 254, Up: 
463 
0.000116* 0.00139* 0.0201* 0.770 
  
PA vs. control 
(temporal 
cortex) 
Down: 466, Up: 





























0.000116* 0.00139* 0.0201* 0.770 
  












AD vs. PSP 
(cerebellum) 
Down: 108, Up: 
659 
0.0019* 0.00184* 0.158 0.158 
  




















cortex in AD 
Down: 11,966, 




cortex in PA 
Down: 10,200, 




cortex in PSP 
Down: 11,552, 
Up: 9,576 0.00E+00* 0.00E+00* 0.00E+00* 4.74E-104* 
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Table 4. Enrichment of Iron Responsive Element (IRE) gene sets in fAD-like 
zebrafish dataset. Raw p-values from fry, camera and fgsea were combined with 
Wilkinson's method, with combined p-values then Bonferroni-adjusted for multiple 
testing. The same process was repeated for the K97fs/+ dataset, which involves an 
independent family of fish (†). 
  Comparison 
All 3’ IREs 
enrichment p-
value 
All 5’ IREs 
enrichment p-
value 
HQ 3’ IREs 
enrichment p-
value 
HQ 5’ IREs 
enrichment p-
value 




month-old +/+ all under 




month-old +/+ all under 




month-old +/+ all under 




month-old +/+ all under 
hypoxia 0.000521 0.0461 0.000065 0.0000682 
  
6-month-old K97fs/+ vs. 
6-month-old +/+ all under 
normoxia † 0.199 0.289 0.0197 0.289 
  
24-month-old K97fs/+ vs. 
24-month-old +/+ all 
under normoxia † 0.116 0.115 0.00000118 0.979 
Effect of 
hypoxia 
6-month-old +/+ under 
hypoxia vs. 6-month-old 
+/+ under normoxia 1.10E-18 1.10E-18 8.19E-13 1.27E-08 
  
24-month-old +/+ under 
hypoxia vs. 24-month-old 




hypoxia vs. 6-month-old 
Q96_K97del/+ under 




hypoxia vs. 24-month-old 
Q96_K97del/+ under 
normoxia 0.000521 0.015 0.128 0.770 
Effect of aging 
24-month-old +/+ vs. 6-
month-old +/+ all under 
normoxia 6.80E-35 4.82E-27 3.41E-18 1.26E-21 
  
24-month-old +/+ vs. 6-
month-old +/+ all under 










all under hypoxia 3.77E-30 1.59E-23 2.11E-19 2.46E-16 
  
24-month-old +/+ vs. 6-
month-old +/+ all under 
normoxia (K97fs family) † 1.69E-10 3.96E-08 5.95E-10 4.59E-06 
  
24-month-old K97fs/+ vs. 
6-month-old K97fs/+ all 
under normoxia † 0.199 0.289 0.0197 0.289 
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Figure 1. IRE background. A. Model of altered transcript stability due to the IRP/IRE system 
under iron dyshomeostasis. When cellular iron levels (through FeS) are low, ACO1 will undergo 
a conformational transformation and act as an IRP to bind IREs in the 5’ or 3’ untranslated 
region (UTR) of genes involved in iron homeostasis. In general, genes with IREs in their 3’ UTR 
will be stabilised and increased in expression while genes with IREs in their 5’ UTR will have 
their translation inhibited by the IRP. B. Consensus IRE secondary structure and examples 
of high-quality and IRE-like motifs predicted by SIREs. IRE-like motifs with non-canonical 
structure are able to be detected by SIREs if they have up to one mismatch pair in the upper stem 
(e.g. Hao1) or 1 unpaired bulge nucleotide on the 3’ strand of the upper stem (e.g. EPAS1). For 




























































































All predicted 3’ IRE genes All predicted 5’ IRE genes
High-quality predicted 3’ IRE genes High-quality predicted 5’ IRE genes
Figure 1. Overlap between predicted IRE gene sets for human, mouse, and zebrafish. The number of genes in the gene set for each 
species is shown at the bottom-left bars of each UpSet plot, while genes with shared homologs across species are indicated in the main plot 
region. IRE genes in mouse and zebrafish gene sets were excluded from this plot if they did not have a human homolog. 
Figure 2. Overlap between predicted IRE gene sets for human, mouse, and zebrafish. The 
number of genes in the gene set for each species is shown at the bottom-left bars of each UpSet 
plot, while genes with shared homologs across species are indicated in the main plot region. IRE 
genes in mouse and zebrafish gene sets were excluded from this plot if they did not have a human 
homolog. 
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Figure 3. MSigDB gene sets showing over-representation of predicted 3’ and 5’ IRE 
genes in human, mouse, and zebrafish. The top 15 MSigDB gene sets ranked by Fisher’s 
exact test p-value (testing for over-representation of the all 3’ IREs and/or all 5’ IREs sets) 
are shown for each species. In the network plots, the top 15 MSigDB gene sets are shown as 
large nodes, with genes represented as small nodes. Edges connecting genes to gene sets in-
dicate the gene set(s) that a gene belongs to. Overall, the all 3’ IREs and all 5’ IREs gene sets 
have a large proportion of genes which are not included in any of the top ranked MSigDB 
















• Predicted IRE gene sets





Combine raw p-values with 
Wilkinson’s method + 
adjustment for multiple tests
• Differentially 
expressed genes
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(design, contrasts, 
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Welch’s t-test on logFC of 
spliced and unspliced genes 
to determine if changes in 
stability between 
experimental conditions are 





• Leading edge genes 
contributing to fgsea
enrichment signal for IRE 
gene sets• Proportions of genes in 
each gene set showing 
increased or decreased 
expression 
Figure 4. IRE-containing gene expression analysis workflow. The section including identification of can-
didate 3’ IRE genes stabilised under iron deficiency was only applied to the fAD-like zebrafish dataset due 




















All predicted 3’ IRE genes All predicted 5’ IRE genes
Figure 4. Analysis of Caco-2 cultured cell line microarray dataset. A. Gene 
set enrichment testing results for human predicted IRE gene sets for the iron 
overload and iron deficiency treatments. Dots indicate if a gene set was consid-
ered significantly enriched (Bonferroni-adjusted p-value < 0.05) in the iron overload 
(on left) or iron deficiency (on right) treatment. B. Gene set enrichment testing 
results for MSigDB Hallmark gene sets in the iron overload and iron deficien-
cy treatments. Dots indicate if a gene set was considered significantly enriched 
(FDR-adjusted p-value < 0.05) in the iron overload (on left) or iron deficiency (on 
right) treatments. C. UpSet plots showing overlap between iron overload and 
iron deficiency treatments in GSEA leading-edge genes for the “All predict-
ed 3’ IRE genes” and “All predicted 5’ IRE genes” gene sets.  The bars to the 
lower-left indicate the number of the leading-edge genes for iron overload and iron 
deficiency treatments, while the bars in the main plot region indicate the number of 
leading-edge genes which are unique or shared between the treatments. 
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Figure 5. Analysis of Caco-2 cultured cell line microarray dataset. A. Gene set enrichment testing results for human pre-
dicted IRE gene sets for the iron overload and iron deficiency treat ents. Dots indicate if a gene set was considered signifi-
cantly enriched (Bonferroni-adjusted p-value < 0.05) in the iron overload (on left) or iron deficiency (on right) treatment. B. 
Gene set enrichment testing results for MSigDB Hallmark gene sets in the iron overload and iron deficiency treatments. 
Dots indicate if a gene set was considered significantly enriched (FDR-adjusted p-value < 0.05) in the iron overload (on left) or 
iron deficiency (on right) treatments. C. UpSet plots showing overlap between iron overload and iron deficiency treatments 
in GSEA leading-edge genes for the “All predicted 3’ IRE genes” and “All predicted 5’ IRE genes” gene sets.  The bars to the 
lower-left indicate the number of the leading-edge genes for ir n overload and iron deficiency treatments, while the bars in the 
main plot region ind cate he number of leading-edge genes which are unique or shared b tween the treatments. 144
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Cerebellum
Figure 6. Analysis of Mayo Clinic RNA-seq dataset with human IRE gene sets. A. Enrichment anal-
ysis results of IRE gene sets in comparisons of AD (Alzheimer’s Disease), PA (Pathological Aging), 
and PSP (Progressive Supranuclear Palsy) vs. control. The proportions of IRE genes within each 
IRE gene set with increased, decreased, or unchanged expression are indicated as coloured bars. The 
dots indicate that the IRE gene set was significantly enriched (Bonferroni-adjusted enrichment p-value 
< 0.05). B. UpSet plots showing overlap between leading-edge IRE genes in comparisons of AD 
(Alzheimer’s Disease), PA (Pathological Aging), and PSP (Progressive Supranuclear Palsy) vs. con-
trol. The bars to the lower-left region of each UpSet plot indicate the number of leading-edge IRE genes 
for each comparison, while bars in the main plot region indicate the number of leading-edge IRE genes 
which are unique or shared between comparisons. 
Figu  6. Analysis of Mayo Clinic RNA- eq dataset with human IRE gene sets. A. Enrichment anal-
ysis results of IRE gene sets in comparisons of AD (Alzheimer’s Disease), PA (Pathological Aging), 
and PSP (Progressive Supranuclear Palsy) vs. control. The proportions of IRE genes within each IRE 
gene set with increased, decreased, or unchanged expression are indicated as coloured bars. The dots in-
dicate that the IRE gene set was significantly enriched (Bonferroni-adjusted enrichment p-value < 0.05). 
B. UpSet plots showing overlap between leading-edge IRE genes in comparisons of AD (Alzheimer’s 
Dis se), PA (Pathological Aging), and PSP (P ogressive Supranuclear Palsy) vs. control. The bars to 
the lower-left regi n of each UpSet pl t indicate the number of leading-edge IRE genes for each compar-
ison, while bars in the main plot region indicate the number of leading-edge IRE genes which are unique 
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Figure 7. Analysis of 5XFAD mouse dataset. A. Experimental design and results of IRE gene set enrichment 
analysis. The gene sets all 3’ IREs and all 5’ IREs derived from searching for IRE sequences in the UTRs of genes in the 
reference mouse genome mm10 are represented here as “3’ IRE” and “5’ IRE” respectively. Asterisks (*) indicate that the 
gene set was significantly enriched in a particular comparison (Bonferroni-adjusted p-value < 0.05). B. Proportions of 
genes in IRE and MSigDB Hallmark gene sets which are increased (t > 2) or decreased (t < -2) in expression in all 
“5XFAD vs. wild type” comparisons. A dot next to a bar indicates that the gene set was significantly enriched (FDR-
adjusted p-value < 0.05). 
Figure 7. Analysi  of 5XFAD ous  dataset. A. Experimental design and ults of IRE gene set enrichment analysis. 
The gene sets all 3’ IREs and all 5’ IREs derived from searching for IRE sequences in the UTRs of genes in the reference 
mouse genome mm10 are represented here as “3’ IRE” and “5’ IRE” respectively. Asterisks (*) indicate that the gene set was 
significantly enriched in a particular comparison (Bonferroni-adjusted p-value < 0.05). B. Proportions of genes in IRE and 
MSigDB Hallmark gene sets which are increased (t > 2) or decreased (t < -2) in expression in all “5XFAD vs. wild type” 
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Figure 8. UpSet plots showing the overlap in GSEA leading-edge genes between all comparisons in the 5XFAD 
mouse datasets for the gene sets all 3’ IREs and all 5’ IREs. Numbers of genes for each intersection are shown 
above intersection bars.
Figure 8. UpSet plots showing the overlap in GSEA leading-edge genes between all comparisons in 
the 5XFAD mouse datasets for the gene sets all 3’ IREs and all 5’ IREs. Numbers of genes for each 
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Figure 9. Differential gene expression and gene set enrichment analysis in the fAD-like zebrafish dataset. A. Re-
sults of differential gene expression analysis. Genes which were significantly increased or decreased in expression 
are indicated in boxes. These differentially expressed genes have FDR-adjusted p-value < 0.05. B. Gene set enrich-
ment with MSigDB Hallmark gene sets. The comparisons between Q96_K97del/+ fAD-like mutants and their
wild-type siblings are shown for the 6-month-old (young adult) and 24-month-old (infertile adult) age groups. 
Dots indicate gene sets which are significantly enriched (FDR-adjusted p-value < 0.05). 
Figure 9. Differential gene expression and gene set enrichment analysis in the fAD-like zeb afish data-
set. A. Results of differential gene expression analysis. Genes which were significantly increased or de-
creased in expression are indicated in boxes. These differentially expressed genes have FDR-adjusted p-value 
< 0.05. B. Gene set enrichment with MSigDB Hallmark gene sets. The comparisons between Q96_
K97del/+ fAD-like mutants and their wild-type siblings are shown for the 6-month-old (young adult) 
and 24-month-old (infertile adult) age groups. Dots indicate gene sets which are significantly enriched 
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Figure 10. Iron Responsive Element (IRE)-containing gene expression in the fAD-like zebrafish dataset. A. 
Results of gene set enrichment testing using predicted IRE gene sets. We represent the gene sets all 3’ IREs 
and all 5’ IREs derived from searching for IRE and IRE-like sequences from z11 reference zebrafish gene UTRs as 
“3’ IRE” and “5’ IRE” in the panel. B. Proportions of predicted IRE genes which are increased (t > 2)  or de-
creased (t < -2) in expression  for each pairwise comparison in the dataset. C. Principal component analysis 
of all genes in the sets all 3’ IREs and all 5’ IREs for all samples. Circles on the 3’ IRE plot show that different 
conditions generally have distinct expression of genes in the all 3’ IREs set but not in the all 5’ IREs set. D. UpSet 
plot showing overlap in leading-edge genes for the “all predicted 3’ IRE genes” for select comparisons. 
Figure 10. Iron Responsive Element (IRE)-containing gene expression in the fAD-like zebrafish dataset. A. 
Results of gene set enrichment testing using predicted IRE g ne sets. We represent the gene sets all 3’ IREs and all 
5’ IREs d riv  from searching for IRE and IRE-like sequences from z11 refer nce zebrafish gene UTRs as “3’ IRE” 
and “5’ IRE” in the panel. B. Proportions of predicted IRE genes which are increased (t > 2)  or decreased (t < -2) 
in expression  for each pairwise comparison in the dataset. C. Principal component analysis of all genes in the 
sets all 3’ IREs and all 5’ IREs for all samples. Circles on the 3’ IRE plot show that different conditions generally 
have distinct expression of genes in the all 3’ IREs set but not in the all 5’ IREs set. D. UpSet plot showing overlap 
in leading-edge genes for the “all predicted 3’ IRE genes” for select comparisons. 149
Supplementary Information Legends 
 
Note: Supplementary Tables and Text files are hosted on Figshare 
(https://figshare.com/s/104097febc1b8970fc5d).  
 
Supplementary Table 1. Iron Responsive Element (IRE) gene sets defined from 
human, mouse, and zebrafish transcriptomes. The untranslated regions (UTR) of 
all known genes were searched for IRE and IRE-like motifs. Four gene sets are 
included for each species: all 3’ IREs (all genes with predicted IRE in their 3’ UTR), 
all 5’ IREs (all genes with predicted IRE in their 5’ UTR), HQ 3’ IREs (genes with 
high-quality predicted IRE in 3’ UTR), and HQ 5’ IREs (genes with high-quality 
predicted IRE in 5’ UTR).  
 
Supplementary Table 2. MSigDB gene sets with significant over-representation 
of IRE gene sets in human, mouse, and zebrafish. Gene sets were defined to 
have significant over-representation of IRE gene sets if the FDR-adjusted Fisher’s 
exact test p-value was < 0.05.  
 
Supplementary Table 3. Promoter motif over-representation analysis results 
for all IRE gene sets in human, mouse, and zebrafish. Promoter regions were 
defined as being 1500 bp upstream and 500 bp downstream of genes. See methods 
for details. Significant over-representation of a promoter occurred when the FDR-
adjusted enrichment p-value < 0.05.  
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Supplementary Text 1. Identifying predicted 3’ IRE genes with altered stability.  
 
Supplementary Text 2. Additional discussion.  
Supplementary Text 3. Proportions of  neural cell type markers (in astrocytes, 
neurons, oligodendrocytes, and microglia) in datasets analysed.  
 
Supplementary Figure 1. Principal Component Analysis of results from 
different gene set testing methods. 
 
Supplementary Figure 2. Analysis of cultured Caco-2 cell line dataset. A. 
Principal Component Analysis plot of gene expression in the cultured Caco-2 cell line 
dataset. B. Volcano plots indicating differential gene expression due to iron overload 
(DMEM-FBS Medium + Hemin vs. DMEM-FBS Medium) and iron deficiency (Iron-
free medium vs. Iron-free medium + FAC) treatments in the Caco-2 cell line dataset. 
 
Supplementary Figure 3. Gene set enrichment testing results for the AD vs. 
control comparison in cerebellum and temporal cortex.  
 
Supplementary Figure 4. STRINGR protein-protein interaction network plot 
between the 19 shared leading-edge genes between the psen1Q96_K97del/+ 
and psen1+/+ comparisons at 6 and 24-months-old. 
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Supplementary Figure 5. Principal Component Analysis plots demonstrating 
the minimal association between IRE gene expression and the psen1K97fs/+ 
mutant genotype. 
 
Supplementary Figure 6. Predicted 3’ IRE containing transcripts with 
significant differences in stability between conditions in the fAD-like zebrafish 
dataset. 
 
Supplementary Figure 7. Age-dependent expression of neural marker genes 
(microglia, astrocyte, neuron, oligodendrocyte) in human Mayo Clinic RNA-seq 
dataset analysed. 
 
Supplementary Figure 8. Age-dependent expression of neural marker genes 
(microglia, astrocyte, neuron, oligodendrocyte) in 5XFAD mouse cortex RNA-
seq dataset. 
 
Supplementary Figure 9. Age- and hypoxia- dependent expression of neural 
marker genes (microglia, astrocyte, neuron, oligodendrocyte) in fAD-like 








Principal Component Analysis of results from different gene set testing 
methods.  
 
We used EGSEA (v.1.10.1) with default settings with R objects (design, contrasts, 
voom) from limma analysis of the fAD-like zebrafish dataset (n=32). EGSEA was run 
with the following methods: camera (limma v.3.38.3), safe (safe v.3.22.0), gage 
(gage v.2.32.1), plage (GSVA v.1.30.0), zscore (GSVA v.1.30.0), gsva 
(GSVA:1.30.0), ssgsea (GSVA v.1.30.0), globaltest (globaltest v.5.36.0), ora (stats 
v.3.5.2), fry (limma v.3.38.3). The Principal Component Analysis plot shows the 
relative similarity of the results obtained from running different methods, overall 
revealing three main groupings. To minimise the chance of p-value inflation from 
combining multiple methods that give essentially the same results, we decided to 
use one representative method from each group in our final analyses: camera, fry, 
and fgsea. Although fgsea is not a method included in EGSEA, we chose to include 
it as it implements the classic GSEA algorithm and also includes information about 




















A. Principal Component Analysis plot of gene expression in the cultured 
Caco-2 cell line dataset. The plot uses pre-processed and normalised 
expression values for 22,153 probesets across all samples.  
 
B. Volcano plots indicating differential gene expression due to iron overload 
(DMEM-FBS Medium + Hemin vs. DMEM-FBS Medium) and iron deficiency 
(Iron-free medium vs. Iron-free medium + FAC) treatments in the Caco-2 cell 
line dataset. Horizontal lines indicate an FDR-adjusted p-value of 0.05, with all 
genes with FDR-adjusted p-value < 0.05 considered significantly differentially 
expressed (DE). In the iron deficiency treatment, this resulted in 96 significantly 
DE genes (65 down, 31 up), while in the iron overload treatment there were 212 
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Gene set enrichment testing results for the AD vs. control comparisons in 
cerebellum and temporal cortex.  
 
A. Enrichment results for MSigDB Hallmark gene sets 
B. Enrichment results for human IRE gene sets 
Dots to either the left or right side of the gene set name indicate that the gene set is 
significantly enriched in either the “AD vs. control with cerebellum tissue” or “AD vs. 
control with temporal cortex tissue” comparisons respectively (Bonferroni-adjusted p-
value < 0.05). 
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STRINGR protein-protein interaction network plot between the 19 shared 
leading-edge genes between the psen1Q96_K97del/+ and psen1+/+ comparisons at 6 
and 24-months-old. Nodes are named with gene symbols and edges indicate a 
known or predicted protein-protein interaction. Coloured nodes indicate genes 
contributing to significant over-representation of particular gene sets (FDR-adjusted 
p-value < 0.05).  
 
  
KEGG: MAPK signaling pathway
INTERPRO: Jun-like transcription factor
INTERPRO: AP-1 transcription factor
Reactome: Signaling by TGF-beta family members
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Supplementary Figure 5. 
A    3’ IRE genes  5’ IRE genes 
B   All genes (18,296 genes) 
Principal Component Analysis plots demonstrating the minimal association 
between IRE gene expression and the psen1K97fs/+ mutant genotype. A. 
Principal Component Analysis plots using expression of the zebrafish “all 
predicted 3’ IRE genes” and “all predicted 5’ IRE genes” gene sets. B. 
Principal Component Analysis plot of all genes detected in the dataset. Unlike 
for the fAD-like psen1Q96_K97del/+ mutant, the non fAD-like psen1K97fs/+ mutant does 
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Supplementary Figure 6. Predicted 3’ IRE-
containing transcripts with significant 
differences in stability between conditions 
in the fAD-like zebrafish dataset. Tran-
scripts are defined to be stabilised if the log2 
fold-change of the spliced transcript is sig-
nificantly greater than the log2 fold-change 
of the unspliced transcript. Likewise, tran-
scripts are defined to be destabilised if the 
log2 fold-change of the spliced transcript is 
significantly less than the log2 fold-change of 
the unspliced transcript. All tests were done 
using Welch’s t-test with FDR-adjusted p-val-
ue < 0.05. 
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Supplementary Figure 7.  
 
Age-dependent expression of neural marker genes (microglia, astrocyte, 
neuron, oligodendrocyte) in human Mayo Clinic RNA-seq dataset analysed.  
 
Microglia marker gene expression (20 genes) 
 





Neuron marker gene expression (74 genes) 
 
 
Oligodendrocyte marker gene expression (83 genes) 
 
 
Error bars represent the 95% confidence interval. Overall, while we see differences 
in expression, there does not appear to be an overall systematic difference between 
AD vs. control for oligodendrocyte, neuron and microglial marker gene expression. 
For the astrocyte markers, AD brains appear to systemically have higher expression 
of these genes.   
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Supplementary Figure 8. 
 
Age-dependent expression of neural marker genes (microglia, astrocyte, 
neuron, oligodendrocyte) in 5XFAD mouse cortex RNA-seq dataset.  
 
Microglial marker gene expression (22 genes) 
 
 




Neuron marker gene expression (67 genes) 
 
 





Supplementary Figure 9. 
 
Age- and hypoxia- dependent expression of neural marker genes (microglia, 
astrocyte, neuron, oligodendrocyte) in fAD-like zebrafish whole-brain RNA-seq 
dataset analysed.  
 
Microglial marker gene expression (16 genes) 
 
 





Neuron marker gene expression (87 genes) 
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Abstract 
Characterisation of the global transcriptional states underlying Alzheimer’s disease 
(AD) is an ongoing effort, challenged by the complexity and heterogeneity of the 
disease as well as access to samples. Many publicly available gene expression 
datasets representing different animal models of AD and human cohorts are not 
immediately applicable to general research due to technical and biological batch 
effects. Here, we describe the application of a advanced dimensionality reduction 
technique, Adaptive, Elastic-Net Principal Component Analysis (AES-PCA) on the 
integrative analysis of several animal model and human familial and sporadic AD 
datasets. Notably, we find that latent variables captured by AES-PCA and the 
Hallmark gene set collection effectively reduce noise within datasets and batch 
effects between datasets, thus enabling (a) interpretable visualisation of key 
differences underlying the early pathology of two different animal models of AD 
(psen1Q96_K97del/+ fAD mutation-like zebrafish and 5XFAD mice), (b) cross-species 
comparison of alterations in these animal models to a human familial AD dataset, 
and (c) integrative analysis of human familial and sporadic AD in a biologically 






Conventional approaches to gene expression analysis have focused on identifying 
marker (differentially expressed) genes to gain insight into the molecular biology and 
gene expression changes underlying a particular biological condition (reviewed in [1, 
2]). This has posed difficult in the context of Alzheimer’s disease (AD), where 
typically, human brain tissue available for analysis is derived from post-mortem 
brains displaying significant pathology and alteration of diverse biological activities 
[3–6]. Fortunately, utilising animal models of AD allows for the extraction of brain 
tissue at a younger age, which in turn permits characterisation of early AD pathology. 
Many such studies have been performed on various animal models of AD, 
particularly humanised transgenic models with multiple fAD-linked mutations such as 
the 5XFAD model [7–9] (reviewed in [10])  and knock-in models that introduce fAD-
like mutations into endogenous genes [11–18]. However, detailed analyses 
comparing gene expression patterns between different animal models of AD to each 
other and to the human disease are rare. Largely, this is due to the presence of 
noise within datasets and batch effects (e.g. platform, tissue, library preparation) 
between datasets (reviewed in [19]). This has meant that a large amount of publicly 
available gene expression data from many different animal models of AD and human 
AD cohorts is not immediately usable for integrative and comparative analyses.  
 
Previous research has addressed the difficulty behind integration and comparison of 
different gene expression datasets through several approaches, including meta-
analysis (e.g. [20]), matrix factorisation (reviewed in [21]), as well as methods that 
attempt to compare overall systematic changes in the biology of a system at the 
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gene set or pathway level (e.g. GSEA [22] and PLAGE [23]). Recently, pathwayPCA 
was released which provides an R/Bioconductor interface to the Adaptive, Elastic-net 
Sparse Principal Component Analysis (AES-PCA) approach [24, 25]. AES-PCA is an 
unsupervised method for dimension reduction developed for preserving biologically 
correlated information in gene expression data while reducing noise. Similar to other 
dimension reduction methods (e.g. non-negative matrix factorisation, PCA) it is able 
to summarise a gene expression dataset into latent variables that can then be used 
to calculate significant associations with experimental conditions/groups, similar to 
the purposes of using conventional gene set enrichment analysis (GSEA) 
approaches. However, as AES-PCA is specifically designed for use with predefined 
gene sets with biological relevance, the latent variables themselves are also 
amenable to a variety of further analyses including clustering of samples and 
integration of different datasets at both the gene- and gene set levels. 
 
Here, we present applications of AES-PCA to address currently unanswered 
research questions relevant to gene expression changes underlying Alzheimer’s 
disease, including: 
1. How do animal models of AD differ in the gene expression patterns underlying 
the earliest detectable changes? 
2. How can we make preliminary comparisons between the overall biological 
activities that are altered in animal models vs. familial AD in humans? 
3. For large, complex and heterogeneous datasets (e.g. sAD cohort), how can 
we find biologically meaningful and interpretable clusters 
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Importantly, we illustrate the utility of AES-PCA for the integration and comparison of 
different datasets by (a) reducing noise and emphasising relevant biological activities 
correlated to particular conditions within datasets, (b) enabling cross-species 
analysis and comparison of different animal models and human AD, and (c) 
improving integration of different datasets through enabling cross-platform analysis 




Overview of method 
We consider a gene expression matrix, M, consisting of n samples arranged as 
columns and p genes arranged as rows, which we use to characterise transcriptional 
states of interest. When applying the unsupervised dimension reduction method 
known as AES-PCA [25], the first step is to map the p genes to pre-defined gene 
sets s, such as those provided by external databases such as MSigDB [26], KEGG 
[27] or WikiPathways [28]. This is followed by selecting a coherent subset of genes 
for each predefined gene set using the elastic-net estimator [29], which combines 
both L1 (absolute values) and L2 (quadratic) penalties into the model. The adaptive 
lasso component (L1) of the AES-PCA enables a consistent subset of genes to be 
chosen for each dataset via the shrinkage properties of the lasso. The latent 
variables (i.e. Principal Components) extracted by AES-PCA represent activities 
within each gene set (i.e. overall up-regulation or down-regulation of genes within 
these gene sets). As these latent variables are calculated for each sample, they 
represent sample-specific estimates of gene set activities, and their sparse loadings 
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allow for the extraction of relevant genes contributing to variation in gene set activity 
across samples. In addition, latent variables can be used to calculate significant 
associations with experimental conditions/groups similar to the purposes of using 
conventional gene set enrichment testing approaches (e.g. GSEA), through using a 
linear regression model or permutation test [24, 25]. 
 
In our analyses below, we use AES-PCA with the Hallmark gene set collection from 
the Molecular Signatures Database (MSigDB). The Hallmark gene set collection 
comprises 50 gene sets representing diverse and well-characterised biological 
activities (e.g. “oxidative phosphorylation”, “inflammation”), each containing ~200 
non-redundant genes, based on expert manual curation from multiple studies and 
existing gene sets [30]. The AES-PCA approach we use in our analyses is 
summarised in Figure 1 and more detail can be found in [24, 25, 30].  
 
 
Gene expression data can be summarised using the Hallmark gene set 
collection and AES-PCA to provide an interpretable representation of 
altered biological activities 
 
The first step of the AES-PCA approach involves summarisation of gene expression 
data into gene set activities. Because we use the Hallmark gene set collection 
throughout our analyses, we first demonstrate that the biological activities 
represented within the Hallmark gene set collection are sufficient to distinguish 
subtle, early changes within young adult brains of two different animal models of AD 
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(transgenic 5XFAD mouse model and psen1Q96_K97del/+ fAD-like zebrafish model) in a 
biologically-interpretable manner. 
 
The transgenic 5XFAD mouse model is a popular animal model of AD, expressing 
human APP and PSEN1 transgenes with a total of 5 fAD-linked mutations. It is 
characterised by extensive and rapid development of amyloid and tau brain 
pathology with age [7, 8, 31]. In contrast, the psen1Q96_K97del/+ zebrafish model is a 
knock-in model that possesses a single fAD-like mutation in a heterozygous state 
[13]. Knock-in models with similar fAD-like genetic backgrounds typically do not 
show amyloid and tau brain pathology with aging [14, 32]. The clearly different 
genetic backgrounds of these two animal models would be expected to result in 
different changes to their brains at the molecular level. For example, a previous 
transcriptome comparison of different transgenic mouse models such as 5XFAD and 
3xTg showed extensive differences between these models [20]. However, to our 
knowledge, analyses comparing the 5XFAD mouse model to any fAD-like model 
have not previously been done.  
 
We first applied conventional gene set analysis methods (fgsea [33], fry [34], camera 
[35]) with the Hallmark gene set collection to these two datasets, resulting in the 
identification of significantly enriched gene sets in young adult (6-month-old) 
psen1Q96_K97del/+ zebrafish brains and young adult (3-month-old) 5XFAD mouse 
brains when compared to their wild-type siblings (FDR-adjusted Wilkinson’s p < 
0.05) (Figure 2). The gene sets which were significantly enriched in the 
psen1Q96_K97del/+ zebrafish and 5XFAD mouse brains were largely non-overlapping, 
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indicating clear differences in the earliest detectable pathological changes in the 
brains of these models. Hallmark gene sets uniquely enriched in 5XFAD brains 
included “interferon alpha response”, “interferon gamma response”, “complement”, 
and “inflammatory response” while those uniquely enriched in fAD mutation-like 
zebrafish brains included “glycolysis”, “oxidative phosphorylation” and “MTORC1 
signalling”. Gene sets that were enriched in both mouse and zebrafish included “fatty 
acid metabolism”, “heme metabolism”, “E2F targets” and “cholesterol homeostasis”. 
The enriched gene sets in young adult 5XFAD and fAD mutation-like brains are 
consistent with known information about these models: previous transcriptome 
analyses of young adult psen1Q96_K97del/+ brains demonstrated highly significant 
changes in gene expression corresponding to energy metabolism deficits [13, 36], 
while previous transcriptome analyses of young 5XFAD mouse brains indicated that 
2-3 month-old brains were characterised by immune activation gene expression 
responses [9]. This gave us confidence that the subset of genes represented in the 
Hallmark gene set collection would likely be sufficient to capture relevant biological 
signals within our analysed datasets.   
 
We repeated the above analysis using the AES-PCA method (see Supplementary 
Figure 1 for a more detailed comparison of results from conventional gene set 
testing methods and AES-PCA). The sparse loadings of the latent variables (PCs) 
calculated with AES-PCA give additional information on relevant genes accounting 
for the variation in gene set activity between samples within each dataset, hence 
giving further insight on the differences between the psen1Q96_K97del/+ zebrafish and 
5XFAD mouse models at the gene expression level (Figure 3). In the previous 
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result, our gene set analysis results indicated that several gene sets were 
significantly enriched in both the psen1Q96_K97del/+ zebrafish and 5XFAD mouse brains 
compared to their wild-type siblings. However, by inspecting the sparse loadings of 
these gene sets, we are able to see that there are extensive differences in the genes 
contributing to enrichment of these gene sets in most cases (Figure 3). Only two 
genes are in common: zebrafish oxtr and mouse Oxtr [oxytocin receptor] for the 
“epithelial mesenchymal transition” gene set; and, zebrafish tsc2 and mouse Tsc2 
[tuberin] for the “PI3K AKT MTOR signalling” gene set. Notably, both of these genes 
are in opposite directions, supporting overall differences between these models at 
the gene expression level.  
 
Overall, while there are some similarities in the biological activities being altered in 
the young adult brains of these two animal models at the gene set level, there are 
extensive and biologically relevant differences at the gene expression level. We 
hence show that the AES-PCA approach in conjunction with the Hallmark gene set 
collection is able to provide unique and complementary biological insights to 
conventional GSEA methods. 
 
 
AES-PCA latent variables enable cross-species comparison of global 
transcriptional states of human familial AD and animal models of AD 
 
An important area of AD research focuses on evaluating similarities and differences 
between animal models of AD and the human disease at the molecular level. These 
types of studies are important in the context of translational uses for animal AD 
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models (e.g. identification of relevant molecular pathways for therapeutic 
intervention). Currently, comparing animal and human gene expression datasets is 
not straightforward due to biological and technical sources of variation that cause 
batch effects and noise within and between datasets. Additionally, the lack of 
statistical power within low-replicate published datasets, and differences in scope 
between experimental design for studies in human and model organisms, can make 
meta-analytic approaches challenging. This motivated us to investigate whether the 
sparse latent variables calculated using AES-PCA could reduce noise and batch 
effects sufficiently to enable preliminary cross-platform and cross-species 
comparisons of different datasets.  
 
Here, we consider a comparison of gene expression alterations in post-mortem 
brains of human early-onset familial AD (eofAD) patients compared to aged adult 
brains of the two animal models of AD introduced earlier (24-month-old 
psen1Q96_K97del/+ fAD-like zebrafish and 11-month-old 5XFAD mice). Typically, gene 
expression studies involving fAD patients are rare, and the only gene expression 
study of fAD that is available publicly to our knowledge is a microarray dataset by 
Antonell et al. [37]. Samples in this dataset are derived from posterior cingulate 
tissue from post-mortem brains of eofAD patients with PSEN1 mutations (n=7), 
early-onset AD (eoAD) patients without mutations in fAD-causing genes (n=7), and 
age-matched healthy controls (n=7). Note that the psen1Q96_K97del/+ zebrafish and 
5XFAD mouse datasets differ in the platform used to acquire gene expression data 
(RNA-seq) as well as on the brain tissue sampled (zebrafish: whole brain; mouse: 
cortex tissue). An initial Principal Component Analysis (PCA) plot of the gene 
176
expression data from the three datasets supports the presence of batch effects that 
would normally make it difficult to analyse these datasets together (Supplementary 
Figure 2). In addition, applying a conventional GSEA approach using the Hallmark 
gene set collection indicates extensive disruption to many biological activities, which 
is difficult to interpret. 
 
We applied AES-PCA separately to each dataset and applied dataset-specific 
standardisation (z-score) to transform the AES-PCA latent variable PC1 of each 
dataset to a comparable scale. The reason why we only consider PC1 is because 
this latent variable represents the major source of variation in each dataset, and in 
the AES-PCA method, the direction of PC1 corresponds directly to the overall 
direction of gene set activity. This gives the PC1 values a straightforward 
interpretation as the “pathway activity” of each gene set per sample. Interestingly, 
the PC1 latent variable representing Hallmark gene set activities for patients with 
early-onset fAD strongly resemble those with early-onset AD (without mutations in 
fAD-causing genes) (Supplementary Figure 3), indicating that the overall biological 
activities in eoAD in this particular dataset (regardless of whether they have an fAD-
causing mutation or not) appear similar.  
 
Finally, we used a mixed effects linear model on the AES-PCA latent variable PC1 to 
investigate whether similar biological changes were present in either aged 5XFAD 
mice or psen1Q96_K97del/+ zebrafish brains when compared to the eoAD human 
patients. The majority of Hallmark gene sets (48/50) in human eoAD were 
significantly captured by at least one of the zebrafish or mouse models (FDR-
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adjusted p-value < 0.05) (Figure 4). Overall, aged fAD mutation-like zebrafish and 
5XFAD mouse brains tended to capture complementary biological activities to each 
other, suggesting that perhaps these models may have complementary utility when 
studying molecular activities altered during human eoAD and eofAD. There were 
also several gene sets showing similar changes in both the aged psen1Q96_K97del/+ 
zebrafish and 5XFAD mouse brains when compared to human eoAD (including 
“xenobiotic metabolism”, “heme metabolism”). We stress that the similarities and 
differences shown in these comparisons should be considered preliminary results as 
only one dataset was used for each animal model and for human eoAD, and the 
brain tissue sampled in each dataset was different. This represents a common 
scenario when relying on publicly available data, where it may not be possible to find 
datasets that are comparable in terms of tissue, platform, and other factors. Our 
results demonstrate that AES-PCA is capable of reducing noise within datasets and 
batch effects between datasets to allow for preliminary cross-species and cross-




AES-PCA reduces platform-specific batch effects to enable integrative 
analysis of independent familial and sporadic AD datasets 
 
We next investigated whether AES-PCA would enable us to analyse two human 
Alzheimer’s disease datasets differing in key aspects including tissue, platform, and 
whether AD was early-onset vs. late-onset. One dataset comprises posterior 
cingulate cortex-derived microarray data from early-onset AD (n=7), familial early-
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onset AD (n=7) brains and healthy controls (n=7) (dataset referred to as eoAD, 
microarray) while the other comprises temporal cortex-derived RNA-seq data from 
sporadic AD brains (majority late-onset cases) (n=67) and healthy controls (n=65) 
(dataset referred to as sAD, RNA-seq).  
 
After applying AES-PCA to both datasets separately, latent variables representing 
Hallmark gene set activity across all samples demonstrated reduced noise (e.g. 
dataset-, platform- and tissue-specific batch effects) and greater emphasis of the 
biologically meaningful signal in the data corresponding to AD diagnosis. Figure 5 
shows PCAs of both datasets before and after applying AES-PCA. While the sAD, 
RNA-seq samples still display a high level of heterogeneity compared to the eoAD, 
microarray samples, applying AES-PCA results in clearly improved separation of 
AD and control samples across Principal Component 2 in both datasets.  
 
 
While separation between AD and control samples in the eoAD, microarray was 
pronounced based on latent variables captured by AES-PCA, samples in the sAD, 
RNA-seq dataset still displayed high heterogeneity, with some AD samples 
overlapping with control samples across PCs. We tested whether this variation 
might be explained through different age at death or ApoE genotype and found no 
significant correlation between age at death with AD diagnosis (Logistic regression 
p = 0.82) along with a strong association between ApoE genotype and AD diagnosis 
(Fisher’s exact test p = 7.7e-07) consistent with increased AD risk through 
possessing at least one copy of ApoE4.  
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To explore other biologically-relevant signals within the data that could explain this 
variation in the sAD, RNA-seq samples besides ApoE genotype, we applied 
bootstrapped k-means clustering to the Hallmark AES-PCA latent variable PC1 of 
the sAD, RNA-seq samples, resulting in the identification of three clusters with high 
stability (Jaccard index > 0.9) (Supplementary Text 1). Interestingly, while each of 
the three clusters contains both AD and control samples, Clusters 1 and 2 display 
distinct patterns of gene set activity (AES-PCA PC1 values) that are both 
remarkably homogenous for the samples within and are in the opposite direction to 
each other (Figure 6). It would seem that Cluster 3 is comprised of samples with 
Hallmark gene set activity that does not clearly resemble either Clusters 1 or 2. The 
opposite Hallmark gene set activity shown by Clusters 1 and 2 is biologically 
interesting as both clusters contain both AD and control samples showing very 
similar activities in Hallmark gene sets. This may imply that AD samples exhibit a 
large amount of diversity in the underlying molecular pathology at the gene 
expression level. Additionally, the idea that AD and control samples could show 
such similar gene set activity (AES PC1 values) within either Clusters 1 or 2 may 
indicate that perhaps the Hallmark gene set collection may not be sufficient to 
capture all aspects of AD pathology that differentiate them from healthy controls. 
To test whether choice of gene set used in the calculation of AES-PCA latent 
variables would be able to detect these differences between AD and control within 
clusters, we used a different gene set collection (IRE gene sets) previously found to 
have little overlap with the Hallmark gene set collection [36]. The IRE gene sets 
comprise four gene sets containing genes computationally predicted to contain Iron 
Responsive Elements in their 3’ or 5’ UTR. Without clustering, running AES-PCA 
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with the IRE gene sets from the sAD, RNA-seq data results in no significant 
differences detected between AD and control samples for any of the IRE gene sets 
(Figure 7B). Notably however, when samples are separated into the three clusters 
defined based on the Hallmark gene set AES-PCA PC1 values, each cluster shows 
distinct differences in AES-PCA PC1 activity for the IRE gene sets. Notably, there 
are clear significant differences between AD and control samples in AES-PCA PC1 
activity for the “high-quality 3’ IRE genes”, “all predicted 5’ IRE genes” and “high-
quality 5’ IRE genes” sets for Cluster 2 (Figure 7A, p-value from t-test < 0.05). The 
decreased activity of the “all predicted 5’ IRE genes” set along with the increased 
activity of the “high-quality 5’ IRE genes” set is similar to that observed in the early-
onset AD dataset (Supplementary Figure 5). This result highlights how the reduced 
representation of gene expression data by AES-PCA is amenable to clustering, 
particularly in the identification of potentially biologically relevant subgroups.  
 
In this example, we have shown that AES-PCA is an effective approach to 
comparing gene set activity across different platforms and sources of data and 
provides a noise-reduced representation of data that is amenable for identifying 
potentially biologically relevant subgroups or clusters of samples. However, we also 
note that effective use of AES-PCA to distinguish differences between conditions 
require careful consideration of gene sets that are representative of these gene 








AD is a complex and heterogeneous disease that necessitates the use of animal 
models to explore early pathological states of the disease at the molecular level. In 
this paper we highlight an application of the AES-PCA approach and the utility in 
addressing problems related to the interpretation, integration, and comparison of 
different gene expression datasets across different platforms and species in the 
context of AD. Notably, we find that latent variables captured by AES-PCA and the 
Hallmark gene set collection effectively reduce noise within datasets and batch 
effects between datasets, thus enabling (a) interpretable visualisation of key 
differences underlying the early pathology of two different animal models of AD 
(psen1Q96_K97del/+ fAD mutation-like zebrafish and 5XFAD mice), (b) cross-species 
comparison of alterations in these animal models to human eofAD dataset, and (c) 
integrative analysis of human fAD and sAD in a biologically interpretable manner 
despite major platform-specific differences.  
 
AES-PCA compared to conventional batch correction and meta-analytic 
approaches 
Beyond finding enriched gene sets, a unique aspect of AES-PCA is the dimension 
reduction step where genes are selected to summarise overall gene set expression. 
In AES-PCA, the unsupervised nature of this step also shows effectiveness at 
implicitly reducing batch effects between datasets, which we demonstrated in this 
work. It is important to note that conventional batch effect removal methods such as 
RUVseq [38] and ComBat [39, 40] may also be used to explicitly remove batch 
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effects in gene expression datasets. However, the removal of batch effects using 
these methods works on the entire gene expression dataset, and typically require 
tuning of parameters (e.g. manually selecting the value of k in RUVseq, which is 
typically dataset-dependent) or specifying the experimental design (e.g. defining 
which samples belong to which groups in ComBat). RUVseq and ComBat estimate 
batch effects by using the entire set of genes for each dataset, and do not take gene 
set information into account by design. Instead, after batch correction, gene set tests 
are performed as a separate step using methods such as GSEA [22] or ROAST/FRY 
[34, 41]. This means that use of conventional batch correction methods is not directly 
comparable to the batch effect reduction that AES-PCA accomplishes. AES-PCA 
performs integrated analysis across all datasets, and appears to achieve batch effect 
reduction by prioritising the most representative genes of each gene set across all 
samples. In doing this, AES-PCA appears to reduce technical noise and batch 
effects between datasets in a reproducible manner when viewed at the gene set-
level. This suggests that by reducing the complexity in the batch correction step 
compared to conventional methods such as ComBat or RUVseq, AES-PCA may be 
a useful alternative approach to these methods. 
 
AES-PCA also differs fundamentally to traditional meta-analysis approaches like p-
value combination methods and joint-analysis of datasets using a generalised linear 
model (GLM) (described in [42]). p-value combination methods (e.g. Fisher’s method 
or Stouffer’s method) occur after results have been independently obtained for each 
dataset separately. In contrast, AES-PCA analyses datasets simultaneously. GLMs 
are also a popular meta-analytic approach used to perform integrated analysis 
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between datasets, and a strength of this method is that known batch effects are able 
to be specified as random or fixed effects in the model. However, using a GLM 
requires that all batch effects must be known beforehand. In contrast, the 
unsupervised nature of the AES-PCA method means that knowledge of batch effects 
present within or between datasets is not required, meaning that use of AES-PCA 
may serve as a useful complementary approach to independently assess results 
from established methods like GLMs.     
 
Applicability of AES-PCA in analysing Alzheimer’s disease datasets 
Our results reveal several preliminary insights of relevance to AD research that are 
consistent with existing literature and may act as starting points for further research.  
 
As the first gene expression comparison of a knock-in fAD model and a transgenic 
model of AD, our results highlight clear, interpretable differences in the underlying 
molecular pathology in their young adult brains. Our results are consistent with 
previous work on these models suggesting that immune activation responses form 
the earliest pathological changes in the 5XFAD model [9], while young 
psen1Q96_K97del/+ zebrafish brains are characterised by early deficits in energy 
metabolism [13, 36]. In general, knock-in models have recently shown increasing 
popularity in AD research despite showing milder pathology compared to transgenic 
models as their genetic background is considered to resemble more closely that of 
human fAD [11, 12, 43]. Our results are in support of this idea (see Figure 4) and 
indicate that changes present in aged psen1Q96_K97del/+ zebrafish brains are better 
able to capture changes in human eoAD and eofAD related to energy metabolism 
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and other biological activities that are not captured in aged 5XFAD mouse brains. 
However, our results also suggest that 5XFAD mice are able to provide 
complementary information by capturing activity of other gene sets involving immune 
responses that are similar in human AD. Overall, our results highlight the importance 
of having access to younger age groups from animal AD models to investigate early 
changes in the brain at the molecular level, and emphasise the importance of 
comparative studies to assess the utility of different animal models of AD.  
 
It has been well-established that the progression of symptoms and molecular 
pathology present in fAD resembles sAD [44, 45]. Our comparison of eofAD, eoAD 
(without known fAD mutation) and an independent cohort of sporadic AD brains 
supports this overall similarity at the gene expression level for the first time. The 
latent variables captured by AES-PCA suggest that overall changes in molecular 
activities in eoAD and eofAD are very similar to each other and largely consistent 
with sAD brains, despite the extensive heterogeneity observed in the sAD brains that 
remained even after AES-PCA. In our analyses, clustering of the sAD samples 
based on latent variables captured by AES-PCA indicated that some cases of sAD 
resembled fAD more than others. This may reflect the extensive diversity in sAD 
cases (e.g. environmental and genetic factors) in addition to diverse effects on the 
aging brain in both controls and sAD, and further highlights the need to better 
understand molecular differences underlying the heterogeneity of sAD.  
 
Importantly, with the increasing popularity of data integration approaches and 
comparative analysis of different datasets across species and platforms (reviewed by 
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[46]), our results reveal the need for robust and representative gene sets across 
different biological activities of interest. In general, AES-PCA used in conjunction 
with the Hallmark gene set collection enabled interpretable, biologically relevant 
insights into the molecular activities underlying different conditions that could be 
straightforwardly compared between different species, platforms, and datasets. 
However, this approach was not able to distinguish all important differences between 
AD and control samples in the sAD dataset, which showed extensive heterogeneity. 
The use of IRE gene sets with AES-PCA however, was able to reveal significant 
differences in iron homeostasis activity between AD and control samples that were 
not captured by the Hallmark gene sets. This suggests that results can be influenced 
by the initial choice of gene sets chosen for inclusion, which is an important limitation 
to acknowledge in cases where the system under study (e.g. AD) is complex and not 
well-characterised at the molecular level. Despite this, we suggest that unsupervised 
techniques such as AES-PCA are a useful complementary approach alongside 
conventional gene expression analysis techniques as they have several unique 
advantages including ease of interpretation and reduction of biological and technical 
noise. These advantages make AES-PCA highly applicable to cross-platform and 
cross-species integration of multiple datasets, opening up possibilities for extracting 
further value from publicly available datasets which may otherwise have not been 




Dataset availability, pre-processing and normalisation 
The animal model RNA-seq datasets used in this work include: a zebrafish fAD 
mutation-like model derived from psen1Q96_K97del/+ and +/+ whole brains from 6- and 
24-month-old fish (see [13, 36]; GEO accession GSE149149); and 5XFAD (C57BL6) 
mice derived from 5XFAD and +/+ cortex tissue from 3-, 6-, 11- and 12-month-old 
mice (GEO accessions GSE140286 and GSE142633). Raw fastq files were 
downloaded from GEO and re-processed using AdapterRemoval to perform quality 
trimming with default parameters, followed by pseudoalignment with Kallisto (v.0.45) 
to either the zebrafish or mouse reference transcriptome using transcript descriptions 
from Ensembl Release 96 [47]. The “catchKallisto” function from the edgeR 
R/Bioconductor package was used to import count estimates [48]. Transcript-level 
count estimates were then summed to result in gene-level count estimates. Raw 
gene-level counts were normalised using the TMM method using the 
“calcNormFactors” function in edgeR. Normalised counts were transformed into log2 
cpm counts prior to analysis with AES-PCA. 
 
The human eoAD dataset is a microarray dataset (Affymetrix Human Gene 1.1 ST 
Array) originally from a study by Antonell et al. [37]. We obtained raw data from GEO 
(accession GSE39420) and converted raw probe intensities to probeset expression 
while applying RMA normalisation using the “rma” function from the oligo 
R/Bioconductor package [49]. For probeset to gene annotations, we used the 
hugene11sttranscriptcluster.db R/Bioconductor package [50]. However, as there 
were many 1:many probeset:gene annotations, we performed analyses at the 
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probeset level. Normalised probeset expression was log2 transformed prior to 
analysis. 
 
The human sAD dataset is a subset of AD and control RNA-seq samples obtained 
from the Mayo Clinic RNA-seq study [51]. As raw data was not available for public 
download, we downloaded pre-processed, normalised count data from the Synapse 
database (https://www.synapse.org/#!Synapse:syn5550404) and filtered to only 
contain temporal cortex AD and control samples. Data was log2 cpm transformed 
prior to analysis using the “cpm” function from edgeR.  
 
Conversion of gene IDs in the Hallmark gene set collection 
Gene sets used were Hallmark collection gene sets from MSigDB (v.7.0) [26, 30] 
which were downloaded from https://www.gsea-
msigdb.org/gsea/msigdb/collections.jsp as .gmt files and imported into R using the 
GSEABase R/Bioconductor package [52]. The imported gene sets contained human 
entrezgene identifiers, so we used the biomaRt R/Bioconductor package [53] to 
retrieve homologous Ensembl gene IDs for human, zebrafish, and mouse, in order to 
maintain compatibility with our processed RNA-seq datasets which used Ensembl 
gene identifiers for their respective species. For the human eoAD microarray dataset 
which used Affymetrix Human Gene 1.1 ST Array probesets, we used the 
hugene11sttranscriptcluster.db R/Bioconductor package to convert human 




Gene set enrichment analysis 
Initially, gene set enrichment analysis was performed on the zebrafish and mouse 
normalised datasets using 3 gene set enrichment methods, fgsea [33], camera [35], 
and fry [34, 41] inspired by the EGSEA methodology [54]. Raw p-values were 
combined using Wilkinson’s method and FDR-adjusted, with significantly enriched 
gene sets defined as having an FDR-adjusted p-value < 0.05. See Hin et al. [36] for 
further details on the gene set enrichment testing method.  
 
AES-PCA  
AES-PCA with the MSigDB Hallmark gene set collection was performed using the 
“AESPCA_pVals” function from the pathwayPCA R/Bioconductor package [24, 25] 
with default parameters, including FDR-adjustment for raw p-values calculated using 
permutation tests.  
 
Testing for significant preservation of PC1 changes between different datasets 
Prior to integrated analysis, PC1 latent variables calculated using AES-PCA for each 
dataset were standardised (z-score) by scaling by the dataset-specific mean and 
standard deviation. PC1 only was chosen as this variable captures the largest 
amount of variability, and was assumed to capture the majority of the biological 
signal. 
 
Using the lme4 [55] and lmerTest [56] R packages, we set up a mixed linear effects 
model (lmer(value ~ group + (1|dataset)) with dataset as a random effect 
(i.e. nesting term) in order to detect significant differences between AD (or AD-like 
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condition) and controls that were preserved across the following comparisons: fAD 
mutation-like zebrafish brains and human eofAD; 5XFAD mouse brains and human 
eofAD. Gene sets with AES-PCA PC1 values significantly preserved across 
comparisons were defined as having FDR-adjusted p-value < 0.05.  
 
Clustering of sAD human dataset 
The “clusterboot” function from the fpc R package [57] was used to identify stable 
clusters in the sAD human dataset including AD and control samples. The default 
“bootmethod = boot” was used along with 1000 bootstraps and k-means clustering 
as the clustering method. We repeated this for k = 3, 4, 5. The Jaccard index 
(measure of cluster stability) was calculated for each cluster in each case. We used 
k=3 for the final clusters as cluster stability of all 3 clusters had Jaccard index > 0.9 
indicating highly stable clusters (Clusters with Jaccard index > 0.85 are considered 
highly stable while those with Jaccard index < 0.6 indicate unstable clusters).  
 
AES-PCA using IRE gene sets 
For the human datasets, we ran AES-PCA again with default settings but with 
numCores = 8 and human IRE gene sets obtained from [36] instead of Hallmark 
gene sets, as the IRE gene sets have been previously shown to have little overlap 
with Hallmark gene sets [36]. Differences in AES-PCA PC1 values between AD and 
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Figure 1. Schematic showing the application of AES-PCA method to gene 
expression analysis. Refer to Chen [25] for further details on the AES-PCA 
method.  
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Zebrafish (6 months old)      Mouse (3 months old) 
psen1Q96_K97del/+ vs. +/+       5XFAD vs. +/+ 
 
Figure 2. Comparison of molecular pathological changes in young adult brains of fAD 
mutation-like (psen1Q96_K97del/+) zebrafish (6 months old) and 5XFAD mice (3 months 
old) compared to wild-type siblings using gene set enrichment testing of the MSigDB 
Hallmark sets. Gene sets were considered significantly enriched if the Wilkinson FDR-
adjusted p-value (from fgsea, fry, and camera) was < 0.05 (indicated with dots to either left 
or right of gene set names). The proportion of genes within each gene set which were 






































Figure 3. Genes contributing significantly to variation in gene set activity as 
determined from AES-PC1 in young adult fAD mutation-like zebrafish (6 months old) 
and 5XFAD mouse (3 months old) brains when compared to wild-type siblings. Gene 
sets shown here were found to be significant in both the young adult (6 month old) fAD 
mutation-like zebrafish (psen1Q96_K97del/+) and young adult (3 month old) 5XFAD mice 
using a combination of fgsea, fry and camera. Homologous genes which are present in both 


























Figure 4. Preservation of brain gene expression changes between AD-like models and 
human early-onset fAD. Gene expression changes shown here are PC1 values calculated 
using AES-PCA and standardised through scaling by dataset-specific mean and standard 
deviation. Significant preservation was determined through linear mixed model (FDR-
adjusted p-value < 0.05). Zebrafish values derived from whole-brain gene expression, 
mouse values derived from cortex gene expression, human values derived from posterior 





























Figure 5. Principal Component Analysis (PCA) plots for two human AD gene 
expression datasets obtained from different platforms (eoAD, microarray; sAD, RNA-
seq). A. PCA plot of genes expressed in both datasets. The eoAD, microarray dataset 
contained 23,076 genes identified by Ensembl gene identifiers (from 33,297 probesets), 
while the sAD, RNA-seq dataset contained 48,984 genes identified by Ensembl gene 
identifers. Only 19,583 genes which were present in both datasets were used for the PCA. 
Gene expression values were log2 transformed for each dataset prior to PCA. B. PCA plot 
of PC1 values from AES-PCA from 50 Hallmark gene sets for both datasets. AES-PCA 























































Figure 6. Heatmap of PC1 values calculated using AES-PCA for MSigDB Hallmark 
gene set activities in the sAD, RNA-seq dataset. PC1 values for the samples were 
clustered using bootstrapped k-means clustering (k=3). Annotations on top of the heatmap 
indicate ApoE genotype, age at death, diagnosis, and cluster assigned for each sample. 
There was no significant association between Cluster and ApoE genotype or age at death. 






































Figure 7. AES-PCA PC1 values for IRE gene sets (“all 3’ IRE genes”, “high-quality 3’ 
IRE genes”, “all 5’ IRE genes”, high-quality 5’ IRE genes”) calculated for the sAD, 
RNA-seq samples. A. Dataset split into three clusters determined using bootstrapped 
k-means with k=3. B. Full dataset. Differences between AD and control groups were 
tested using t-test (significance defined as p < 0.05). For further information on how IRE 
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Supplementary Figures  
Supplementary Figure 1 
 
psen1Q96_K97del/+ vs. +/+ zebrafish (6-months-old) 
 
5XFAD vs. +/+ mice (6-months-old) 
 
Comparison of significantly enriched gene sets using conventional GSEA 
methods and AES-PCA in 6-month-old age groups of zebrafish and mouse 
datasets. The gene set enrichment analysis methods used (indicated as “GSEA” in 
the diagrams) were fgsea, camera, and fry, with raw p-values being combined using 
Wilkinson’s method and FDR-adjusted (gene sets significantly enriched have FDR-
adj. p < 0.05). For the zebrafish and mouse datasets shown, fgsea, camera, and fry 
were run on the complete dataset (including all age groups), using limma contrasts 
to test for associations between gene sets and specific comparisons (i.e. 6-month-
old psen1Q96_K97del/+ vs. +/+ zebrafish and 6-month-old 5XFAD vs. +/+ mice). In 
contrast, AES-PCA was run on each age group for each dataset separately. AES-
PCA is an unsupervised technique and hence requires additional permutation testing 












associations with conditions exist. Currently, this permutation testing does not allow 
for “contrasts” to be specified in the same way as limma, and it is possible that 
running AES-PCA on age groups separately may result in decreased power to detect 
significant gene set associations compared to limma with conventional gene set 
enrichment testing methods. However, other properties of AES-PCA were proposed 
by Chen [25] to result in increased power for detecting significant gene set 
associations. The comparisons here suggest that neither AES-PCA or conventional 
gene set enrichment methods tested are clearly better than each other. The 
permutation testing for AES-PCA is implemented in the default functionality of the 
“AESPCA_pVals” function in pathwayPCA, and all p-values were FDR-adjusted 
(significantly enriched gene sets have FDR-adj. p < 0.05).  Given that AES-PCA 
uses a different method to test for significant gene set associations compared to the 
way that fgsea, fry, and camera were used in a limma workflow, we would not expect 
results to be exactly the same, but somewhat similar. Here, the similarity between 
AES-PCA to the conventional gene set enrichment analysis methods tested (fgsea, 
fry, and camera) appears acceptable.  
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Supplementary Figure 2 
 
 
Principal Component Analysis (PCA) plot of log2 normalised brain gene 
expression for three datasets: post-mortem human eoAD and controls 
(posterior cingulate tissue), 24-month-old psen1Q96_K97del/+ zebrafish and wild-
type siblings (whole brains), and 11-month-old 5XFAD and wild-type siblings 
(cortex tissue). The PCA indicates clear differences (batch effects) between the 
three datasets, with the largest source of variation (PC1) correlating with 
platform/technology (Mouse and Zebrafish datasets are RNA-seq while Human is 
microarray). The second largest source of variation (PC2) correlates with the 
differences between the Zebrafish and Mouse datasets. Only the 12,638 genes 
which were in common across all datasets were included in this PCA.  
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Supplementary Figure 3 
 
Heatmap of latent variables (PC1) representing Hallmark gene set activities 
calculated using AES-PCA for a microarray eoAD (early onset Alzheimer’s 
disease) dataset. eoAD samples include tissue samples with known psen1 fAD 
mutations (“eoAD_psen1” group) and without known fAD mutations (“eoAD” group). 
Overall, the latent variables representing Hallmark gene set biological activities are 
similar between eoAD_psen1 and eoAD samples, and clearly distinct from the age-









































































































































Supplementary Figure 4 
 
 
Heatmap of latent variables (PC1) representing Hallmark gene set activities 
calculated using AES-PCA for a sAD (sporadic Alzheimer’s disease) dataset. 
This visualisation shows a clear trend of differences between AD and control 
samples, although a large amount of heterogeneity is still present. This 
heterogeneity was not fully explained by ApoE genotype and was not correlated to 
age (see main manuscript text), which formed the motivation to perform additional 


















































































































































































































































































































































Supplementary Figure 5 
 
AES-PCA PC1 values for IRE gene sets (“all 3’ IRE genes”, “high-quality 3’ IRE 
genes”, “all 5’ IRE genes”, high-quality 5’ IRE genes”) calculated for the 
microarray eoAD dataset. Differences between AD and control groups were tested 
using t-test (significance defined as p < 0.05). For further information on how IRE 
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Supplementary Text 1. Determination of stable clusters for 
the RNA-seq, sAD dataset. 
 
Prior to clustering, the PC1 values were standardised by scaling the data to have 
zero mean and unit variance. Bootstrapped k-means clustering was performed using 
the fpc R package [1] and the “clusterboot” function, using the clustering method 
“kmeansCBI” and 1000 bootstraps, for k = 3, 4, and 5. Running the “clusterboot” 
function gives cluster assignments (i.e. which genes are assigned to which clusters) 
as well as cluster stability assessments which are shown below. As a general guide, 
Hennig [2] suggests that a valid, stable cluster should have a mean Jaccard 
similarity value ≥ 0.75, while clusters considered highly stable should have a mean 
Jaccard similarities ≥ 0.85. Clusters with mean Jaccard similarity values between 0.6 
and 0.75 are not considered stable, although may indicate patterns in the data. 
Clusters with mean Jaccard similarity values < 0.6 are considered unstable [2]. For 
the purposes of our analysis, we used k = 3 as all three clusters had Jaccard 
similarity values > 0.85 indicating highly stable clusters.  
 
k = 3 
* Cluster stability assessment * 
Cluster method:  kmeans  
Full clustering results are given as parameter result 
of the clusterboot object, which also provides further statistics 
of the resampling results. 
Number of resampling runs:  1000  
Number of clusters found in data:  3  
 Clusterwise Jaccard bootstrap (omitting multiple points) mean: 
[1] 0.9391498 0.9486744 0.9019909 
dissolved: 
[1]  1  4 12 
recovered: 
[1] 985 964 913 
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k = 4 
* Cluster stability assessment * 
Cluster method:  kmeans  
Full clustering results are given as parameter result 
of the clusterboot object, which also provides further statistics 
of the resampling results. 
Number of resampling runs:  1000  
Number of clusters found in data:  4  
 
 Clusterwise Jaccard bootstrap (omitting multiple points) mean: 
[1] 0.8238979 0.5824745 0.6560716 0.4268291 
dissolved: 
[1]  52 361 161 781 
recovered: 
[1] 721 147 232  91 
 
k = 5 
* Cluster stability assessment * 
Cluster method:  kmeans  
Full clustering results are given as parameter result 
of the clusterboot object, which also provides further statistics 
of the resampling results. 
Number of resampling runs:  1000  
Number of clusters found in data:  5  
 Clusterwise Jaccard bootstrap (omitting multiple points) mean: 
[1] 0.5658384 0.6252707 0.5852597 0.5082613 0.6743152 
dissolved: 
[1] 578 315 414 618 215 
recovered: 








Conclusions and Future Directions 
A significant gap in the field of AD research lies in our understanding of the 
molecular mechanisms underlying incipient stages of AD. This is particularly relevant 
in familial AD, where subtle changes in the brain may begin as early as young 
adulthood. To better understand these early stages of AD at the molecular level, 
transcriptome analyses of accurate animal models is essential. This strategy 
underpins the research within the manuscripts here, where transcriptome analysis 
and other bioinformatics-focused approaches are applied to knock-in zebrafish 
models to investigate molecular mechanisms relevant to human AD. 
It is important to note that prior to these manuscripts, no transcriptome analysis of 
any knock-in animal model of a mutation causing AD had been performed. This is a 
major gap in the field considering that the biological effects of knock-in familial AD 
mutations are known to be subtle and potentially overlooked without appropriate 
methodologies to capture these effects [1–4]. To address this research gap, the 
manuscripts in Chapters 2, 3, and 4 contained the first such transcriptome analyses 
on two different knock-in zebrafish models capturing different aspects of AD 
pathology. Chapter 2 described the analysis of a unique zebrafish model of the 
human K115fs mutation (psen1K97fs zebrafish) that modelled a particular aspect of 
sporadic AD (increased expression of the PS2V isoform). Importantly, the results of 
this chapter indicated the presence of biologically relevant stress and immune gene 
expression responses in young adult brains despite no visible amyloid pathology. 
Meanwhile, Chapters 3 and 4 highlighted a viewpoint more relevant to familial AD by 
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describing the first transcriptome analysis of a familial AD mutation-like model 
(psen1Q96_K97del). In particular, glucose metabolism deficits were shown to be 
amongst the most significant changes in young adult familial AD mutation-like brains 
(see Chapter 3). As the first transcriptome analysis of a knock-in model of a familial 
AD-like mutation, these results represent an important contribution to the field as 
they provide support for a potential role of decreased glucose metabolism in early 
stages of familial AD. Decreased glucose metabolism has been similarly observed in 
the brains of cognitively normal young adults predisposed to sporadic AD (carrying 
the ε4 APOE allele) [5], which highlights the importance of studying these early 
events in AD to determine if it is possible to slow or prevent the progression of AD. 
Existing evidence points towards a role for decreased glucose metabolism in both 
early-onset familial AD and later-onset sporadic AD, as FDG-PET scans show 
hypometabolism occurs in similar brain regions across both early-onset and late-
onset AD patients (although early-onset brains show a greater magnitude of 
hypometabolism) [6]. Because of this, further studies elucidating the molecular 
mechanisms of glucose metabolism in familial AD mutation-like models may be 
useful for giving insights relevant to AD in general. In addition, there is evidence that 
the specific glucose hypometabolism patterns in AD may be important for 
distinguishing AD from other dementias, particularly in the parieto-temporal, frontal 
and posterior cingulate cortices [7], and this further underscores the ongoing 
importance of ‘omics studies to characterise differences between AD and other 
dementias at the molecular level. 
214 
The results shown in Chapter 4 extend upon the findings of glucose metabolism 
deficits in the familial AD mutation-like model and showed that transcriptional 
changes indicative of iron dyshomeostasis were also likely to be important in the 
early stages of the disease. Importantly, this finding has not been previously shown. 
Given that iron dyshomeostasis pathways have been known to interact with diverse 
pathways implicated in AD (e.g. energy metabolism, immune responses and 
inflammation, hypoxia) [8], the results in Chapter 4 contribute to current knowledge 
regarding the early pathogenesis of AD, and generate new questions regarding the 
events surrounding iron dyshomeostasis in early stages of AD. Overall, as the first 
transcriptome analyses of zebrafish knock-in models of AD, the results in Chapters 
2, 3, and 4 represent the first steps towards characterisation of the transcriptional 
states underlying early stages of AD.  
Future steps continuing this work may involve integration of transcriptomes from 
different knock-in models to further define key molecular mechanisms that are 
common or different between familial AD and sporadic AD. For example, the brain 
transcriptome of a sorl1 zebrafish knock-in mutation model developed by the 
Alzheimer’s Disease Genetics Laboratory has recently been characterised [9]. In 
humans, SORL1 has been implicated in both familial and sporadic AD, so the 
analysis of a zebrafish sorl1 mutation model could provide further insight into how 
these two subtypes of AD are similar at the molecular level. Similarly, knock-in 
models of APP and PSEN1 in mice have been developed [10, 11], and comparative 
analysis with zebrafish knock-in mutation models would be useful for further 
elucidating conserved molecular mechanisms and how gene regulation and 
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expression may differ between these animals. Unfortunately, no transcriptome 
analysis has been performed for these mouse models yet, meaning that currently, a 
key gap still remains in the field.  
Another important future step will involve the integration of different ‘omics layers 
including proteomics and metabolomics from zebrafish knock-in mutation models. 
The majority of the work here has relied on transcriptome data. Findings in Chapter 2 
indicated only mild correlation between genes in the transcriptome and encoded 
proteins in the proteome of the psen1K97fs mutation model. This lack of correlation 
between genes and proteins has been well-documented in other species and studies 
[12, 13]. Recently, modelling the interactions between genes, proteins, and 
metabolites in interaction networks has emerged as a powerful method of integration 
of these ‘omics types to give more biologically relevant results [14]. The 
incorporation of different ‘omics data types will continue to play an important role in 
providing a greater understanding of the molecular changes and regulatory programs 
underlying familial and sporadic AD.  
The rapidly improving availability of high-throughput omics technologies implies that 
bioinformatics will also continue to play an important role in elucidating molecular 
mechanisms of complex diseases such as AD. A recurring theme of the manuscripts 
included in this work involved the use of bioinformatics to provide systems-level 
insights into relationships between gene expression patterns, molecular pathways, 
and regulatory factors in human AD and animal models. For example, in Chapter 2, 
a network representation of gene co-expression patterns was instrumental in 
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summarising the expression patterns of over 20,000 expressed genes to less than 
30 interpretable modules of co-expressed genes in a zebrafish dataset. Using the 
same technique on an independent human sporadic AD dataset allowed for a 
systems-level comparison of biological processes represented by these modules 
between these datasets. This revealed an important molecular mechanism 
(microglial responses regulated by ETS transcription factors) preserved between the 
zebrafish and human datasets and also independently replicated by another lab 
using human datasets [15] (see Chapter 2 for more details). This finding was not 
evident in a straightforward differential gene expression analysis of the datasets, 
hence highlighting the importance of bioinformatics strategies that incorporate 
analysis at multiple levels (e.g. promoter motif analysis to identify potential 
transcription factors regulating a common group of genes, identifying gene co-
expression modules to group genes meaningfully) across different datasets to 
ensure that findings are replicable and relevant to the human disease. 
Comparison of clusters of co-expressed genes was not the only effective method for 
data integration found, with Chapter 4 focusing on the use of gene sets for 
summarising overall changes in biological activities between biological groups and 
datasets. Typically, gene sets are defined based on prior knowledge and manual 
curation of genes involved in a particular pathway or biological activity. The unique 
approach taken here to investigate iron homeostasis changes at the gene 
expression level (by defining gene sets computationally based on genes predicted to 
contain Iron Responsive Element motifs) underscores the importance of tailoring a 
bioinformatics strategy to the biological question being asked. The success of this 
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approach was demonstrated by finding that iron dyshomeostasis is implicated at the 
transcriptional level across human sporadic AD and two animal models 
(psen1Q96_K97del zebrafish and 5XFAD mice) which was not captured by gene sets 
from existing databases. Similar approaches of defining gene sets based on 
predicted regulatory motifs might be useful to explore further a range of different 
regulatory systems at the transcriptional level, beyond those currently available in 
existing gene set databases. For example, sterol regulatory elements are present on 
genes involved in cholesterol homeostasis, a biological activity known to be 
disrupted in AD (reviewed in [16]) and also shown to be significantly enriched in 
familial AD mutation-like (psen1Q96_K97del) zebrafish (see Chapter 4). There is some 
evidence that sterol regulatory element-binding proteins are dysregulated by tau 
alterations in AD [17], but no gene set exists that contains all genes with sterol 
regulatory elements. In addition, AD-linked genes including APP and PSEN1 are 
under the control of several regulatory elements [18], yet comprehensive gene sets 
containing other genes with these elements have not been defined. The definition of 
gene sets based on regulatory elements still appears to be an under-explored 
strategy for investigating regulatory systems at the transcriptome level. This strategy 
would be particularly relevant for further delineating molecular mechanisms and 
regulatory systems of complex diseases such as AD.  
Currently, many different animal models of AD are available to researchers, with 
different models potentially recapitulating different aspects of AD pathology. 
Understanding the key differences between these models at the molecular level is an 
ongoing area of research. Through the manuscripts included here, it is evident that 
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bioinformatics will continue to play an important role in accomplishing this goal. The 
integration of different datasets is a key area of current research in bioinformatics, 
and Chapters 2 and 4 investigated two targeted approaches to exploration and 
comparison of particular biological activities between zebrafish and human datasets 
(using gene co-expression modules and gene sets respectively). The manuscript in 
Chapter 5 extended this work and used a combination of advanced dimension 
reduction (the AES-PCA approach) and predefined gene sets to compare broadly 
the global transcriptional states of zebrafish, mouse, and familial and sporadic 
human AD datasets while allowing for cross-species and cross-platform differences. 
Overall, the approach was successful at performing preliminary integration of 
different datasets in a straightforward and interpretable manner, whilst also providing 
biological insights to generate further hypotheses.  
Currently, data integration studies between animal model and human AD datasets 
are not widely described in the literature despite their importance for assessing the 
relevance of different animal models to AD. One of the only studies directly 
comparing the brain transcriptomes between animal models of AD and human AD 
was performed by Hargis and Blalock [19], where meta-analysis was used to assess 
concordance of brain gene expression patterns between several transgenic mouse 
models and human AD. The results indicated that different transgenic mouse models 
of AD did not show concordance to each other, and no transgenic mouse model was 
able to fully recapitulate the transcriptional changes characteristic of human AD. In 
Chapters 4 and 5, it was further demonstrated that 5XFAD mouse brain 
transcriptomes also differed extensively compared to familial AD mutation-like 
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zebrafish. Considering that many drugs developed to treat human AD have showed 
success when tested in transgenic mouse models but not in human AD (reviewed in 
[20]), it will be important in coming years to further compare a number of different 
transgenic and knock-in models of AD to each other and determine which models 
accurately capture important aspects of human AD.  
Another limitation of the work shown here is the reliance on bulk tissue samples 
where results give insight into global transcriptional states while obscuring potential 
differences in transcriptional programs between different cell types. Single-cell RNA-
seq technology is emerging as an important approach for overcoming this limitation. 
For the first time, a large-scale study in 2019 used single-cell RNA-seq to capture 
80,660 cell transcriptomes over 48 individuals with varying amounts of AD pathology 
[21]. Importantly, the study showed that when AD pathology was not severe, many 
disease-associated gene expression changes involved in myelination and 
inflammation were highly cell-type specific. However, when AD pathology was 
severe (i.e. late stages of the disease), many of the gene expression changes that 
occurred were common across cell types and indicative of a global stress response 
[21]. Given that the results in Chapters 2, 3, 4, and 5 indicated important events 
occurring in young adult brains with relevance to human AD, it will be important in 
future work to delineate these global transcriptional states observed by 
understanding the cell types responsible for specific gene expression changes.  
Overall, these manuscripts have described the first steps to characterisation of the 
early AD transcriptome through the use of zebrafish models. The results further our 
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understanding of familial and sporadic AD at the molecular level and are a valuable 
source of hypothesis generation for future work. In addition, bioinformatics-focused 
strategies were instrumental in extracting biologically relevant insights from these 
datasets and aiding in their integration. Collectively, the work here represents an 
initial contribution towards the ultimate goal of being able to develop therapeutic 
interventions capable of slowing or preventing the molecular progression of AD using 
a data-driven, bioinformatics-led approach.   
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